[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fE2NWol_GGwFWw1taIwMEY7tBp8uprlRLNTlF4WVGUX0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"The University of Texas Health Science Center, Houston",[4],868,false,207,25,277851,67,584,[14,17,20,23,25,28,31,33],{"name":15,"count":16},"Stroke",21,{"name":18,"count":19},"Obesity",20,{"name":21,"count":22},"Cardiovascular Diseases",13,{"name":24,"count":22},"HIV Infections",{"name":26,"count":27},"Heart Diseases",12,{"name":29,"count":30},"Traumatic Brain Injury",11,{"name":32,"count":30},"Smoking Cessation",{"name":34,"count":35},"Spinal Cord Injuries",10,[37,42,47,52,57,62,67,72,77,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04584983","Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration","2024-03-14","usual prescribed intralipid (UL) regimen",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06029049","Comparison of Intubation Conditions During Rapid Sequence Induction Obtained With Modified Time Principal Induction With a Standard Intubation Dose of Rocuronium Versus Succinylcholine","2025-06-01","Modified Time Principle Induction (MTPI) with rocuronium",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT05623514","Ultrasound Evaluation for Improving Patient Selection in vNOTES","2025-12","Trans-vaginal ultrasound",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06819033","Effects of Photobiomodulation (PBM) on Pain After Presentation of Aphthous Ulcers in Pediatric Dental Patients","2026-02-27","Maalox plus Benadryl",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05937269","Assessing Impact of Early Physiotherapy on Lymphatic Dysfunction in Head and Neck Cancer Survivorship","2026-02-28","Near-infrared fluorescence lymphatic imaging",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT07031206","Investigating Pre-Procedural Anxiety and Effect of Analgesia on Intrauterine Device Placement and Endometrial Biopsy","2026-05-05","Paracervical block- Lidocaine without epinephrine",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06827977","A Study of Microbiome Transplantation for the Treatment of Constipation and\u002For Significant Bloating in Patients With Systemic Sclerosis","2026-05-30","PRIM-DJ2727",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT07165340","Evaluation of Lymphatic Response to Physiotherapy in Patients With Swelling Associated With Superficial Venous Disease","2026-06","Indocyanine Green near infrared fluorescence imaging",{"nctId":78,"briefTitle":79,"date":75,"intervention":80},"NCT00439049","Substance Abuse Pre-Treatment Screening Study","modafinil",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT06705842","APPI-Cost Trial for Perforated Appendicitis","2026-06-30","PVI",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,161,197,243,264,292,310,335,361,384,402,427,445,469,487,513,531,556,578,596,621,648,666,684,710,737,755,829,866,905,931,959,977,995,1013,1037,1055,1073,1099,1117,1138,1156,1174,1199,1217,1239,1264,1282,1327,1351,1375,1396,1414,1432,1450,1468,1494,1512,1537,1560,1618,1659,1689,1714,1732,1750,1770,1795,1871,1935,1987,2032,2063,2100,2136,2158,2196,2225,2247,2269,2297,2333,2361,2388,2406,2424,2442,2465,2491,2509,2534,2552,2577,2595,2622,2640,2658,2682,2706,2730,2748,2766,2793,2811,2839,2857,2875,2898,2924,2942,2960,2978,3007,3025,3043,3061,3086,3115,3133,3158,3176,3201,3227,3254,3282,3300,3332,3350,3368,3386,3414,3432,3457,3475,3500,3518,3536,3561,3579,3605,3623,3647,3665,3688,3706,3732,3750,3768,3789,3816,3834,3859,3877,3905,3923,3941,3959,3977,3995,4013,4031,4049,4067,4085,4103,4121,4147,4175,4193,4220,4238,4256,4274,4299,4325,4343,4361,4385,4403,4426,4451,4469,4487,4509,4534,4552,4570,4595,4613,4631,4649,4673,4691,4716,4739,4757,4775,4798,4824,4848,4866,4891,4909,4935,4953,4971,4989,5014,5039,5057,5075,5101,5119,5143,5169,5197,5221,5239,5264,5289,5307,5333,5351,5376,5394,5417,5443,5461,5484,5510,5528,5546,5570,5588,5614,5632,5650,5705,5756,5796,5840,5881,5922,5951,5988,6010,6042,6064,6086,6119,6150,6179,6201,6223,6245,6267,6301,6333,6355,6382,6419,6443,6461,6479,6497,6515,6533,6551,6569,6594,6612,6638,6664,6690,6714,6732,6756,6781,6799,6822,6846,6869,6896,6914,6932,6956,6979,7004,7022,7045,7070,7097,7115,7133,7151,7176,7201,7219,7247,7265,7283,7301,7326,7344,7370,7388,7406,7424,7448,7470,7494,7518,7541,7564,7590,7617,7635,7653,7679,7697,7719,7737,7755,7773,7791,7809,7833,7851,7875,7898,7916,7939,7962,7980,8008,8033,8051,8085,8103,8124,8150,8168,8194,8212,8230,8254,8276,8297,8322,8344,8367,8391,8414,8439,8457,8481,8499,8523,8547,8565,8583,8606,8630,8648,8673,8698,8722,8749,8767,8785,8807,8831,8849,8874,8897,8921,8957,8992,9017,9039,9061,9089,9117,9150,9173,9191,9214,9237,9260,9278,9301,9319,9344,9362,9383,9408,9426,9444,9468,9486,9504,9526,9554,9572,9598,9616,9634,9657,9675,9697],{"intervention":95,"totalTrials":96,"cells":97},"Usual Care",4,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":121,"NA":159},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":120,"soonestReadout":112},[107],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},"NCT06702670","Anticholinergics for Cervical Edema in Labor","RECRUITING",[89,90],"2027-03-25","2027-04-09","2025-03-25",200,[117],"Labor Dystocia",[119,95],"Treatment with Diphenhydramine",1,{"trials":122,"activeCount":120,"soonestReadout":84},[123,138,151],{"nctId":124,"briefTitle":125,"status":126,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":136},"NCT04129086","Ketamine for Acute Pain Management After Trauma","COMPLETED",[91],"2022-03-30","2022-09-30","2020-07-01",305,[133,134,135],"Trauma Injury","Pain","Opioid Use",[137,95],"Ketamine plus usual care",{"nctId":139,"briefTitle":140,"status":141,"phases":142,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":148},"NCT06110546","Impact of Methadone on Prolonged Mechanical Ventilation in Patients on Continuous Treatment With Opioids","TERMINATED",[91],"2024-02-22","2024-02-18",2,[147],"Effect of Methadone on the Duration on Mechanical Ventilation",[149,150],"Methadone group","Usual care",{"nctId":82,"briefTitle":83,"status":110,"phases":152,"primaryCompletion":84,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":158},[91],"2027-03-31","2025-04-07",346,[157],"Perforated Appendicitis",[85,95],{"trials":160,"activeCount":100},[],{"intervention":162,"totalTrials":145,"cells":163},"Semaglutide",{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":181,"PHASE4":183,"NA":195},{"trials":165,"activeCount":100},[],{"trials":167,"activeCount":100},[],{"trials":169,"activeCount":120,"soonestReadout":174},[170],{"nctId":171,"briefTitle":172,"status":110,"phases":173,"primaryCompletion":174,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":180},"NCT07227948","Repurposing Semaglutide for the Treatment of Cocaine Use Disorder",[89],"2029-01-28","2029-02-28","2026-01-15",75,[179],"Cocaine Use Disorder",[162],{"trials":182,"activeCount":100},[],{"trials":184,"activeCount":120,"soonestReadout":189},[185],{"nctId":186,"briefTitle":187,"status":110,"phases":188,"primaryCompletion":189,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":194},"NCT05119179","Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes",[91],"2026-10-31","2021-11-22",300,[193],"PreDiabetes",[162],{"trials":196,"activeCount":100},[],{"intervention":198,"totalTrials":145,"cells":199},"Ketorolac",{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":206,"PHASE4":208,"NA":241},{"trials":201,"activeCount":100},[],{"trials":203,"activeCount":100},[],{"trials":205,"activeCount":100},[],{"trials":207,"activeCount":100},[],{"trials":209,"activeCount":120,"soonestReadout":234},[210,230],{"nctId":211,"briefTitle":212,"status":126,"phases":213,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":219},"NCT03472469","MAST Trial: Multi-modal Analgesic Strategies in Trauma",[91],"2019-07-03","2018-04-02",1561,[218],"Nonspecific Pain Post Traumatic Injury",[220,221,198,222,223,224,225,226,227,228,229],"Acetaminophen IV\u002FPO","Acetaminophen PO","Celebrex","Naproxen","Tramadol","Pregabalin","Gabapentin","Lidocaine","Opioids","Regional anesthesia",{"nctId":231,"briefTitle":232,"status":110,"phases":233,"primaryCompletion":234,"completion":235,"start":236,"enrollment":237,"conditions":238,"interventions":240},"NCT04771156","Ketorolac in Palatoplasty",[91],"2027-03-01","2027-04-01","2021-09-17",74,[239],"Cleft Lip and Palate",[198],{"trials":242,"activeCount":100},[],{"intervention":56,"totalTrials":120,"cells":244},{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":251,"PHASE4":253,"NA":262},{"trials":246,"activeCount":100},[],{"trials":248,"activeCount":100},[],{"trials":250,"activeCount":100},[],{"trials":252,"activeCount":100},[],{"trials":254,"activeCount":120,"soonestReadout":55},[255],{"nctId":53,"briefTitle":54,"status":110,"phases":256,"primaryCompletion":55,"completion":60,"start":257,"enrollment":258,"conditions":259,"interventions":261},[91],"2025-03-10",30,[260],"Aphthous Ulcer",[56],{"trials":263,"activeCount":100},[],{"intervention":265,"totalTrials":120,"cells":266},"Phenylephrine",{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":271,"PHASE3":273,"PHASE4":275,"NA":290},{"trials":268,"activeCount":100},[],{"trials":270,"activeCount":100},[],{"trials":272,"activeCount":100},[],{"trials":274,"activeCount":100},[],{"trials":276,"activeCount":120,"soonestReadout":282},[277],{"nctId":278,"briefTitle":279,"status":280,"phases":281,"primaryCompletion":282,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":288},"NCT04934748","The GUARDIAN Trial - Vasopressor Sub-Study","ENROLLING_BY_INVITATION",[91],"2026-12-31","2027-04-25","2021-07-25",6254,[287],"Blood Pressure",[265,289],"Norepinephrine",{"trials":291,"activeCount":100},[],{"intervention":289,"totalTrials":120,"cells":293},{"EARLY_PHASE1":294,"PHASE1":296,"PHASE2":298,"PHASE3":300,"PHASE4":302,"NA":308},{"trials":295,"activeCount":100},[],{"trials":297,"activeCount":100},[],{"trials":299,"activeCount":100},[],{"trials":301,"activeCount":100},[],{"trials":303,"activeCount":120,"soonestReadout":282},[304],{"nctId":278,"briefTitle":279,"status":280,"phases":305,"primaryCompletion":282,"completion":283,"start":284,"enrollment":285,"conditions":306,"interventions":307},[91],[287],[265,289],{"trials":309,"activeCount":100},[],{"intervention":311,"totalTrials":120,"cells":312},"Irrigation with PVI",{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":319,"PHASE4":321,"NA":333},{"trials":314,"activeCount":100},[],{"trials":316,"activeCount":100},[],{"trials":318,"activeCount":100},[],{"trials":320,"activeCount":100},[],{"trials":322,"activeCount":120,"soonestReadout":328},[323],{"nctId":324,"briefTitle":325,"status":326,"phases":327,"primaryCompletion":328,"completion":328,"start":234,"enrollment":329,"conditions":330,"interventions":332},"NCT04200729","Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis: a Multi-center Stepped Wedge Cluster Randomized Study","NOT_YET_RECRUITING",[91],"2030-03-01",1750,[331],"Acute, Perforated Appendicitis",[311],{"trials":334,"activeCount":100},[],{"intervention":336,"totalTrials":120,"cells":337},"Inhaled Nitric Oxide (iNO) use",{"EARLY_PHASE1":338,"PHASE1":340,"PHASE2":342,"PHASE3":344,"PHASE4":346,"NA":359},{"trials":339,"activeCount":100},[],{"trials":341,"activeCount":100},[],{"trials":343,"activeCount":100},[],{"trials":345,"activeCount":100},[],{"trials":347,"activeCount":120,"soonestReadout":352},[348],{"nctId":349,"briefTitle":350,"status":110,"phases":351,"primaryCompletion":352,"completion":353,"start":354,"enrollment":355,"conditions":356,"interventions":358},"NCT05213676","De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia",[91],"2030-10-31","2031-04-30","2025-11-01",600,[357],"Congenital Diaphragmatic Hernia",[336],{"trials":360,"activeCount":100},[],{"intervention":362,"totalTrials":120,"cells":363},"Etomidate Induction",{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":372,"NA":382},{"trials":365,"activeCount":100},[],{"trials":367,"activeCount":100},[],{"trials":369,"activeCount":100},[],{"trials":371,"activeCount":100},[],{"trials":373,"activeCount":120,"soonestReadout":282},[374],{"nctId":375,"briefTitle":376,"status":280,"phases":377,"primaryCompletion":282,"completion":283,"start":284,"enrollment":285,"conditions":378,"interventions":380},"NCT04934683","The GUARDIAN Trial - Induction Agent Sub-Study",[91],[379],"Major Surgery",[362,381],"Propofol Induction",{"trials":383,"activeCount":100},[],{"intervention":381,"totalTrials":120,"cells":385},{"EARLY_PHASE1":386,"PHASE1":388,"PHASE2":390,"PHASE3":392,"PHASE4":394,"NA":400},{"trials":387,"activeCount":100},[],{"trials":389,"activeCount":100},[],{"trials":391,"activeCount":100},[],{"trials":393,"activeCount":100},[],{"trials":395,"activeCount":120,"soonestReadout":282},[396],{"nctId":375,"briefTitle":376,"status":280,"phases":397,"primaryCompletion":282,"completion":283,"start":284,"enrollment":285,"conditions":398,"interventions":399},[91],[379],[362,381],{"trials":401,"activeCount":100},[],{"intervention":403,"totalTrials":120,"cells":404},"Intervention group",{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":411,"PHASE4":413,"NA":425},{"trials":406,"activeCount":100},[],{"trials":408,"activeCount":100},[],{"trials":410,"activeCount":100},[],{"trials":412,"activeCount":100},[],{"trials":414,"activeCount":120,"soonestReadout":419},[415],{"nctId":416,"briefTitle":417,"status":110,"phases":418,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":423},"NCT04234971","Cost Effectiveness in Alveolar Bone Grafting in Patients With Cleft Lip and Palate",[91],"2028-01-01","2021-06-14",40,[239],[403,424],"Control group",{"trials":426,"activeCount":100},[],{"intervention":424,"totalTrials":120,"cells":428},{"EARLY_PHASE1":429,"PHASE1":431,"PHASE2":433,"PHASE3":435,"PHASE4":437,"NA":443},{"trials":430,"activeCount":100},[],{"trials":432,"activeCount":100},[],{"trials":434,"activeCount":100},[],{"trials":436,"activeCount":100},[],{"trials":438,"activeCount":120,"soonestReadout":419},[439],{"nctId":416,"briefTitle":417,"status":110,"phases":440,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":441,"interventions":442},[91],[239],[403,424],{"trials":444,"activeCount":100},[],{"intervention":446,"totalTrials":120,"cells":447},"Ertapenem",{"EARLY_PHASE1":448,"PHASE1":450,"PHASE2":452,"PHASE3":454,"PHASE4":456,"NA":467},{"trials":449,"activeCount":100},[],{"trials":451,"activeCount":100},[],{"trials":453,"activeCount":100},[],{"trials":455,"activeCount":100},[],{"trials":457,"activeCount":120,"soonestReadout":153},[458],{"nctId":459,"briefTitle":460,"status":326,"phases":461,"primaryCompletion":153,"completion":153,"start":462,"enrollment":191,"conditions":463,"interventions":465},"NCT06920147","PRevention Of Trauma-related Infections Through an Embedded Clinical Trials Network",[91],"2025-05-01",[464],"Surgical Site Infection",[446,466],"Cefazolin and Metronidazole.",{"trials":468,"activeCount":100},[],{"intervention":466,"totalTrials":120,"cells":470},{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":477,"PHASE4":479,"NA":485},{"trials":472,"activeCount":100},[],{"trials":474,"activeCount":100},[],{"trials":476,"activeCount":100},[],{"trials":478,"activeCount":100},[],{"trials":480,"activeCount":120,"soonestReadout":153},[481],{"nctId":459,"briefTitle":460,"status":326,"phases":482,"primaryCompletion":153,"completion":153,"start":462,"enrollment":191,"conditions":483,"interventions":484},[91],[464],[446,466],{"trials":486,"activeCount":100},[],{"intervention":488,"totalTrials":120,"cells":489},"Human Albumin",{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":494,"PHASE3":496,"PHASE4":498,"NA":511},{"trials":491,"activeCount":100},[],{"trials":493,"activeCount":100},[],{"trials":495,"activeCount":100},[],{"trials":497,"activeCount":100},[],{"trials":499,"activeCount":120,"soonestReadout":504},[500],{"nctId":501,"briefTitle":502,"status":326,"phases":503,"primaryCompletion":504,"completion":504,"start":505,"enrollment":506,"conditions":507,"interventions":509},"NCT06107335","Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia",[91],"2026-12-01","2025-07-01",62,[508],"Pre-Eclampsia",[488,510],"Lactated Ringer's",{"trials":512,"activeCount":100},[],{"intervention":510,"totalTrials":120,"cells":514},{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":521,"PHASE4":523,"NA":529},{"trials":516,"activeCount":100},[],{"trials":518,"activeCount":100},[],{"trials":520,"activeCount":100},[],{"trials":522,"activeCount":100},[],{"trials":524,"activeCount":120,"soonestReadout":504},[525],{"nctId":501,"briefTitle":502,"status":326,"phases":526,"primaryCompletion":504,"completion":504,"start":505,"enrollment":506,"conditions":527,"interventions":528},[91],[508],[488,510],{"trials":530,"activeCount":100},[],{"intervention":532,"totalTrials":120,"cells":533},"Fenfluramine treatment",{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":540,"PHASE4":542,"NA":554},{"trials":535,"activeCount":100},[],{"trials":537,"activeCount":100},[],{"trials":539,"activeCount":100},[],{"trials":541,"activeCount":100},[],{"trials":543,"activeCount":120,"soonestReadout":548},[544],{"nctId":545,"briefTitle":546,"status":326,"phases":547,"primaryCompletion":548,"completion":549,"start":550,"enrollment":9,"conditions":551,"interventions":553},"NCT07112365","The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project",[91],"2027-09-30","2028-03-31","2026-04",[552],"Dravet Syndrome",[532],{"trials":555,"activeCount":100},[],{"intervention":46,"totalTrials":120,"cells":557},{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":562,"PHASE3":564,"PHASE4":566,"NA":576},{"trials":559,"activeCount":100},[],{"trials":561,"activeCount":100},[],{"trials":563,"activeCount":100},[],{"trials":565,"activeCount":100},[],{"trials":567,"activeCount":120,"soonestReadout":45},[568],{"nctId":43,"briefTitle":44,"status":110,"phases":569,"primaryCompletion":45,"completion":505,"start":570,"enrollment":571,"conditions":572,"interventions":574},[91],"2023-09-13",152,[573],"Anesthesia",[46,575],"RSI succinylcholine",{"trials":577,"activeCount":100},[],{"intervention":575,"totalTrials":120,"cells":579},{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":586,"PHASE4":588,"NA":594},{"trials":581,"activeCount":100},[],{"trials":583,"activeCount":100},[],{"trials":585,"activeCount":100},[],{"trials":587,"activeCount":100},[],{"trials":589,"activeCount":120,"soonestReadout":45},[590],{"nctId":43,"briefTitle":44,"status":110,"phases":591,"primaryCompletion":45,"completion":505,"start":570,"enrollment":571,"conditions":592,"interventions":593},[91],[573],[46,575],{"trials":595,"activeCount":100},[],{"intervention":597,"totalTrials":120,"cells":598},"Suboxone",{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":605,"PHASE4":607,"NA":619},{"trials":600,"activeCount":100},[],{"trials":602,"activeCount":100},[],{"trials":604,"activeCount":100},[],{"trials":606,"activeCount":100},[],{"trials":608,"activeCount":120,"soonestReadout":613},[609],{"nctId":610,"briefTitle":611,"status":280,"phases":612,"primaryCompletion":613,"completion":613,"start":614,"enrollment":615,"conditions":616,"interventions":618},"NCT03396276","Houston Emergency Opioid Engagement System",[91],"2030-08-31","2018-04-01",3000,[617],"Opioid Use Disorder",[597],{"trials":620,"activeCount":100},[],{"intervention":622,"totalTrials":120,"cells":623},"Buprenorphine, Naloxone Drug Combination",{"EARLY_PHASE1":624,"PHASE1":626,"PHASE2":628,"PHASE3":630,"PHASE4":632,"NA":646},{"trials":625,"activeCount":100},[],{"trials":627,"activeCount":100},[],{"trials":629,"activeCount":100},[],{"trials":631,"activeCount":100},[],{"trials":633,"activeCount":120,"soonestReadout":613},[634],{"nctId":635,"briefTitle":636,"status":110,"phases":637,"primaryCompletion":613,"completion":613,"start":638,"enrollment":639,"conditions":640,"interventions":645},"NCT04811014","Young Houston Emergency Opioid Engagement System",[91],"2021-04-19",250,[641,642,643,135,644],"Opioid-use Disorder","Opioid Dependence","Opioid Overdose","Substance Use Disorders",[622],{"trials":647,"activeCount":100},[],{"intervention":85,"totalTrials":120,"cells":649},{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":654,"PHASE3":656,"PHASE4":658,"NA":664},{"trials":651,"activeCount":100},[],{"trials":653,"activeCount":100},[],{"trials":655,"activeCount":100},[],{"trials":657,"activeCount":100},[],{"trials":659,"activeCount":120,"soonestReadout":84},[660],{"nctId":82,"briefTitle":83,"status":110,"phases":661,"primaryCompletion":84,"completion":153,"start":154,"enrollment":155,"conditions":662,"interventions":663},[91],[157],[85,95],{"trials":665,"activeCount":100},[],{"intervention":119,"totalTrials":120,"cells":667},{"EARLY_PHASE1":668,"PHASE1":670,"PHASE2":672,"PHASE3":674,"PHASE4":680,"NA":682},{"trials":669,"activeCount":100},[],{"trials":671,"activeCount":100},[],{"trials":673,"activeCount":100},[],{"trials":675,"activeCount":120,"soonestReadout":112},[676],{"nctId":108,"briefTitle":109,"status":110,"phases":677,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":678,"interventions":679},[89,90],[117],[119,95],{"trials":681,"activeCount":100},[],{"trials":683,"activeCount":100},[],{"intervention":685,"totalTrials":120,"cells":686},"Saline delivered using an intrauterine pressure catheter",{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":693,"PHASE4":706,"NA":708},{"trials":688,"activeCount":100},[],{"trials":690,"activeCount":100},[],{"trials":692,"activeCount":100},[],{"trials":694,"activeCount":120,"soonestReadout":699},[695],{"nctId":696,"briefTitle":697,"status":326,"phases":698,"primaryCompletion":699,"completion":700,"start":701,"enrollment":702,"conditions":703,"interventions":705},"NCT06691945","Prophylactic Amnioinfusion for Prevention of Postpartum Hemorrhage",[90],"2026-11-11","2027-05-01","2024-11-11",700,[704],"Postpartum Hemorrhage",[685],{"trials":707,"activeCount":100},[],{"trials":709,"activeCount":100},[],{"intervention":711,"totalTrials":120,"cells":712},"Protonix (Pantoprazole) 40 mg q 12 hrs for 2 days",{"EARLY_PHASE1":713,"PHASE1":715,"PHASE2":717,"PHASE3":719,"PHASE4":733,"NA":735},{"trials":714,"activeCount":100},[],{"trials":716,"activeCount":100},[],{"trials":718,"activeCount":100},[],{"trials":720,"activeCount":120,"soonestReadout":725},[721],{"nctId":722,"briefTitle":723,"status":110,"phases":724,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":729,"interventions":731},"NCT06531642","Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients",[89,90],"2026-07-31","2026-09-01","2024-09-07",100,[730],"Acute Kidney Injury",[711,732],"Protonix (pantoprazole) 40 mg q 24 hrs for 2 days",{"trials":734,"activeCount":100},[],{"trials":736,"activeCount":100},[],{"intervention":732,"totalTrials":120,"cells":738},{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":745,"PHASE4":751,"NA":753},{"trials":740,"activeCount":100},[],{"trials":742,"activeCount":100},[],{"trials":744,"activeCount":100},[],{"trials":746,"activeCount":120,"soonestReadout":725},[747],{"nctId":722,"briefTitle":723,"status":110,"phases":748,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":749,"interventions":750},[89,90],[730],[711,732],{"trials":752,"activeCount":100},[],{"trials":754,"activeCount":100},[],{"intervention":71,"totalTrials":756,"cells":757},6,{"EARLY_PHASE1":758,"PHASE1":760,"PHASE2":773,"PHASE3":823,"PHASE4":825,"NA":827},{"trials":759,"activeCount":100},[],{"trials":761,"activeCount":100},[762],{"nctId":763,"briefTitle":764,"status":126,"phases":765,"primaryCompletion":766,"completion":767,"start":768,"enrollment":769,"conditions":770,"interventions":772},"NCT03671785","Study of the Fecal Microbiome in Patients With Parkinson's Disease",[88],"2022-10-09","2022-10-12","2019-05-15",15,[771],"Parkinson Disease",[71],{"trials":774,"activeCount":145,"soonestReadout":70},[775,786,796,805,813],{"nctId":776,"briefTitle":777,"status":110,"phases":778,"primaryCompletion":282,"completion":779,"start":780,"enrollment":781,"conditions":782,"interventions":784},"NCT04373473","Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis",[89],"2027-12-31","2020-09-14",58,[783],"Adults With Ulcerative Colitis",[71,785],"Placebos",{"nctId":787,"briefTitle":788,"status":789,"phases":790,"primaryCompletion":791,"completion":791,"start":792,"enrollment":100,"conditions":793,"interventions":795},"NCT04371653","A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With Nonalcoholic Fatty Liver Disease","WITHDRAWN",[89],"2024-12-01","2023-12-01",[794],"Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus",[71],{"nctId":797,"briefTitle":798,"status":789,"phases":799,"primaryCompletion":800,"completion":800,"start":801,"enrollment":100,"conditions":802,"interventions":804},"NCT03026231","Characterization of Fecal Microbiome Changes After Administration of PRIM-DJ2727 in Parkinson's Disease Patients",[88,89],"2018-07-17","2017-07-15",[803],"Parkinson's Disease",[71],{"nctId":68,"briefTitle":69,"status":110,"phases":806,"primaryCompletion":70,"completion":807,"start":808,"enrollment":16,"conditions":809,"interventions":812},[89],"2026-09-26","2025-03-03",[810,811],"Constipation","Bloating",[71],{"nctId":814,"briefTitle":815,"status":789,"phases":816,"primaryCompletion":817,"completion":818,"start":819,"enrollment":100,"conditions":820,"interventions":822},"NCT04729790","Randomized Clinical Trial of Standard FMT Treatments",[89],"2022-01-30","2022-04-30","2020-01-10",[821],"Clostridium Difficile",[71],{"trials":824,"activeCount":100},[],{"trials":826,"activeCount":100},[],{"trials":828,"activeCount":100},[],{"intervention":830,"totalTrials":145,"cells":831},"Neoadjuvant Chemotherapy",{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":860,"PHASE4":862,"NA":864},{"trials":833,"activeCount":100},[],{"trials":835,"activeCount":100},[],{"trials":837,"activeCount":145,"soonestReadout":504},[838,850],{"nctId":839,"briefTitle":840,"status":110,"phases":841,"primaryCompletion":842,"completion":843,"start":844,"enrollment":845,"conditions":846,"interventions":848},"NCT06831136","Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma",[89],"2028-01-20","2030-01-20","2025-03-26",24,[847],"Pancreatic Ductal Adenocarcinoma",[830,849],"Immunotherapy",{"nctId":851,"briefTitle":852,"status":110,"phases":853,"primaryCompletion":504,"completion":854,"start":855,"enrollment":856,"conditions":857,"interventions":859},"NCT04990609","EUS-RFA PANCARDINAL-1 Trial",[89],"2028-05-30","2021-08-13",60,[858],"Pancreatic Ductal Adenocarcinoma (PDAC)",[830],{"trials":861,"activeCount":100},[],{"trials":863,"activeCount":100},[],{"trials":865,"activeCount":100},[],{"intervention":867,"totalTrials":145,"cells":868},"Nicotine Replacement Therapy",{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":888,"PHASE4":890,"NA":903},{"trials":870,"activeCount":100},[],{"trials":872,"activeCount":100},[],{"trials":874,"activeCount":120,"soonestReadout":879},[875],{"nctId":876,"briefTitle":877,"status":110,"phases":878,"primaryCompletion":879,"completion":880,"start":881,"enrollment":882,"conditions":883,"interventions":886},"NCT06173778","Semaglutide for Post-Smoking Cessation Weight Management",[89],"2026-07-01","2026-08-01","2024-04-23",197,[18,884,885],"Overweight","Cigarette Smoking",[887,867],"semaglutide 2.4mg",{"trials":889,"activeCount":100},[],{"trials":891,"activeCount":100},[892],{"nctId":893,"briefTitle":894,"status":126,"phases":895,"primaryCompletion":896,"completion":896,"start":897,"enrollment":898,"conditions":899,"interventions":901},"NCT04045964","Nicotine Patch as an Adjunctive Intervention to Reduce Secondhand Smoke Among NICU Families",[91],"2018-06-28","2017-10-29",32,[900,32],"Environmental Tobacco Smoke",[902],"nicotine replacement therapy",{"trials":904,"activeCount":100},[],{"intervention":906,"totalTrials":120,"cells":907},"Psilocybin",{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":925,"PHASE4":927,"NA":929},{"trials":909,"activeCount":100},[],{"trials":911,"activeCount":100},[],{"trials":913,"activeCount":120,"soonestReadout":918},[914],{"nctId":915,"briefTitle":916,"status":110,"phases":917,"primaryCompletion":918,"completion":918,"start":919,"enrollment":35,"conditions":920,"interventions":924},"NCT06706232","Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality",[89],"2027-01","2025-07-07",[921,922,923],"Bipolar II Disorder","Depression, Bipolar","Suicidality",[906],{"trials":926,"activeCount":100},[],{"trials":928,"activeCount":100},[],{"trials":930,"activeCount":100},[],{"intervention":932,"totalTrials":120,"cells":933},"SOLE",{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":938,"PHASE3":953,"PHASE4":955,"NA":957},{"trials":935,"activeCount":100},[],{"trials":937,"activeCount":100},[],{"trials":939,"activeCount":120,"soonestReadout":944},[940],{"nctId":941,"briefTitle":942,"status":110,"phases":943,"primaryCompletion":944,"completion":945,"start":946,"enrollment":947,"conditions":948,"interventions":951},"NCT06915441","Lipid Infusions to Optimize Nutrition Trial",[89],"2028-07-30","2030-12-31","2026-05-01",230,[949,950],"Bronchopulmonary Dysplasia","Neurodevelopmental Impairment",[932,952],"MOLE",{"trials":954,"activeCount":100},[],{"trials":956,"activeCount":100},[],{"trials":958,"activeCount":100},[],{"intervention":952,"totalTrials":120,"cells":960},{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":971,"PHASE4":973,"NA":975},{"trials":962,"activeCount":100},[],{"trials":964,"activeCount":100},[],{"trials":966,"activeCount":120,"soonestReadout":944},[967],{"nctId":941,"briefTitle":942,"status":110,"phases":968,"primaryCompletion":944,"completion":945,"start":946,"enrollment":947,"conditions":969,"interventions":970},[89],[949,950],[932,952],{"trials":972,"activeCount":100},[],{"trials":974,"activeCount":100},[],{"trials":976,"activeCount":100},[],{"intervention":849,"totalTrials":120,"cells":978},{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":983,"PHASE3":989,"PHASE4":991,"NA":993},{"trials":980,"activeCount":100},[],{"trials":982,"activeCount":100},[],{"trials":984,"activeCount":120,"soonestReadout":842},[985],{"nctId":839,"briefTitle":840,"status":110,"phases":986,"primaryCompletion":842,"completion":843,"start":844,"enrollment":845,"conditions":987,"interventions":988},[89],[847],[830,849],{"trials":990,"activeCount":100},[],{"trials":992,"activeCount":100},[],{"trials":994,"activeCount":100},[],{"intervention":785,"totalTrials":120,"cells":996},{"EARLY_PHASE1":997,"PHASE1":999,"PHASE2":1001,"PHASE3":1007,"PHASE4":1009,"NA":1011},{"trials":998,"activeCount":100},[],{"trials":1000,"activeCount":100},[],{"trials":1002,"activeCount":120,"soonestReadout":282},[1003],{"nctId":776,"briefTitle":777,"status":110,"phases":1004,"primaryCompletion":282,"completion":779,"start":780,"enrollment":781,"conditions":1005,"interventions":1006},[89],[783],[71,785],{"trials":1008,"activeCount":100},[],{"trials":1010,"activeCount":100},[],{"trials":1012,"activeCount":100},[],{"intervention":41,"totalTrials":120,"cells":1014},{"EARLY_PHASE1":1015,"PHASE1":1017,"PHASE2":1019,"PHASE3":1031,"PHASE4":1033,"NA":1035},{"trials":1016,"activeCount":100},[],{"trials":1018,"activeCount":100},[],{"trials":1020,"activeCount":120,"soonestReadout":40},[1021],{"nctId":38,"briefTitle":39,"status":1022,"phases":1023,"primaryCompletion":40,"completion":1024,"start":1025,"enrollment":1026,"conditions":1027,"interventions":1029},"ACTIVE_NOT_RECRUITING",[89],"2026-06-14","2021-02-11",134,[1028],"Bilirubin Encephalopathy",[41,1030],"restricted prescribed intralipid (RL) regimen",{"trials":1032,"activeCount":100},[],{"trials":1034,"activeCount":100},[],{"trials":1036,"activeCount":100},[],{"intervention":1030,"totalTrials":120,"cells":1038},{"EARLY_PHASE1":1039,"PHASE1":1041,"PHASE2":1043,"PHASE3":1049,"PHASE4":1051,"NA":1053},{"trials":1040,"activeCount":100},[],{"trials":1042,"activeCount":100},[],{"trials":1044,"activeCount":120,"soonestReadout":40},[1045],{"nctId":38,"briefTitle":39,"status":1022,"phases":1046,"primaryCompletion":40,"completion":1024,"start":1025,"enrollment":1026,"conditions":1047,"interventions":1048},[89],[1028],[41,1030],{"trials":1050,"activeCount":100},[],{"trials":1052,"activeCount":100},[],{"trials":1054,"activeCount":100},[],{"intervention":887,"totalTrials":120,"cells":1056},{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1067,"PHASE4":1069,"NA":1071},{"trials":1058,"activeCount":100},[],{"trials":1060,"activeCount":100},[],{"trials":1062,"activeCount":120,"soonestReadout":879},[1063],{"nctId":876,"briefTitle":877,"status":110,"phases":1064,"primaryCompletion":879,"completion":880,"start":881,"enrollment":882,"conditions":1065,"interventions":1066},[89],[18,884,885],[887,867],{"trials":1068,"activeCount":100},[],{"trials":1070,"activeCount":100},[],{"trials":1072,"activeCount":100},[],{"intervention":1074,"totalTrials":120,"cells":1075},"Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weekly",{"EARLY_PHASE1":1076,"PHASE1":1078,"PHASE2":1080,"PHASE3":1093,"PHASE4":1095,"NA":1097},{"trials":1077,"activeCount":100},[],{"trials":1079,"activeCount":100},[],{"trials":1081,"activeCount":120,"soonestReadout":1086},[1082],{"nctId":1083,"briefTitle":1084,"status":110,"phases":1085,"primaryCompletion":1086,"completion":1087,"start":1088,"enrollment":258,"conditions":1089,"interventions":1091},"NCT07325500","Incretin Microdosing for Cardiometabolic Health in People With HIV",[89],"2028-05-31","2029-06-30","2026-02-12",[1090],"Weight Gain",[1074,1092],"Dose escalation to 2 mg semaglutide weekly then no semaglutide",{"trials":1094,"activeCount":100},[],{"trials":1096,"activeCount":100},[],{"trials":1098,"activeCount":100},[],{"intervention":1092,"totalTrials":120,"cells":1100},{"EARLY_PHASE1":1101,"PHASE1":1103,"PHASE2":1105,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1102,"activeCount":100},[],{"trials":1104,"activeCount":100},[],{"trials":1106,"activeCount":120,"soonestReadout":1086},[1107],{"nctId":1083,"briefTitle":1084,"status":110,"phases":1108,"primaryCompletion":1086,"completion":1087,"start":1088,"enrollment":258,"conditions":1109,"interventions":1110},[89],[1090],[1074,1092],{"trials":1112,"activeCount":100},[],{"trials":1114,"activeCount":100},[],{"trials":1116,"activeCount":100},[],{"intervention":66,"totalTrials":120,"cells":1118},{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1132,"PHASE4":1134,"NA":1136},{"trials":1120,"activeCount":100},[],{"trials":1122,"activeCount":100},[],{"trials":1124,"activeCount":120,"soonestReadout":65},[1125],{"nctId":63,"briefTitle":64,"status":326,"phases":1126,"primaryCompletion":65,"completion":65,"start":505,"enrollment":571,"conditions":1127,"interventions":1129},[89],[1128,134],"Anxiety",[66,1130,1131],"Benzocaine Gel applied to the cervix","Hydroxyzine Hydrochloride",{"trials":1133,"activeCount":100},[],{"trials":1135,"activeCount":100},[],{"trials":1137,"activeCount":100},[],{"intervention":1130,"totalTrials":120,"cells":1139},{"EARLY_PHASE1":1140,"PHASE1":1142,"PHASE2":1144,"PHASE3":1150,"PHASE4":1152,"NA":1154},{"trials":1141,"activeCount":100},[],{"trials":1143,"activeCount":100},[],{"trials":1145,"activeCount":120,"soonestReadout":65},[1146],{"nctId":63,"briefTitle":64,"status":326,"phases":1147,"primaryCompletion":65,"completion":65,"start":505,"enrollment":571,"conditions":1148,"interventions":1149},[89],[1128,134],[66,1130,1131],{"trials":1151,"activeCount":100},[],{"trials":1153,"activeCount":100},[],{"trials":1155,"activeCount":100},[],{"intervention":1131,"totalTrials":120,"cells":1157},{"EARLY_PHASE1":1158,"PHASE1":1160,"PHASE2":1162,"PHASE3":1168,"PHASE4":1170,"NA":1172},{"trials":1159,"activeCount":100},[],{"trials":1161,"activeCount":100},[],{"trials":1163,"activeCount":120,"soonestReadout":65},[1164],{"nctId":63,"briefTitle":64,"status":326,"phases":1165,"primaryCompletion":65,"completion":65,"start":505,"enrollment":571,"conditions":1166,"interventions":1167},[89],[1128,134],[66,1130,1131],{"trials":1169,"activeCount":100},[],{"trials":1171,"activeCount":100},[],{"trials":1173,"activeCount":100},[],{"intervention":1175,"totalTrials":120,"cells":1176},"Protonix (Pantoprazole) 40 mg q 12 hrs for 3 days",{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1193,"PHASE4":1195,"NA":1197},{"trials":1178,"activeCount":100},[],{"trials":1180,"activeCount":100},[],{"trials":1182,"activeCount":120,"soonestReadout":504},[1183],{"nctId":1184,"briefTitle":1185,"status":110,"phases":1186,"primaryCompletion":504,"completion":1187,"start":1188,"enrollment":1189,"conditions":1190,"interventions":1191},"NCT06706258","Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)",[89],"2027-07-01","2025-01-24",400,[730],[1175,1192],"Pepcid (Famotidine) 20 mg q 12 hrs for 3 days",{"trials":1194,"activeCount":100},[],{"trials":1196,"activeCount":100},[],{"trials":1198,"activeCount":100},[],{"intervention":1192,"totalTrials":120,"cells":1200},{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1205,"PHASE3":1211,"PHASE4":1213,"NA":1215},{"trials":1202,"activeCount":100},[],{"trials":1204,"activeCount":100},[],{"trials":1206,"activeCount":120,"soonestReadout":504},[1207],{"nctId":1184,"briefTitle":1185,"status":110,"phases":1208,"primaryCompletion":504,"completion":1187,"start":1188,"enrollment":1189,"conditions":1209,"interventions":1210},[89],[730],[1175,1192],{"trials":1212,"activeCount":100},[],{"trials":1214,"activeCount":100},[],{"trials":1216,"activeCount":100},[],{"intervention":76,"totalTrials":120,"cells":1218},{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1233,"PHASE4":1235,"NA":1237},{"trials":1220,"activeCount":100},[],{"trials":1222,"activeCount":100},[],{"trials":1224,"activeCount":120,"soonestReadout":75},[1225],{"nctId":73,"briefTitle":74,"status":280,"phases":1226,"primaryCompletion":75,"completion":1227,"start":1228,"enrollment":1229,"conditions":1230,"interventions":1232},[88,89],"2026-08","2025-09",34,[1231],"Chronic Venous Disease",[76],{"trials":1234,"activeCount":100},[],{"trials":1236,"activeCount":100},[],{"trials":1238,"activeCount":100},[],{"intervention":1240,"totalTrials":120,"cells":1241},"SUVO",{"EARLY_PHASE1":1242,"PHASE1":1244,"PHASE2":1246,"PHASE3":1258,"PHASE4":1260,"NA":1262},{"trials":1243,"activeCount":100},[],{"trials":1245,"activeCount":100},[],{"trials":1247,"activeCount":120,"soonestReadout":1252},[1248],{"nctId":1249,"briefTitle":1250,"status":110,"phases":1251,"primaryCompletion":1252,"completion":1252,"start":1253,"enrollment":19,"conditions":1254,"interventions":1256},"NCT06444256","Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder",[89],"2027-01-30","2024-07-25",[1255],"Stimulant Use Disorder",[1240,1257],"TAU",{"trials":1259,"activeCount":100},[],{"trials":1261,"activeCount":100},[],{"trials":1263,"activeCount":100},[],{"intervention":1257,"totalTrials":120,"cells":1265},{"EARLY_PHASE1":1266,"PHASE1":1268,"PHASE2":1270,"PHASE3":1276,"PHASE4":1278,"NA":1280},{"trials":1267,"activeCount":100},[],{"trials":1269,"activeCount":100},[],{"trials":1271,"activeCount":120,"soonestReadout":1252},[1272],{"nctId":1249,"briefTitle":1250,"status":110,"phases":1273,"primaryCompletion":1252,"completion":1252,"start":1253,"enrollment":19,"conditions":1274,"interventions":1275},[89],[1255],[1240,1257],{"trials":1277,"activeCount":100},[],{"trials":1279,"activeCount":100},[],{"trials":1281,"activeCount":100},[],{"intervention":1283,"totalTrials":145,"cells":1284},"Intranasal capsaicin",{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1308,"PHASE3":1310,"PHASE4":1323,"NA":1325},{"trials":1286,"activeCount":100},[],{"trials":1288,"activeCount":120,"soonestReadout":1086},[1289],{"nctId":1290,"briefTitle":1291,"status":280,"phases":1292,"primaryCompletion":1086,"completion":1086,"start":1293,"enrollment":1294,"conditions":1295,"interventions":1303},"NCT03511846","Pain Biomarker Study",[88],"2018-03-21",371,[1296,1297,1298,1299,1300,1301,1302],"Migraine","Cluster Headache","Trigeminal Autonomic Cephalgia","Hemicrania Continua","Paroxysmal Hemicrania","SUNCT","Short-Lasting Unilateral Neuralgiform Headache With Conjunctival Injection and Tearing",[1304,1305,1283,1306,1307],"Oral capsaicin","Topical capsaicin","Low Flow Oxygen","High Flow Oxygen",{"trials":1309,"activeCount":100},[],{"trials":1311,"activeCount":100},[1312],{"nctId":1313,"briefTitle":1314,"status":126,"phases":1315,"primaryCompletion":1316,"completion":1316,"start":1317,"enrollment":1318,"conditions":1319,"interventions":1321},"NCT05093478","The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population",[90],"2023-11-30","2019-09-10",28,[1320],"Non-allergic Rhinitis",[1283,1322],"topical lidocaine",{"trials":1324,"activeCount":100},[],{"trials":1326,"activeCount":100},[],{"intervention":1328,"totalTrials":120,"cells":1329},"PET with radiotracer [11C]PBR-28",{"EARLY_PHASE1":1330,"PHASE1":1332,"PHASE2":1343,"PHASE3":1345,"PHASE4":1347,"NA":1349},{"trials":1331,"activeCount":100},[],{"trials":1333,"activeCount":120,"soonestReadout":1338},[1334],{"nctId":1335,"briefTitle":1336,"status":110,"phases":1337,"primaryCompletion":1338,"completion":1338,"start":1339,"enrollment":115,"conditions":1340,"interventions":1342},"NCT03705715","Identifying Correlates of Brain Microglial Activation in Neuropsychiatric Syndromes: a Dimensional Approach",[88],"2028-08","2017-05-01",[1341],"Neuropsychiatric Syndromes",[1328],{"trials":1344,"activeCount":100},[],{"trials":1346,"activeCount":100},[],{"trials":1348,"activeCount":100},[],{"trials":1350,"activeCount":100},[],{"intervention":1352,"totalTrials":120,"cells":1353},"Nicotinamide riboside",{"EARLY_PHASE1":1354,"PHASE1":1356,"PHASE2":1367,"PHASE3":1369,"PHASE4":1371,"NA":1373},{"trials":1355,"activeCount":100},[],{"trials":1357,"activeCount":120,"soonestReadout":1362},[1358],{"nctId":1359,"briefTitle":1360,"status":110,"phases":1361,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":769,"conditions":1364,"interventions":1366},"NCT06280482","Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)",[88],"2027-07-25","2024-03-06",[1365],"Smooth Muscle Dysfunction Syndrome (SMDS)",[1352],{"trials":1368,"activeCount":100},[],{"trials":1370,"activeCount":100},[],{"trials":1372,"activeCount":100},[],{"trials":1374,"activeCount":100},[],{"intervention":61,"totalTrials":120,"cells":1376},{"EARLY_PHASE1":1377,"PHASE1":1379,"PHASE2":1388,"PHASE3":1390,"PHASE4":1392,"NA":1394},{"trials":1378,"activeCount":100},[],{"trials":1380,"activeCount":120,"soonestReadout":60},[1381],{"nctId":58,"briefTitle":59,"status":280,"phases":1382,"primaryCompletion":60,"completion":60,"start":1383,"enrollment":19,"conditions":1384,"interventions":1387},[88],"2023-10-12",[1385,1386],"Lymphedema of Face","Head and Neck Cancer",[61],{"trials":1389,"activeCount":100},[],{"trials":1391,"activeCount":100},[],{"trials":1393,"activeCount":100},[],{"trials":1395,"activeCount":100},[],{"intervention":1304,"totalTrials":120,"cells":1397},{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1406,"PHASE3":1408,"PHASE4":1410,"NA":1412},{"trials":1399,"activeCount":100},[],{"trials":1401,"activeCount":120,"soonestReadout":1086},[1402],{"nctId":1290,"briefTitle":1291,"status":280,"phases":1403,"primaryCompletion":1086,"completion":1086,"start":1293,"enrollment":1294,"conditions":1404,"interventions":1405},[88],[1296,1297,1298,1299,1300,1301,1302],[1304,1305,1283,1306,1307],{"trials":1407,"activeCount":100},[],{"trials":1409,"activeCount":100},[],{"trials":1411,"activeCount":100},[],{"trials":1413,"activeCount":100},[],{"intervention":1305,"totalTrials":120,"cells":1415},{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1424,"PHASE3":1426,"PHASE4":1428,"NA":1430},{"trials":1417,"activeCount":100},[],{"trials":1419,"activeCount":120,"soonestReadout":1086},[1420],{"nctId":1290,"briefTitle":1291,"status":280,"phases":1421,"primaryCompletion":1086,"completion":1086,"start":1293,"enrollment":1294,"conditions":1422,"interventions":1423},[88],[1296,1297,1298,1299,1300,1301,1302],[1304,1305,1283,1306,1307],{"trials":1425,"activeCount":100},[],{"trials":1427,"activeCount":100},[],{"trials":1429,"activeCount":100},[],{"trials":1431,"activeCount":100},[],{"intervention":1306,"totalTrials":120,"cells":1433},{"EARLY_PHASE1":1434,"PHASE1":1436,"PHASE2":1442,"PHASE3":1444,"PHASE4":1446,"NA":1448},{"trials":1435,"activeCount":100},[],{"trials":1437,"activeCount":120,"soonestReadout":1086},[1438],{"nctId":1290,"briefTitle":1291,"status":280,"phases":1439,"primaryCompletion":1086,"completion":1086,"start":1293,"enrollment":1294,"conditions":1440,"interventions":1441},[88],[1296,1297,1298,1299,1300,1301,1302],[1304,1305,1283,1306,1307],{"trials":1443,"activeCount":100},[],{"trials":1445,"activeCount":100},[],{"trials":1447,"activeCount":100},[],{"trials":1449,"activeCount":100},[],{"intervention":1307,"totalTrials":120,"cells":1451},{"EARLY_PHASE1":1452,"PHASE1":1454,"PHASE2":1460,"PHASE3":1462,"PHASE4":1464,"NA":1466},{"trials":1453,"activeCount":100},[],{"trials":1455,"activeCount":120,"soonestReadout":1086},[1456],{"nctId":1290,"briefTitle":1291,"status":280,"phases":1457,"primaryCompletion":1086,"completion":1086,"start":1293,"enrollment":1294,"conditions":1458,"interventions":1459},[88],[1296,1297,1298,1299,1300,1301,1302],[1304,1305,1283,1306,1307],{"trials":1461,"activeCount":100},[],{"trials":1463,"activeCount":100},[],{"trials":1465,"activeCount":100},[],{"trials":1467,"activeCount":100},[],{"intervention":1469,"totalTrials":120,"cells":1470},"PRIM-DJ2727 - FROZEN",{"EARLY_PHASE1":1471,"PHASE1":1473,"PHASE2":1486,"PHASE3":1488,"PHASE4":1490,"NA":1492},{"trials":1472,"activeCount":100},[],{"trials":1474,"activeCount":120,"soonestReadout":1479},[1475],{"nctId":1476,"briefTitle":1477,"status":110,"phases":1478,"primaryCompletion":1479,"completion":1480,"start":1481,"enrollment":19,"conditions":1482,"interventions":1484},"NCT05786404","Study to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis",[88],"2026-12-15","2027-12-15","2023-12-15",[1483],"Active Ulcerative Colitis (UC)",[1469,1485],"PRIM-DJ2727 -",{"trials":1487,"activeCount":100},[],{"trials":1489,"activeCount":100},[],{"trials":1491,"activeCount":100},[],{"trials":1493,"activeCount":100},[],{"intervention":1485,"totalTrials":120,"cells":1495},{"EARLY_PHASE1":1496,"PHASE1":1498,"PHASE2":1504,"PHASE3":1506,"PHASE4":1508,"NA":1510},{"trials":1497,"activeCount":100},[],{"trials":1499,"activeCount":120,"soonestReadout":1479},[1500],{"nctId":1476,"briefTitle":1477,"status":110,"phases":1501,"primaryCompletion":1479,"completion":1480,"start":1481,"enrollment":19,"conditions":1502,"interventions":1503},[88],[1483],[1469,1485],{"trials":1505,"activeCount":100},[],{"trials":1507,"activeCount":100},[],{"trials":1509,"activeCount":100},[],{"trials":1511,"activeCount":100},[],{"intervention":1513,"totalTrials":120,"cells":1514},"Scented Oil",{"EARLY_PHASE1":1515,"PHASE1":1517,"PHASE2":1529,"PHASE3":1531,"PHASE4":1533,"NA":1535},{"trials":1516,"activeCount":100},[],{"trials":1518,"activeCount":120,"soonestReadout":1523},[1519],{"nctId":1520,"briefTitle":1521,"status":326,"phases":1522,"primaryCompletion":1523,"completion":1524,"start":45,"enrollment":421,"conditions":1525,"interventions":1528},"NCT07010718","Improving Sleep in a Psychiatric Hospital",[88],"2027-06-01","2028-06-01",[1526,1527],"Sleep Disorder","Mental Health Issue",[1513],{"trials":1530,"activeCount":100},[],{"trials":1532,"activeCount":100},[],{"trials":1534,"activeCount":100},[],{"trials":1536,"activeCount":100},[],{"intervention":1538,"totalTrials":120,"cells":1539},"Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells",{"EARLY_PHASE1":1540,"PHASE1":1542,"PHASE2":1552,"PHASE3":1554,"PHASE4":1556,"NA":1558},{"trials":1541,"activeCount":100},[],{"trials":1543,"activeCount":120,"soonestReadout":504},[1544],{"nctId":1545,"briefTitle":1546,"status":110,"phases":1547,"primaryCompletion":504,"completion":504,"start":1548,"enrollment":258,"conditions":1549,"interventions":1551},"NCT03522545","Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression",[88],"2022-04-20",[1550],"Treatment-resistant Bipolar Depression",[1538],{"trials":1553,"activeCount":100},[],{"trials":1555,"activeCount":100},[],{"trials":1557,"activeCount":100},[],{"trials":1559,"activeCount":100},[],{"intervention":1561,"totalTrials":96,"cells":1562},"Naltrexone",{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1576,"PHASE3":1589,"PHASE4":1591,"NA":1605},{"trials":1564,"activeCount":100},[],{"trials":1566,"activeCount":100},[1567],{"nctId":1568,"briefTitle":1569,"status":141,"phases":1570,"primaryCompletion":1571,"completion":1571,"start":1572,"enrollment":145,"conditions":1573,"interventions":1574},"NCT06374290","Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia",[88],"2024-12-04","2024-07-16",[32],[1561,1575],"Bupropion",{"trials":1577,"activeCount":100},[1578],{"nctId":1579,"briefTitle":1580,"status":126,"phases":1581,"primaryCompletion":1582,"completion":1582,"start":1583,"enrollment":1584,"conditions":1585,"interventions":1588},"NCT00218569","Combined Treatment for Cocaine-Alcohol Dependence - 1",[89],"2007-12","2003-04",87,[1586,1587],"Alcohol Dependence","Cocaine Dependence",[1561],{"trials":1590,"activeCount":100},[],{"trials":1592,"activeCount":100},[1593],{"nctId":1594,"briefTitle":1595,"status":126,"phases":1596,"completion":1597,"start":1598,"enrollment":115,"conditions":1599,"interventions":1602},"NCT00000447","Behavioral\u002FDrug Therapy for Alcohol-Nicotine Dependence (Naltrexone\u002FNicotine Patch)",[91],"2003-05","1998-09",[1600,1601],"Alcoholism","Smoking",[1603,1604],"naltrexone","nicotine replacement patch",{"trials":1606,"activeCount":120,"soonestReadout":75},[1607],{"nctId":78,"briefTitle":79,"status":110,"phases":1608,"primaryCompletion":75,"completion":75,"start":1609,"enrollment":1610,"conditions":1611,"interventions":1615},[],"2005-10",7500,[1612,1587,1613,1586,1614],"Cocaine Abuse","Opiate Dependence","Substance Abuse",[80,1616,1617,1561],"d-amphetamine","L-Dopa",{"intervention":1619,"totalTrials":1620,"cells":1621},"Modafinil",3,{"EARLY_PHASE1":1622,"PHASE1":1624,"PHASE2":1626,"PHASE3":1649,"PHASE4":1651,"NA":1653},{"trials":1623,"activeCount":100},[],{"trials":1625,"activeCount":100},[],{"trials":1627,"activeCount":100},[1628,1640],{"nctId":1629,"briefTitle":1630,"status":126,"phases":1631,"primaryCompletion":1632,"completion":1632,"start":1633,"enrollment":1634,"conditions":1635,"interventions":1637},"NCT00218023","Medications for Stopping Cocaine Dependence and Preventing Relapse",[89],"2012-04","2006-03",101,[1612,1636],"Cocaine-Related Disorders",[1619,1638,1639],"Levodopa\u002FCarbidopa","Naltrexone HCl",{"nctId":1641,"briefTitle":1642,"status":126,"phases":1643,"primaryCompletion":1644,"completion":1644,"start":1645,"enrollment":1646,"conditions":1647,"interventions":1648},"NCT02896712","Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention",[89],"2021-09-13","2016-11-18",118,[1636],[1619],{"trials":1650,"activeCount":100},[],{"trials":1652,"activeCount":100},[],{"trials":1654,"activeCount":120,"soonestReadout":75},[1655],{"nctId":78,"briefTitle":79,"status":110,"phases":1656,"primaryCompletion":75,"completion":75,"start":1609,"enrollment":1610,"conditions":1657,"interventions":1658},[],[1612,1587,1613,1586,1614],[80,1616,1617,1561],{"intervention":1660,"totalTrials":120,"cells":1661},"NIRFLI with ICG",{"EARLY_PHASE1":1662,"PHASE1":1664,"PHASE2":1666,"PHASE3":1668,"PHASE4":1670,"NA":1672},{"trials":1663,"activeCount":100},[],{"trials":1665,"activeCount":100},[],{"trials":1667,"activeCount":100},[],{"trials":1669,"activeCount":100},[],{"trials":1671,"activeCount":100},[],{"trials":1673,"activeCount":120,"soonestReadout":1678},[1674],{"nctId":1675,"briefTitle":1676,"status":280,"phases":1677,"primaryCompletion":1678,"completion":1678,"start":1679,"enrollment":1680,"conditions":1681,"interventions":1688},"NCT00833599","Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders",[],"2030-12-01","2009-01",283,[1682,1683,1684,1685,1686,1687],"Lymphedema","Lymphatic Disorders","Lipedema","Vascular Malformation","Vascular Anomaly","Dercum Disease",[1660],{"intervention":1690,"totalTrials":120,"cells":1691},"Research genetic tests",{"EARLY_PHASE1":1692,"PHASE1":1694,"PHASE2":1696,"PHASE3":1698,"PHASE4":1700,"NA":1702},{"trials":1693,"activeCount":100},[],{"trials":1695,"activeCount":100},[],{"trials":1697,"activeCount":100},[],{"trials":1699,"activeCount":100},[],{"trials":1701,"activeCount":100},[],{"trials":1703,"activeCount":120,"soonestReadout":1708},[1704],{"nctId":1705,"briefTitle":1706,"status":110,"phases":1707,"primaryCompletion":1708,"completion":1709,"start":1710,"enrollment":115,"conditions":1711,"interventions":1713},"NCT03185702","UTHealth Turner Syndrome Research Registry",[],"2030-01-01","2035-01-01","2015-08-28",[1712],"Turner Syndrome",[1690],{"intervention":1616,"totalTrials":120,"cells":1715},{"EARLY_PHASE1":1716,"PHASE1":1718,"PHASE2":1720,"PHASE3":1722,"PHASE4":1724,"NA":1726},{"trials":1717,"activeCount":100},[],{"trials":1719,"activeCount":100},[],{"trials":1721,"activeCount":100},[],{"trials":1723,"activeCount":100},[],{"trials":1725,"activeCount":100},[],{"trials":1727,"activeCount":120,"soonestReadout":75},[1728],{"nctId":78,"briefTitle":79,"status":110,"phases":1729,"primaryCompletion":75,"completion":75,"start":1609,"enrollment":1610,"conditions":1730,"interventions":1731},[],[1612,1587,1613,1586,1614],[80,1616,1617,1561],{"intervention":1617,"totalTrials":120,"cells":1733},{"EARLY_PHASE1":1734,"PHASE1":1736,"PHASE2":1738,"PHASE3":1740,"PHASE4":1742,"NA":1744},{"trials":1735,"activeCount":100},[],{"trials":1737,"activeCount":100},[],{"trials":1739,"activeCount":100},[],{"trials":1741,"activeCount":100},[],{"trials":1743,"activeCount":100},[],{"trials":1745,"activeCount":120,"soonestReadout":75},[1746],{"nctId":78,"briefTitle":79,"status":110,"phases":1747,"primaryCompletion":75,"completion":75,"start":1609,"enrollment":1610,"conditions":1748,"interventions":1749},[],[1612,1587,1613,1586,1614],[80,1616,1617,1561],{"intervention":51,"totalTrials":120,"cells":1751},{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1758,"PHASE4":1760,"NA":1762},{"trials":1753,"activeCount":100},[],{"trials":1755,"activeCount":100},[],{"trials":1757,"activeCount":100},[],{"trials":1759,"activeCount":100},[],{"trials":1761,"activeCount":100},[],{"trials":1763,"activeCount":120,"soonestReadout":50},[1764],{"nctId":48,"briefTitle":49,"status":110,"phases":1765,"primaryCompletion":50,"completion":50,"start":1766,"enrollment":177,"conditions":1767,"interventions":1769},[92],"2022-05-16",[1768],"Surgery",[51],{"intervention":1771,"totalTrials":120,"cells":1772},"Sterile Water as control",{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1779,"PHASE4":1781,"NA":1783},{"trials":1774,"activeCount":100},[],{"trials":1776,"activeCount":100},[],{"trials":1778,"activeCount":100},[],{"trials":1780,"activeCount":100},[],{"trials":1782,"activeCount":100},[],{"trials":1784,"activeCount":120,"soonestReadout":1789},[1785],{"nctId":1786,"briefTitle":1787,"status":326,"phases":1788,"primaryCompletion":1789,"completion":1790,"start":1791,"enrollment":258,"conditions":1792,"interventions":1794},"NCT07261527","Characterization of Skin and Facial Fat Pad Thickness Changes Following Microneedling Radiofrequency With and Without Topical Poly-L-Lactic Acid for Facial Rejuvenation",[92],"2027-07-31","2027-11-30","2025-11-24",[1793],"Skin Texture",[1771],{"intervention":1796,"totalTrials":1797,"cells":1798},"Normal Saline",5,{"EARLY_PHASE1":1799,"PHASE1":1801,"PHASE2":1814,"PHASE3":1828,"PHASE4":1830,"NA":1869},{"trials":1800,"activeCount":100},[],{"trials":1802,"activeCount":100},[1803],{"nctId":1804,"briefTitle":1805,"status":141,"phases":1806,"primaryCompletion":1807,"completion":1807,"start":1808,"enrollment":1809,"conditions":1810,"interventions":1812},"NCT03523767","Effect of Systemic Inflammation on Emotion and Cognition in Patients With Mood Disorder - A Vaccine Study",[88],"2020-02-07","2018-02-07",19,[1811],"Major Depressive Disorder",[1813,1796],"S.typhi",{"trials":1815,"activeCount":100},[1816],{"nctId":1817,"briefTitle":1818,"status":126,"phases":1819,"primaryCompletion":1820,"completion":1820,"start":1821,"enrollment":258,"conditions":1822,"interventions":1826},"NCT02247193","Botulinum Toxin to Improve Cosmesis of Primary Cleft Lip Repair",[88,89],"2020-01-13","2015-12",[1823,1824,1825],"Cleft Lip","Scarring","Cleft Palate",[1827,1796],"Botulinum Toxin Type A",{"trials":1829,"activeCount":100},[],{"trials":1831,"activeCount":100},[1832,1844,1855],{"nctId":1833,"briefTitle":1834,"status":141,"phases":1835,"primaryCompletion":1836,"completion":1836,"start":1837,"enrollment":1838,"conditions":1839,"interventions":1841},"NCT02120261","Using Saline for Myofascial Pain Syndromes (USAMPS)",[91],"2016-11","2014-05",51,[1840],"Myofascial Pain Syndrome",[1796,1842,1843],"Lidocaine Hydrochloride","Triamcinolone acetonide",{"nctId":1845,"briefTitle":1846,"status":789,"phases":1847,"primaryCompletion":1848,"completion":1848,"start":1849,"enrollment":100,"conditions":1850,"interventions":1852},"NCT03679481","The Effect of Tranexamic Acid on Blood Loss and Transfusion Requirements Following Open Femur Fracture Surgery",[91],"2021-04-01","2020-04-01",[1851],"Blood Loss Following Open Femur Fracture Surgery",[1853,1854],"Tranexamic acid","Normal saline",{"nctId":1856,"briefTitle":1857,"status":1858,"phases":1859,"primaryCompletion":1860,"completion":1861,"start":1862,"enrollment":1863,"conditions":1864,"interventions":1866},"NCT02773602","Dexamethasone or Clonidine as Adjuncts to Ropivacaine for Caudal Analgesia on Analgesia Duration in Children","UNKNOWN",[91],"2016-12","2017-12","2011-05",155,[1865],"Postoperative Pain",[1867,1868,1796],"Dexamethasone","Clonidine",{"trials":1870,"activeCount":100},[],{"intervention":227,"totalTrials":1797,"cells":1872},{"EARLY_PHASE1":1873,"PHASE1":1875,"PHASE2":1877,"PHASE3":1879,"PHASE4":1881,"NA":1933},{"trials":1874,"activeCount":100},[],{"trials":1876,"activeCount":100},[],{"trials":1878,"activeCount":100},[],{"trials":1880,"activeCount":100},[],{"trials":1882,"activeCount":100},[1883,1894,1907,1918,1922],{"nctId":1884,"briefTitle":1885,"status":126,"phases":1886,"primaryCompletion":1887,"completion":1887,"start":1888,"enrollment":1889,"conditions":1890,"interventions":1893},"NCT02904915","Paracervical Block Versus No Paracervical Block During IUD Insertion",[91],"2017-10-09","2017-01-12",50,[1891,1892],"Analgesia","IUD Insertion",[227],{"nctId":1895,"briefTitle":1896,"status":789,"phases":1897,"primaryCompletion":1898,"completion":1898,"start":1899,"enrollment":100,"conditions":1900,"interventions":1905},"NCT02822196","Serratus Anterior Muscle Plane Block vsThoracic Paravertebral Block For Unilateral Mastectomies",[91],"2019-12","2018-12",[1901,1902,1903,1904],"Breast Cancer","Mastectomy","Regional Anesthesia","Post Operative Pain",[227,1906],"Bupivacaine",{"nctId":1908,"briefTitle":1909,"status":126,"phases":1910,"primaryCompletion":1911,"completion":1911,"start":1912,"enrollment":1913,"conditions":1914,"interventions":1916},"NCT02240628","Combining Placing a Synera Patch With Propofol\u002FLidocaine Mixture to Decrease Pain With IV Propofol Injection",[91],"2015-09","2014-08",76,[1915],"Pain on IV Injection of Propofol.",[1917,227],"Saline",{"nctId":211,"briefTitle":212,"status":126,"phases":1919,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":1920,"interventions":1921},[91],[218],[220,221,198,222,223,224,225,226,227,228,229],{"nctId":1923,"briefTitle":1924,"status":126,"phases":1925,"primaryCompletion":1926,"completion":1926,"start":1927,"enrollment":1928,"conditions":1929,"interventions":1931},"NCT05844930","A Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft (ActiveMatrix) Verses Standard of Care in Adhesive Capsulitis of the Shoulder",[91],"2025-02-04","2023-01-03",56,[1930],"Adhesive Capsulitis",[1932,227],"Corticosteroid",{"trials":1934,"activeCount":100},[],{"intervention":1917,"totalTrials":96,"cells":1936},{"EARLY_PHASE1":1937,"PHASE1":1939,"PHASE2":1941,"PHASE3":1954,"PHASE4":1956,"NA":1985},{"trials":1938,"activeCount":100},[],{"trials":1940,"activeCount":100},[],{"trials":1942,"activeCount":100},[1943],{"nctId":1944,"briefTitle":1945,"status":126,"phases":1946,"primaryCompletion":1947,"completion":1947,"start":1948,"enrollment":19,"conditions":1949,"interventions":1951},"NCT01988584","Safety and Effectiveness of Banked Cord Blood or Bone Marrow Stem Cells in Children With Cerebral Palsy (CP).",[89],"2018-02-21","2013-11",[1950],"Cerebral Palsy",[1952,1917,1953],"umbilical cord blood (hUCB) cells","bone marrow derived mononuclear cells",{"trials":1955,"activeCount":100},[],{"trials":1957,"activeCount":100},[1958,1962,1974],{"nctId":1908,"briefTitle":1909,"status":126,"phases":1959,"primaryCompletion":1911,"completion":1911,"start":1912,"enrollment":1913,"conditions":1960,"interventions":1961},[91],[1915],[1917,227],{"nctId":1963,"briefTitle":1964,"status":789,"phases":1965,"primaryCompletion":1966,"completion":1966,"start":1967,"enrollment":100,"conditions":1968,"interventions":1973},"NCT04397458","Rescue Quadratus Lumborum Blocks for Post-cesarean Pain",[91],"2022-06-30","2022-01-01",[1969,1970,1971,1972],"Morphine","Analgesics","Analgesics, Opioid","Peripheral Nervous System Agents",[1917,1906,1867],{"nctId":1975,"briefTitle":1976,"status":126,"phases":1977,"primaryCompletion":1978,"completion":1978,"start":1979,"enrollment":1928,"conditions":1980,"interventions":1983},"NCT04187053","Clinical and Microbiologic Outcomes of aPDT in the Non-surgical Treatment of Implant Inflammation",[91],"2022-12-06","2020-02-14",[1981,1982],"DENT IMPLANTS","LASER",[1917,1984],"Methylene Blue",{"trials":1986,"activeCount":100},[],{"intervention":1988,"totalTrials":1620,"cells":1989},"Acetaminophen",{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":1996,"PHASE4":1998,"NA":2030},{"trials":1991,"activeCount":100},[],{"trials":1993,"activeCount":100},[],{"trials":1995,"activeCount":100},[],{"trials":1997,"activeCount":100},[],{"trials":1999,"activeCount":100},[2000,2008,2020],{"nctId":2001,"briefTitle":2002,"status":126,"phases":2003,"primaryCompletion":2004,"completion":2004,"start":2005,"enrollment":728,"conditions":2006,"interventions":2007},"NCT01598701","Intravenous Acetaminophen in Craniotomy",[91],"2016-03-30","2012-05-02",[1865],[1988],{"nctId":2009,"briefTitle":2010,"status":126,"phases":2011,"primaryCompletion":2012,"completion":2012,"start":2013,"enrollment":2014,"conditions":2015,"interventions":2017},"NCT03372382","Ibuprofen and Acetaminophen Versus Ibuprofen and Acetaminophen Plus Hydrocodone for Analgesia After Cesarean Section",[91],"2018-04-10","2017-12-13",170,[135,2016],"Pain, Postoperative",[2018,1988,2019],"Ibuprofen","Norco",{"nctId":2021,"briefTitle":2022,"status":126,"phases":2023,"primaryCompletion":2024,"completion":2024,"start":2025,"enrollment":2026,"conditions":2027,"interventions":2028},"NCT04790812","Preemptive Analgesia With Celecoxib for Acute Dental Pain Management",[91],"2023-03-01","2021-04-22",65,[2016],[2029,1988],"Celecoxib",{"trials":2031,"activeCount":100},[],{"intervention":1827,"totalTrials":145,"cells":2033},{"EARLY_PHASE1":2034,"PHASE1":2036,"PHASE2":2038,"PHASE3":2044,"PHASE4":2046,"NA":2061},{"trials":2035,"activeCount":100},[],{"trials":2037,"activeCount":100},[],{"trials":2039,"activeCount":100},[2040],{"nctId":1817,"briefTitle":1818,"status":126,"phases":2041,"primaryCompletion":1820,"completion":1820,"start":1821,"enrollment":258,"conditions":2042,"interventions":2043},[88,89],[1823,1824,1825],[1827,1796],{"trials":2045,"activeCount":100},[],{"trials":2047,"activeCount":100},[2048],{"nctId":2049,"briefTitle":2050,"status":126,"phases":2051,"primaryCompletion":2052,"completion":2052,"start":2053,"enrollment":2054,"conditions":2055,"interventions":2058},"NCT03799484","Botulinum Toxin Type A Injection After Topical Anesthesia Versus Petrolatum Ointment",[91],"2019-06-14","2019-01-04",14,[2056,2057],"Forehead Rhytides","Forehead Wrinkles",[2059,2060],"Botulinum toxin type A","2.5% lidocaine\u002F2.5% prilocaine",{"trials":2062,"activeCount":100},[],{"intervention":2064,"totalTrials":145,"cells":2065},"Bupivacaine hydrochloride",{"EARLY_PHASE1":2066,"PHASE1":2068,"PHASE2":2070,"PHASE3":2072,"PHASE4":2074,"NA":2098},{"trials":2067,"activeCount":100},[],{"trials":2069,"activeCount":100},[],{"trials":2071,"activeCount":100},[],{"trials":2073,"activeCount":100},[],{"trials":2075,"activeCount":100},[2076,2088],{"nctId":2077,"briefTitle":2078,"status":126,"phases":2079,"primaryCompletion":2080,"completion":2081,"start":2082,"enrollment":2083,"conditions":2084,"interventions":2085},"NCT02111746","PAIN - Postoperative Analgesia INvestigation",[91],"2017-05-03","2017-06-30","2013-11-20",350,[1865],[2086,2064,2087],"Exparel","Patient Controlled Analgesia",{"nctId":2089,"briefTitle":2090,"status":141,"phases":2091,"primaryCompletion":2092,"completion":2092,"start":2093,"enrollment":1620,"conditions":2094,"interventions":2095},"NCT04368364","A Randomized Control Trial Comparing Analgesic Benefits of Ultrasound-guided Single vs Continuous Quadratus Lumborum Blocks (QLB)vs Intrathecal Morphine(ITM) for Post Cesarean Section Pain",[91],"2020-06-29","2020-05-22",[2016],[2096,2064,2097],"Intrathecal morphine sulfate","ropivacaine hydrochloride",{"trials":2099,"activeCount":100},[],{"intervention":2101,"totalTrials":145,"cells":2102},"Exenatide",{"EARLY_PHASE1":2103,"PHASE1":2105,"PHASE2":2107,"PHASE3":2119,"PHASE4":2121,"NA":2134},{"trials":2104,"activeCount":100},[],{"trials":2106,"activeCount":100},[],{"trials":2108,"activeCount":100},[2109],{"nctId":2110,"briefTitle":2111,"status":126,"phases":2112,"primaryCompletion":2113,"completion":2113,"start":2114,"enrollment":2115,"conditions":2116,"interventions":2117},"NCT02975297","Exenatide Once Weekly for Smoking Cessation",[88,89],"2020-01-03","2016-07",84,[32],[2101,2118],"NRT",{"trials":2120,"activeCount":100},[],{"trials":2122,"activeCount":100},[2123],{"nctId":2124,"briefTitle":2125,"status":126,"phases":2126,"primaryCompletion":2127,"completion":2127,"start":2128,"enrollment":16,"conditions":2129,"interventions":2131},"NCT02104739","Effects of Antidiabetic Medications on the Postprandial State in Prediabetes",[91],"2017-03","2014-04",[2130,18],"Prediabetes",[2101,2132,2133],"Saxagliptin","Exenatide extended-release",{"trials":2135,"activeCount":100},[],{"intervention":1906,"totalTrials":145,"cells":2137},{"EARLY_PHASE1":2138,"PHASE1":2140,"PHASE2":2142,"PHASE3":2144,"PHASE4":2146,"NA":2156},{"trials":2139,"activeCount":100},[],{"trials":2141,"activeCount":100},[],{"trials":2143,"activeCount":100},[],{"trials":2145,"activeCount":100},[],{"trials":2147,"activeCount":100},[2148,2152],{"nctId":1895,"briefTitle":1896,"status":789,"phases":2149,"primaryCompletion":1898,"completion":1898,"start":1899,"enrollment":100,"conditions":2150,"interventions":2151},[91],[1901,1902,1903,1904],[227,1906],{"nctId":1963,"briefTitle":1964,"status":789,"phases":2153,"primaryCompletion":1966,"completion":1966,"start":1967,"enrollment":100,"conditions":2154,"interventions":2155},[91],[1969,1970,1971,1972],[1917,1906,1867],{"trials":2157,"activeCount":100},[],{"intervention":2159,"totalTrials":145,"cells":2160},"Botox",{"EARLY_PHASE1":2161,"PHASE1":2175,"PHASE2":2177,"PHASE3":2179,"PHASE4":2181,"NA":2194},{"trials":2162,"activeCount":100},[2163],{"nctId":2164,"briefTitle":2165,"status":789,"phases":2166,"primaryCompletion":2167,"completion":2167,"start":2168,"enrollment":100,"conditions":2169,"interventions":2173},"NCT01520441","BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)\u002FBenign Prostatic Hyperplasia (BPH)",[87],"2014-03","2011-03",[2170,2171,2172],"Prostate Cancer","Benign Prostatic Hyperplasia","Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)",[2174],"BOTOX",{"trials":2176,"activeCount":100},[],{"trials":2178,"activeCount":100},[],{"trials":2180,"activeCount":100},[],{"trials":2182,"activeCount":100},[2183],{"nctId":2184,"briefTitle":2185,"status":126,"phases":2186,"primaryCompletion":2187,"completion":2187,"start":2188,"enrollment":2189,"conditions":2190,"interventions":2193},"NCT00178646","Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity",[91],"2010-03","2002-01",33,[15,2191,2192],"Brain Injuries","Spasticity",[2159],{"trials":2195,"activeCount":100},[],{"intervention":2029,"totalTrials":145,"cells":2197},{"EARLY_PHASE1":2198,"PHASE1":2200,"PHASE2":2202,"PHASE3":2215,"PHASE4":2217,"NA":2223},{"trials":2199,"activeCount":100},[],{"trials":2201,"activeCount":100},[],{"trials":2203,"activeCount":100},[2204],{"nctId":2205,"briefTitle":2206,"status":141,"phases":2207,"primaryCompletion":2208,"completion":2208,"start":2209,"enrollment":2210,"conditions":2211,"interventions":2213},"NCT04115098","Individualizing Anti-Inflammatory Medications for Adults With Axial Spondyloarthritis: A Series of N-of 1 Trials",[89],"2023-08-11","2020-06-25",42,[2212],"Axial Spondyloarthritis",[2029,223,2214],"Meloxicam",{"trials":2216,"activeCount":100},[],{"trials":2218,"activeCount":100},[2219],{"nctId":2021,"briefTitle":2022,"status":126,"phases":2220,"primaryCompletion":2024,"completion":2024,"start":2025,"enrollment":2026,"conditions":2221,"interventions":2222},[91],[2016],[2029,1988],{"trials":2224,"activeCount":100},[],{"intervention":223,"totalTrials":145,"cells":2226},{"EARLY_PHASE1":2227,"PHASE1":2229,"PHASE2":2231,"PHASE3":2237,"PHASE4":2239,"NA":2245},{"trials":2228,"activeCount":100},[],{"trials":2230,"activeCount":100},[],{"trials":2232,"activeCount":100},[2233],{"nctId":2205,"briefTitle":2206,"status":141,"phases":2234,"primaryCompletion":2208,"completion":2208,"start":2209,"enrollment":2210,"conditions":2235,"interventions":2236},[89],[2212],[2029,223,2214],{"trials":2238,"activeCount":100},[],{"trials":2240,"activeCount":100},[2241],{"nctId":211,"briefTitle":212,"status":126,"phases":2242,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":2243,"interventions":2244},[91],[218],[220,221,198,222,223,224,225,226,227,228,229],{"trials":2246,"activeCount":100},[],{"intervention":1867,"totalTrials":145,"cells":2248},{"EARLY_PHASE1":2249,"PHASE1":2251,"PHASE2":2253,"PHASE3":2255,"PHASE4":2257,"NA":2267},{"trials":2250,"activeCount":100},[],{"trials":2252,"activeCount":100},[],{"trials":2254,"activeCount":100},[],{"trials":2256,"activeCount":100},[],{"trials":2258,"activeCount":100},[2259,2263],{"nctId":1963,"briefTitle":1964,"status":789,"phases":2260,"primaryCompletion":1966,"completion":1966,"start":1967,"enrollment":100,"conditions":2261,"interventions":2262},[91],[1969,1970,1971,1972],[1917,1906,1867],{"nctId":1856,"briefTitle":1857,"status":1858,"phases":2264,"primaryCompletion":1860,"completion":1861,"start":1862,"enrollment":1863,"conditions":2265,"interventions":2266},[91],[1865],[1867,1868,1796],{"trials":2268,"activeCount":100},[],{"intervention":1868,"totalTrials":145,"cells":2270},{"EARLY_PHASE1":2271,"PHASE1":2273,"PHASE2":2275,"PHASE3":2277,"PHASE4":2279,"NA":2295},{"trials":2272,"activeCount":100},[],{"trials":2274,"activeCount":100},[],{"trials":2276,"activeCount":100},[],{"trials":2278,"activeCount":100},[],{"trials":2280,"activeCount":100},[2281,2291],{"nctId":2282,"briefTitle":2283,"status":126,"phases":2284,"primaryCompletion":2285,"completion":2285,"start":2286,"enrollment":2287,"conditions":2288,"interventions":2290},"NCT05575219","Protocolized Initiation of Clonidine to Prevent Dexmedetomidine Withdrawal",[91],"2024-02-15","2022-10-08",128,[2289],"Withdrawal; Therapeutic Substance",[1868,1868],{"nctId":1856,"briefTitle":1857,"status":1858,"phases":2292,"primaryCompletion":1860,"completion":1861,"start":1862,"enrollment":1863,"conditions":2293,"interventions":2294},[91],[1865],[1867,1868,1796],{"trials":2296,"activeCount":100},[],{"intervention":2298,"totalTrials":145,"cells":2299},"Methylphenidate",{"EARLY_PHASE1":2300,"PHASE1":2302,"PHASE2":2304,"PHASE3":2313,"PHASE4":2315,"NA":2331},{"trials":2301,"activeCount":100},[],{"trials":2303,"activeCount":100},[],{"trials":2305,"activeCount":100},[2306],{"nctId":2307,"briefTitle":2308,"status":126,"phases":2309,"primaryCompletion":1821,"completion":1821,"start":2168,"enrollment":1889,"conditions":2310,"interventions":2311},"NCT01267292","Psychopharmacology for Cocaine Dependence - Buspirone",[89],[1587],[2312,2298],"Buspirone",{"trials":2314,"activeCount":100},[],{"trials":2316,"activeCount":100},[2317],{"nctId":2318,"briefTitle":2319,"status":126,"phases":2320,"primaryCompletion":2321,"completion":2321,"start":2322,"enrollment":2323,"conditions":2324,"interventions":2327},"NCT01133847","Interventions for Children With Attention and Reading Disorders",[91],"2015-06","2010-11",222,[2325,2326],"Attention Deficit Hyperactivity Disorder","Reading Disabilities",[2298,2328,2329,2330],"Mixed Salt Amphetamine","Atomoxetine","Guanfacine",{"trials":2332,"activeCount":100},[],{"intervention":2019,"totalTrials":145,"cells":2334},{"EARLY_PHASE1":2335,"PHASE1":2337,"PHASE2":2339,"PHASE3":2341,"PHASE4":2343,"NA":2359},{"trials":2336,"activeCount":100},[],{"trials":2338,"activeCount":100},[],{"trials":2340,"activeCount":100},[],{"trials":2342,"activeCount":100},[],{"trials":2344,"activeCount":100},[2345,2349],{"nctId":2009,"briefTitle":2010,"status":126,"phases":2346,"primaryCompletion":2012,"completion":2012,"start":2013,"enrollment":2014,"conditions":2347,"interventions":2348},[91],[135,2016],[2018,1988,2019],{"nctId":2350,"briefTitle":2351,"status":126,"phases":2352,"primaryCompletion":130,"completion":2353,"start":2354,"enrollment":728,"conditions":2355,"interventions":2357},"NCT03605914","Are NSAIDs Effective Enough for Postoperative Pain Control After Functional Endoscopic Sinus Surgery and Septoplasty",[91],"2020-07-05","2018-08-01",[2356],"Pain Control After Functional Endoscopic Sinus Surgery and Septoplasty",[2358,2019],"diclofenac",{"trials":2360,"activeCount":100},[],{"intervention":2362,"totalTrials":120,"cells":2363},"Local anesthesia at incision site",{"EARLY_PHASE1":2364,"PHASE1":2366,"PHASE2":2368,"PHASE3":2370,"PHASE4":2372,"NA":2386},{"trials":2365,"activeCount":100},[],{"trials":2367,"activeCount":100},[],{"trials":2369,"activeCount":100},[],{"trials":2371,"activeCount":100},[],{"trials":2373,"activeCount":100},[2374],{"nctId":2375,"briefTitle":2376,"status":126,"phases":2377,"primaryCompletion":2378,"completion":2379,"start":2380,"enrollment":1913,"conditions":2381,"interventions":2382},"NCT05480111","The Role of Quadratus Lumborum Blocks Following Minimally Invasive Hysterectomy",[91],"2023-02-24","2023-04-07","2022-09-07",[2016],[2362,2383,2384,2385],"Sham QL","Sham Local","QL",{"trials":2387,"activeCount":100},[],{"intervention":2383,"totalTrials":120,"cells":2389},{"EARLY_PHASE1":2390,"PHASE1":2392,"PHASE2":2394,"PHASE3":2396,"PHASE4":2398,"NA":2404},{"trials":2391,"activeCount":100},[],{"trials":2393,"activeCount":100},[],{"trials":2395,"activeCount":100},[],{"trials":2397,"activeCount":100},[],{"trials":2399,"activeCount":100},[2400],{"nctId":2375,"briefTitle":2376,"status":126,"phases":2401,"primaryCompletion":2378,"completion":2379,"start":2380,"enrollment":1913,"conditions":2402,"interventions":2403},[91],[2016],[2362,2383,2384,2385],{"trials":2405,"activeCount":100},[],{"intervention":2384,"totalTrials":120,"cells":2407},{"EARLY_PHASE1":2408,"PHASE1":2410,"PHASE2":2412,"PHASE3":2414,"PHASE4":2416,"NA":2422},{"trials":2409,"activeCount":100},[],{"trials":2411,"activeCount":100},[],{"trials":2413,"activeCount":100},[],{"trials":2415,"activeCount":100},[],{"trials":2417,"activeCount":100},[2418],{"nctId":2375,"briefTitle":2376,"status":126,"phases":2419,"primaryCompletion":2378,"completion":2379,"start":2380,"enrollment":1913,"conditions":2420,"interventions":2421},[91],[2016],[2362,2383,2384,2385],{"trials":2423,"activeCount":100},[],{"intervention":2385,"totalTrials":120,"cells":2425},{"EARLY_PHASE1":2426,"PHASE1":2428,"PHASE2":2430,"PHASE3":2432,"PHASE4":2434,"NA":2440},{"trials":2427,"activeCount":100},[],{"trials":2429,"activeCount":100},[],{"trials":2431,"activeCount":100},[],{"trials":2433,"activeCount":100},[],{"trials":2435,"activeCount":100},[2436],{"nctId":2375,"briefTitle":2376,"status":126,"phases":2437,"primaryCompletion":2378,"completion":2379,"start":2380,"enrollment":1913,"conditions":2438,"interventions":2439},[91],[2016],[2362,2383,2384,2385],{"trials":2441,"activeCount":100},[],{"intervention":2443,"totalTrials":120,"cells":2444},"Rifaximin",{"EARLY_PHASE1":2445,"PHASE1":2447,"PHASE2":2449,"PHASE3":2451,"PHASE4":2453,"NA":2463},{"trials":2446,"activeCount":100},[],{"trials":2448,"activeCount":100},[],{"trials":2450,"activeCount":100},[],{"trials":2452,"activeCount":100},[],{"trials":2454,"activeCount":100},[2455],{"nctId":2456,"briefTitle":2457,"status":789,"phases":2458,"primaryCompletion":2459,"completion":2459,"start":2459,"enrollment":100,"conditions":2460,"interventions":2462},"NCT00875875","Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea",[91],"2009-06",[2461],"Travelers' Diarrhea",[2443],{"trials":2464,"activeCount":100},[],{"intervention":2466,"totalTrials":120,"cells":2467},"Intralipid, 20% Intravenous Emulsion",{"EARLY_PHASE1":2468,"PHASE1":2470,"PHASE2":2472,"PHASE3":2474,"PHASE4":2476,"NA":2489},{"trials":2469,"activeCount":100},[],{"trials":2471,"activeCount":100},[],{"trials":2473,"activeCount":100},[],{"trials":2475,"activeCount":100},[],{"trials":2477,"activeCount":100},[2478],{"nctId":2479,"briefTitle":2480,"status":126,"phases":2481,"primaryCompletion":2482,"completion":2482,"start":2483,"enrollment":2484,"conditions":2485,"interventions":2487},"NCT03857646","The Effect of Lipid Emulsions on Free Fatty Acids and Free Bilirubin in Premature Newborns",[91],"2020-06-11","2019-03-02",66,[2486],"Prematurity",[2466,2488],"Soybean oil Medium-chain triglycerides Olive oil Fish Oil (SMOF) lipid",{"trials":2490,"activeCount":100},[],{"intervention":2488,"totalTrials":120,"cells":2492},{"EARLY_PHASE1":2493,"PHASE1":2495,"PHASE2":2497,"PHASE3":2499,"PHASE4":2501,"NA":2507},{"trials":2494,"activeCount":100},[],{"trials":2496,"activeCount":100},[],{"trials":2498,"activeCount":100},[],{"trials":2500,"activeCount":100},[],{"trials":2502,"activeCount":100},[2503],{"nctId":2479,"briefTitle":2480,"status":126,"phases":2504,"primaryCompletion":2482,"completion":2482,"start":2483,"enrollment":2484,"conditions":2505,"interventions":2506},[91],[2486],[2466,2488],{"trials":2508,"activeCount":100},[],{"intervention":2510,"totalTrials":120,"cells":2511},"B\u002FFTC\u002FTAF",{"EARLY_PHASE1":2512,"PHASE1":2514,"PHASE2":2516,"PHASE3":2518,"PHASE4":2520,"NA":2532},{"trials":2513,"activeCount":100},[],{"trials":2515,"activeCount":100},[],{"trials":2517,"activeCount":100},[],{"trials":2519,"activeCount":100},[],{"trials":2521,"activeCount":100},[2522],{"nctId":2523,"briefTitle":2524,"status":141,"phases":2525,"primaryCompletion":2526,"completion":2526,"start":2527,"enrollment":2528,"conditions":2529,"interventions":2530},"NCT03348163","(mo)BETTA Trial in Transwomen for Optimization of ART",[91],"2020-12-15","2018-06-06",26,[24],[2510,2531],"Current ART",{"trials":2533,"activeCount":100},[],{"intervention":2531,"totalTrials":120,"cells":2535},{"EARLY_PHASE1":2536,"PHASE1":2538,"PHASE2":2540,"PHASE3":2542,"PHASE4":2544,"NA":2550},{"trials":2537,"activeCount":100},[],{"trials":2539,"activeCount":100},[],{"trials":2541,"activeCount":100},[],{"trials":2543,"activeCount":100},[],{"trials":2545,"activeCount":100},[2546],{"nctId":2523,"briefTitle":2524,"status":141,"phases":2547,"primaryCompletion":2526,"completion":2526,"start":2527,"enrollment":2528,"conditions":2548,"interventions":2549},[91],[24],[2510,2531],{"trials":2551,"activeCount":100},[],{"intervention":2553,"totalTrials":120,"cells":2554},"Standard of Care",{"EARLY_PHASE1":2555,"PHASE1":2557,"PHASE2":2559,"PHASE3":2561,"PHASE4":2563,"NA":2575},{"trials":2556,"activeCount":100},[],{"trials":2558,"activeCount":100},[],{"trials":2560,"activeCount":100},[],{"trials":2562,"activeCount":100},[],{"trials":2564,"activeCount":100},[2565],{"nctId":2566,"briefTitle":2567,"status":141,"phases":2568,"primaryCompletion":2569,"completion":2569,"start":2570,"enrollment":2571,"conditions":2572,"interventions":2573},"NCT05820685","Dronabinol On the Pain Experience",[91],"2024-04-29","2023-07-27",484,[133],[2553,2574],"Dronabinol",{"trials":2576,"activeCount":100},[],{"intervention":2574,"totalTrials":120,"cells":2578},{"EARLY_PHASE1":2579,"PHASE1":2581,"PHASE2":2583,"PHASE3":2585,"PHASE4":2587,"NA":2593},{"trials":2580,"activeCount":100},[],{"trials":2582,"activeCount":100},[],{"trials":2584,"activeCount":100},[],{"trials":2586,"activeCount":100},[],{"trials":2588,"activeCount":100},[2589],{"nctId":2566,"briefTitle":2567,"status":141,"phases":2590,"primaryCompletion":2569,"completion":2569,"start":2570,"enrollment":2571,"conditions":2591,"interventions":2592},[91],[133],[2553,2574],{"trials":2594,"activeCount":100},[],{"intervention":2596,"totalTrials":120,"cells":2597},"30 ml of 0.2% ropivacaine",{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2602,"PHASE3":2604,"PHASE4":2606,"NA":2620},{"trials":2599,"activeCount":100},[],{"trials":2601,"activeCount":100},[],{"trials":2603,"activeCount":100},[],{"trials":2605,"activeCount":100},[],{"trials":2607,"activeCount":100},[2608],{"nctId":2609,"briefTitle":2610,"status":126,"phases":2611,"primaryCompletion":2612,"completion":2612,"start":2613,"enrollment":2614,"conditions":2615,"interventions":2617},"NCT03704376","Clinical Comparison of Femoral Nerve Versus Adductor Canal Block Following Anterior Ligament Reconstruction",[91],"2017-11-16","2016-02-01",125,[2616],"Anterior Cruciate Ligament Injury",[2596,2618,2619],"15 ml of 0.2% ropivacaine","100 mcg clonidine",{"trials":2621,"activeCount":100},[],{"intervention":2618,"totalTrials":120,"cells":2623},{"EARLY_PHASE1":2624,"PHASE1":2626,"PHASE2":2628,"PHASE3":2630,"PHASE4":2632,"NA":2638},{"trials":2625,"activeCount":100},[],{"trials":2627,"activeCount":100},[],{"trials":2629,"activeCount":100},[],{"trials":2631,"activeCount":100},[],{"trials":2633,"activeCount":100},[2634],{"nctId":2609,"briefTitle":2610,"status":126,"phases":2635,"primaryCompletion":2612,"completion":2612,"start":2613,"enrollment":2614,"conditions":2636,"interventions":2637},[91],[2616],[2596,2618,2619],{"trials":2639,"activeCount":100},[],{"intervention":2619,"totalTrials":120,"cells":2641},{"EARLY_PHASE1":2642,"PHASE1":2644,"PHASE2":2646,"PHASE3":2648,"PHASE4":2650,"NA":2656},{"trials":2643,"activeCount":100},[],{"trials":2645,"activeCount":100},[],{"trials":2647,"activeCount":100},[],{"trials":2649,"activeCount":100},[],{"trials":2651,"activeCount":100},[2652],{"nctId":2609,"briefTitle":2610,"status":126,"phases":2653,"primaryCompletion":2612,"completion":2612,"start":2613,"enrollment":2614,"conditions":2654,"interventions":2655},[91],[2616],[2596,2618,2619],{"trials":2657,"activeCount":100},[],{"intervention":2659,"totalTrials":120,"cells":2660},"bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole",{"EARLY_PHASE1":2661,"PHASE1":2663,"PHASE2":2665,"PHASE3":2667,"PHASE4":2669,"NA":2680},{"trials":2662,"activeCount":100},[],{"trials":2664,"activeCount":100},[],{"trials":2666,"activeCount":100},[],{"trials":2668,"activeCount":100},[],{"trials":2670,"activeCount":100},[2671],{"nctId":2672,"briefTitle":2673,"status":1858,"phases":2674,"primaryCompletion":2675,"completion":2676,"start":2168,"enrollment":1889,"conditions":2677,"interventions":2679},"NCT01335334","H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study",[91],"2011-06","2011-08",[2678],"H. Pylori Infection",[2659],{"trials":2681,"activeCount":100},[],{"intervention":2683,"totalTrials":120,"cells":2684},"Rifaximin and loperamide",{"EARLY_PHASE1":2685,"PHASE1":2687,"PHASE2":2689,"PHASE3":2691,"PHASE4":2693,"NA":2704},{"trials":2686,"activeCount":100},[],{"trials":2688,"activeCount":100},[],{"trials":2690,"activeCount":100},[],{"trials":2692,"activeCount":100},[],{"trials":2694,"activeCount":100},[2695],{"nctId":2696,"briefTitle":2697,"status":126,"phases":2698,"completion":2699,"start":2700,"enrollment":2701,"conditions":2702,"interventions":2703},"NCT00292344","Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea",[91],"2005-08","2004-06",316,[2461],[2683],{"trials":2705,"activeCount":100},[],{"intervention":2707,"totalTrials":120,"cells":2708},"Botulinum neurotoxin",{"EARLY_PHASE1":2709,"PHASE1":2711,"PHASE2":2713,"PHASE3":2715,"PHASE4":2717,"NA":2728},{"trials":2710,"activeCount":100},[],{"trials":2712,"activeCount":100},[],{"trials":2714,"activeCount":100},[],{"trials":2716,"activeCount":100},[],{"trials":2718,"activeCount":100},[2719],{"nctId":2720,"briefTitle":2721,"status":126,"phases":2722,"primaryCompletion":2723,"completion":2723,"start":2724,"enrollment":2725,"conditions":2726,"interventions":2727},"NCT03302741","Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface EMG Recordings",[91],"2019-11-18","2017-11-21",17,[2192],[2707],{"trials":2729,"activeCount":100},[],{"intervention":2086,"totalTrials":120,"cells":2731},{"EARLY_PHASE1":2732,"PHASE1":2734,"PHASE2":2736,"PHASE3":2738,"PHASE4":2740,"NA":2746},{"trials":2733,"activeCount":100},[],{"trials":2735,"activeCount":100},[],{"trials":2737,"activeCount":100},[],{"trials":2739,"activeCount":100},[],{"trials":2741,"activeCount":100},[2742],{"nctId":2077,"briefTitle":2078,"status":126,"phases":2743,"primaryCompletion":2080,"completion":2081,"start":2082,"enrollment":2083,"conditions":2744,"interventions":2745},[91],[1865],[2086,2064,2087],{"trials":2747,"activeCount":100},[],{"intervention":2087,"totalTrials":120,"cells":2749},{"EARLY_PHASE1":2750,"PHASE1":2752,"PHASE2":2754,"PHASE3":2756,"PHASE4":2758,"NA":2764},{"trials":2751,"activeCount":100},[],{"trials":2753,"activeCount":100},[],{"trials":2755,"activeCount":100},[],{"trials":2757,"activeCount":100},[],{"trials":2759,"activeCount":100},[2760],{"nctId":2077,"briefTitle":2078,"status":126,"phases":2761,"primaryCompletion":2080,"completion":2081,"start":2082,"enrollment":2083,"conditions":2762,"interventions":2763},[91],[1865],[2086,2064,2087],{"trials":2765,"activeCount":100},[],{"intervention":2767,"totalTrials":120,"cells":2768},"SCTG",{"EARLY_PHASE1":2769,"PHASE1":2771,"PHASE2":2773,"PHASE3":2775,"PHASE4":2777,"NA":2791},{"trials":2770,"activeCount":100},[],{"trials":2772,"activeCount":100},[],{"trials":2774,"activeCount":100},[],{"trials":2776,"activeCount":100},[],{"trials":2778,"activeCount":100},[2779],{"nctId":2780,"briefTitle":2781,"status":126,"phases":2782,"primaryCompletion":190,"completion":190,"start":2783,"enrollment":2784,"conditions":2785,"interventions":2789},"NCT02864862","Esthetic Outcomes Following Immediate Implant Combine With Soft Tissue Augmentation",[91],"2016-10",46,[2786,2787,2788],"Dental Implant","Immediate Dental Implant","Soft Tissue Augmentation",[2767,2790],"ADM",{"trials":2792,"activeCount":100},[],{"intervention":2790,"totalTrials":120,"cells":2794},{"EARLY_PHASE1":2795,"PHASE1":2797,"PHASE2":2799,"PHASE3":2801,"PHASE4":2803,"NA":2809},{"trials":2796,"activeCount":100},[],{"trials":2798,"activeCount":100},[],{"trials":2800,"activeCount":100},[],{"trials":2802,"activeCount":100},[],{"trials":2804,"activeCount":100},[2805],{"nctId":2780,"briefTitle":2781,"status":126,"phases":2806,"primaryCompletion":190,"completion":190,"start":2783,"enrollment":2784,"conditions":2807,"interventions":2808},[91],[2786,2787,2788],[2767,2790],{"trials":2810,"activeCount":100},[],{"intervention":2812,"totalTrials":120,"cells":2813},"Propranolol three times a day",{"EARLY_PHASE1":2814,"PHASE1":2816,"PHASE2":2818,"PHASE3":2820,"PHASE4":2822,"NA":2837},{"trials":2815,"activeCount":100},[],{"trials":2817,"activeCount":100},[],{"trials":2819,"activeCount":100},[],{"trials":2821,"activeCount":100},[],{"trials":2823,"activeCount":100},[2824],{"nctId":2825,"briefTitle":2826,"status":141,"phases":2827,"primaryCompletion":2828,"completion":2829,"start":2830,"enrollment":2831,"conditions":2832,"interventions":2834},"NCT05479123","Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas",[91],"2025-03-31","2025-07-31","2022-06-23",52,[2833],"Infantile Hemangioma",[2812,2835,2836],"Propranolol twice a day","Timolol",{"trials":2838,"activeCount":100},[],{"intervention":2835,"totalTrials":120,"cells":2840},{"EARLY_PHASE1":2841,"PHASE1":2843,"PHASE2":2845,"PHASE3":2847,"PHASE4":2849,"NA":2855},{"trials":2842,"activeCount":100},[],{"trials":2844,"activeCount":100},[],{"trials":2846,"activeCount":100},[],{"trials":2848,"activeCount":100},[],{"trials":2850,"activeCount":100},[2851],{"nctId":2825,"briefTitle":2826,"status":141,"phases":2852,"primaryCompletion":2828,"completion":2829,"start":2830,"enrollment":2831,"conditions":2853,"interventions":2854},[91],[2833],[2812,2835,2836],{"trials":2856,"activeCount":100},[],{"intervention":2836,"totalTrials":120,"cells":2858},{"EARLY_PHASE1":2859,"PHASE1":2861,"PHASE2":2863,"PHASE3":2865,"PHASE4":2867,"NA":2873},{"trials":2860,"activeCount":100},[],{"trials":2862,"activeCount":100},[],{"trials":2864,"activeCount":100},[],{"trials":2866,"activeCount":100},[],{"trials":2868,"activeCount":100},[2869],{"nctId":2825,"briefTitle":2826,"status":141,"phases":2870,"primaryCompletion":2828,"completion":2829,"start":2830,"enrollment":2831,"conditions":2871,"interventions":2872},[91],[2833],[2812,2835,2836],{"trials":2874,"activeCount":100},[],{"intervention":2876,"totalTrials":120,"cells":2877},"Ambisome",{"EARLY_PHASE1":2878,"PHASE1":2880,"PHASE2":2882,"PHASE3":2884,"PHASE4":2886,"NA":2896},{"trials":2879,"activeCount":100},[],{"trials":2881,"activeCount":100},[],{"trials":2883,"activeCount":100},[],{"trials":2885,"activeCount":100},[],{"trials":2887,"activeCount":100},[2888],{"nctId":2889,"briefTitle":2890,"status":141,"phases":2891,"completion":1582,"start":2892,"enrollment":35,"conditions":2893,"interventions":2895},"NCT00161356","Ambisome in Liver Transplant Patients",[91],"2005-09",[2894],"Liver Transplantation",[2876],{"trials":2897,"activeCount":100},[],{"intervention":2899,"totalTrials":120,"cells":2900},"Neutral Protamine Hagedorn",{"EARLY_PHASE1":2901,"PHASE1":2903,"PHASE2":2905,"PHASE3":2907,"PHASE4":2909,"NA":2922},{"trials":2902,"activeCount":100},[],{"trials":2904,"activeCount":100},[],{"trials":2906,"activeCount":100},[],{"trials":2908,"activeCount":100},[],{"trials":2910,"activeCount":100},[2911],{"nctId":2912,"briefTitle":2913,"status":126,"phases":2914,"primaryCompletion":2915,"completion":2915,"start":2916,"enrollment":2917,"conditions":2918,"interventions":2920},"NCT03620890","Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy",[91],"2020-07-29","2018-09-04",108,[2919],"Diabetes Mellitus, Type 2",[2899,2921],"Detemir insulin",{"trials":2923,"activeCount":100},[],{"intervention":2921,"totalTrials":120,"cells":2925},{"EARLY_PHASE1":2926,"PHASE1":2928,"PHASE2":2930,"PHASE3":2932,"PHASE4":2934,"NA":2940},{"trials":2927,"activeCount":100},[],{"trials":2929,"activeCount":100},[],{"trials":2931,"activeCount":100},[],{"trials":2933,"activeCount":100},[],{"trials":2935,"activeCount":100},[2936],{"nctId":2912,"briefTitle":2913,"status":126,"phases":2937,"primaryCompletion":2915,"completion":2915,"start":2916,"enrollment":2917,"conditions":2938,"interventions":2939},[91],[2919],[2899,2921],{"trials":2941,"activeCount":100},[],{"intervention":2132,"totalTrials":120,"cells":2943},{"EARLY_PHASE1":2944,"PHASE1":2946,"PHASE2":2948,"PHASE3":2950,"PHASE4":2952,"NA":2958},{"trials":2945,"activeCount":100},[],{"trials":2947,"activeCount":100},[],{"trials":2949,"activeCount":100},[],{"trials":2951,"activeCount":100},[],{"trials":2953,"activeCount":100},[2954],{"nctId":2124,"briefTitle":2125,"status":126,"phases":2955,"primaryCompletion":2127,"completion":2127,"start":2128,"enrollment":16,"conditions":2956,"interventions":2957},[91],[2130,18],[2101,2132,2133],{"trials":2959,"activeCount":100},[],{"intervention":2133,"totalTrials":120,"cells":2961},{"EARLY_PHASE1":2962,"PHASE1":2964,"PHASE2":2966,"PHASE3":2968,"PHASE4":2970,"NA":2976},{"trials":2963,"activeCount":100},[],{"trials":2965,"activeCount":100},[],{"trials":2967,"activeCount":100},[],{"trials":2969,"activeCount":100},[],{"trials":2971,"activeCount":100},[2972],{"nctId":2124,"briefTitle":2125,"status":126,"phases":2973,"primaryCompletion":2127,"completion":2127,"start":2128,"enrollment":16,"conditions":2974,"interventions":2975},[91],[2130,18],[2101,2132,2133],{"trials":2977,"activeCount":100},[],{"intervention":2979,"totalTrials":120,"cells":2980},"2% lidocaine with 1:200,000 epinephrine and epidural morphine",{"EARLY_PHASE1":2981,"PHASE1":2983,"PHASE2":2985,"PHASE3":2987,"PHASE4":2989,"NA":3005},{"trials":2982,"activeCount":100},[],{"trials":2984,"activeCount":100},[],{"trials":2986,"activeCount":100},[],{"trials":2988,"activeCount":100},[],{"trials":2990,"activeCount":100},[2991],{"nctId":2992,"briefTitle":2993,"status":126,"phases":2994,"primaryCompletion":2995,"completion":2996,"start":2997,"enrollment":2998,"conditions":2999,"interventions":3003},"NCT04369950","Post-cesarean Analgesia With Epidural Morphine Following Epidural 2-chloroprocaine",[91],"2021-05-11","2021-07-11","2020-05-11",44,[3000,1969,1970,1971,3001,3002],"Physiological Effect of Drugs","Central Nervous System Depressants","Narcotics",[2979,3004],"3% 2-chloroprocaine and epidural morphine",{"trials":3006,"activeCount":100},[],{"intervention":3004,"totalTrials":120,"cells":3008},{"EARLY_PHASE1":3009,"PHASE1":3011,"PHASE2":3013,"PHASE3":3015,"PHASE4":3017,"NA":3023},{"trials":3010,"activeCount":100},[],{"trials":3012,"activeCount":100},[],{"trials":3014,"activeCount":100},[],{"trials":3016,"activeCount":100},[],{"trials":3018,"activeCount":100},[3019],{"nctId":2992,"briefTitle":2993,"status":126,"phases":3020,"primaryCompletion":2995,"completion":2996,"start":2997,"enrollment":2998,"conditions":3021,"interventions":3022},[91],[3000,1969,1970,1971,3001,3002],[2979,3004],{"trials":3024,"activeCount":100},[],{"intervention":1842,"totalTrials":120,"cells":3026},{"EARLY_PHASE1":3027,"PHASE1":3029,"PHASE2":3031,"PHASE3":3033,"PHASE4":3035,"NA":3041},{"trials":3028,"activeCount":100},[],{"trials":3030,"activeCount":100},[],{"trials":3032,"activeCount":100},[],{"trials":3034,"activeCount":100},[],{"trials":3036,"activeCount":100},[3037],{"nctId":1833,"briefTitle":1834,"status":141,"phases":3038,"primaryCompletion":1836,"completion":1836,"start":1837,"enrollment":1838,"conditions":3039,"interventions":3040},[91],[1840],[1796,1842,1843],{"trials":3042,"activeCount":100},[],{"intervention":1843,"totalTrials":120,"cells":3044},{"EARLY_PHASE1":3045,"PHASE1":3047,"PHASE2":3049,"PHASE3":3051,"PHASE4":3053,"NA":3059},{"trials":3046,"activeCount":100},[],{"trials":3048,"activeCount":100},[],{"trials":3050,"activeCount":100},[],{"trials":3052,"activeCount":100},[],{"trials":3054,"activeCount":100},[3055],{"nctId":1833,"briefTitle":1834,"status":141,"phases":3056,"primaryCompletion":1836,"completion":1836,"start":1837,"enrollment":1838,"conditions":3057,"interventions":3058},[91],[1840],[1796,1842,1843],{"trials":3060,"activeCount":100},[],{"intervention":3062,"totalTrials":120,"cells":3063},"Gebauer's Ethyl Chloride",{"EARLY_PHASE1":3064,"PHASE1":3066,"PHASE2":3068,"PHASE3":3070,"PHASE4":3072,"NA":3084},{"trials":3065,"activeCount":100},[],{"trials":3067,"activeCount":100},[],{"trials":3069,"activeCount":100},[],{"trials":3071,"activeCount":100},[],{"trials":3073,"activeCount":100},[3074],{"nctId":3075,"briefTitle":3076,"status":1858,"phases":3077,"primaryCompletion":3078,"completion":3079,"start":1632,"enrollment":3080,"conditions":3081,"interventions":3083},"NCT01576770","In Children, Does Using a Synera Patch Decrease Pain When Injecting Propofol at Anesthesia Induction?",[91],"2012-10","2013-01",80,[3082],"Pain on Propofol IV Injection",[3062],{"trials":3085,"activeCount":100},[],{"intervention":3087,"totalTrials":120,"cells":3088},"Cyanocobalamin",{"EARLY_PHASE1":3089,"PHASE1":3091,"PHASE2":3093,"PHASE3":3095,"PHASE4":3097,"NA":3113},{"trials":3090,"activeCount":100},[],{"trials":3092,"activeCount":100},[],{"trials":3094,"activeCount":100},[],{"trials":3096,"activeCount":100},[],{"trials":3098,"activeCount":100},[3099],{"nctId":3100,"briefTitle":3101,"status":126,"phases":3102,"primaryCompletion":3103,"completion":3103,"start":3104,"enrollment":3105,"conditions":3106,"interventions":3111},"NCT04387201","GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response",[91],"2023-10-06","2020-05-15",23,[3107,3108,3109,3110],"Glucose Intolerance","Overweight and Obesity","Drug Effect","Adiposity",[3087,3112],"Dulaglutide",{"trials":3114,"activeCount":100},[],{"intervention":3112,"totalTrials":120,"cells":3116},{"EARLY_PHASE1":3117,"PHASE1":3119,"PHASE2":3121,"PHASE3":3123,"PHASE4":3125,"NA":3131},{"trials":3118,"activeCount":100},[],{"trials":3120,"activeCount":100},[],{"trials":3122,"activeCount":100},[],{"trials":3124,"activeCount":100},[],{"trials":3126,"activeCount":100},[3127],{"nctId":3100,"briefTitle":3101,"status":126,"phases":3128,"primaryCompletion":3103,"completion":3103,"start":3104,"enrollment":3105,"conditions":3129,"interventions":3130},[91],[3107,3108,3109,3110],[3087,3112],{"trials":3132,"activeCount":100},[],{"intervention":3134,"totalTrials":120,"cells":3135},"Sedation",{"EARLY_PHASE1":3136,"PHASE1":3138,"PHASE2":3140,"PHASE3":3142,"PHASE4":3144,"NA":3156},{"trials":3137,"activeCount":100},[],{"trials":3139,"activeCount":100},[],{"trials":3141,"activeCount":100},[],{"trials":3143,"activeCount":100},[],{"trials":3145,"activeCount":100},[3146],{"nctId":3147,"briefTitle":3148,"status":126,"phases":3149,"primaryCompletion":3150,"completion":3150,"start":3151,"enrollment":3152,"conditions":3153,"interventions":3154},"NCT03263117","SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke",[91],"2023-04-22","2018-07-01",260,[15],[3134,3155],"General Anesthesia",{"trials":3157,"activeCount":100},[],{"intervention":3155,"totalTrials":120,"cells":3159},{"EARLY_PHASE1":3160,"PHASE1":3162,"PHASE2":3164,"PHASE3":3166,"PHASE4":3168,"NA":3174},{"trials":3161,"activeCount":100},[],{"trials":3163,"activeCount":100},[],{"trials":3165,"activeCount":100},[],{"trials":3167,"activeCount":100},[],{"trials":3169,"activeCount":100},[3170],{"nctId":3147,"briefTitle":3148,"status":126,"phases":3171,"primaryCompletion":3150,"completion":3150,"start":3151,"enrollment":3152,"conditions":3172,"interventions":3173},[91],[15],[3134,3155],{"trials":3175,"activeCount":100},[],{"intervention":3177,"totalTrials":120,"cells":3178},"BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE",{"EARLY_PHASE1":3179,"PHASE1":3181,"PHASE2":3183,"PHASE3":3185,"PHASE4":3187,"NA":3199},{"trials":3180,"activeCount":100},[],{"trials":3182,"activeCount":100},[],{"trials":3184,"activeCount":100},[],{"trials":3186,"activeCount":100},[],{"trials":3188,"activeCount":100},[3189],{"nctId":3190,"briefTitle":3191,"status":789,"phases":3192,"primaryCompletion":3193,"completion":3194,"start":3195,"enrollment":100,"conditions":3196,"interventions":3198},"NCT03146325","Helicobacter Pylori and Body Iron in Adults",[91],"2016-06","2016-08","2012-11",[3197],"Helicobacter Pylori Infection",[3177],{"trials":3200,"activeCount":100},[],{"intervention":3202,"totalTrials":120,"cells":3203},"Antibiotic",{"EARLY_PHASE1":3204,"PHASE1":3206,"PHASE2":3208,"PHASE3":3210,"PHASE4":3212,"NA":3225},{"trials":3205,"activeCount":100},[],{"trials":3207,"activeCount":100},[],{"trials":3209,"activeCount":100},[],{"trials":3211,"activeCount":100},[],{"trials":3213,"activeCount":100},[3214],{"nctId":3215,"briefTitle":3216,"status":126,"phases":3217,"primaryCompletion":3218,"completion":3218,"start":3219,"enrollment":856,"conditions":3220,"interventions":3224},"NCT03275623","Management of Sub-Clinical Bacteriuria in Pregnancy",[91],"2019-03-18","2017-09-15",[3221,3222,3223],"Cystitis","Cystitis;Puerperium","Pyelonephritis",[3202],{"trials":3226,"activeCount":100},[],{"intervention":3228,"totalTrials":120,"cells":3229},"Retapamulin",{"EARLY_PHASE1":3230,"PHASE1":3232,"PHASE2":3234,"PHASE3":3236,"PHASE4":3238,"NA":3252},{"trials":3231,"activeCount":100},[],{"trials":3233,"activeCount":100},[],{"trials":3235,"activeCount":100},[],{"trials":3237,"activeCount":100},[],{"trials":3239,"activeCount":100},[3240],{"nctId":3241,"briefTitle":3242,"status":126,"phases":3243,"primaryCompletion":3195,"completion":3195,"start":3244,"enrollment":3245,"conditions":3246,"interventions":3251},"NCT01126268","Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection",[91],"2010-04",38,[3247,3248,3249,3250],"Impetigo","Folliculitis","Secondarily Infected Eczema","Minor Soft Tissue Infections",[3228],{"trials":3253,"activeCount":100},[],{"intervention":3255,"totalTrials":120,"cells":3256},"ACE Inhibitors and Diuretics",{"EARLY_PHASE1":3257,"PHASE1":3259,"PHASE2":3261,"PHASE3":3263,"PHASE4":3265,"NA":3280},{"trials":3258,"activeCount":100},[],{"trials":3260,"activeCount":100},[],{"trials":3262,"activeCount":100},[],{"trials":3264,"activeCount":100},[],{"trials":3266,"activeCount":100},[3267],{"nctId":3268,"briefTitle":3269,"status":126,"phases":3270,"primaryCompletion":3271,"completion":3272,"start":3273,"enrollment":3274,"conditions":3275,"interventions":3278},"NCT05049616","Oral Combined Hydrochlorothiazide\u002FLisinopril Versus Oral Nifedipine for Postpartum Hypertension",[91],"2022-06-26","2023-09-01","2021-10-18",70,[3276,3277],"Hypertension in Pregnancy","Postpartum Preeclampsia",[3255,3279],"NIFEdipine ER",{"trials":3281,"activeCount":100},[],{"intervention":3279,"totalTrials":120,"cells":3283},{"EARLY_PHASE1":3284,"PHASE1":3286,"PHASE2":3288,"PHASE3":3290,"PHASE4":3292,"NA":3298},{"trials":3285,"activeCount":100},[],{"trials":3287,"activeCount":100},[],{"trials":3289,"activeCount":100},[],{"trials":3291,"activeCount":100},[],{"trials":3293,"activeCount":100},[3294],{"nctId":3268,"briefTitle":3269,"status":126,"phases":3295,"primaryCompletion":3271,"completion":3272,"start":3273,"enrollment":3274,"conditions":3296,"interventions":3297},[91],[3276,3277],[3255,3279],{"trials":3299,"activeCount":100},[],{"intervention":3301,"totalTrials":120,"cells":3302},"Platelet Transfusion",{"EARLY_PHASE1":3303,"PHASE1":3305,"PHASE2":3307,"PHASE3":3309,"PHASE4":3311,"NA":3330},{"trials":3304,"activeCount":100},[],{"trials":3306,"activeCount":100},[],{"trials":3308,"activeCount":100},[],{"trials":3310,"activeCount":100},[],{"trials":3312,"activeCount":100},[3313],{"nctId":3314,"briefTitle":3315,"status":126,"phases":3316,"primaryCompletion":3317,"completion":3318,"start":3319,"enrollment":2784,"conditions":3320,"interventions":3326},"NCT03045068","Platelet Transfusion During Neonatal Open Heart Surgery",[91],"2018-10-01","2018-11-01","2017-04-11",[3321,3322,3323,3301,3324,3325],"Cardiac Disease","Cardiac Surgery","Cardiopulmonary Bypass","Arrythmia, Cardiac","Mortality",[3301,3327,3328,3329],"FFP and Cryoprecipitate","PRBC and cell saver Transfusion","Factor Concentrate",{"trials":3331,"activeCount":100},[],{"intervention":3327,"totalTrials":120,"cells":3333},{"EARLY_PHASE1":3334,"PHASE1":3336,"PHASE2":3338,"PHASE3":3340,"PHASE4":3342,"NA":3348},{"trials":3335,"activeCount":100},[],{"trials":3337,"activeCount":100},[],{"trials":3339,"activeCount":100},[],{"trials":3341,"activeCount":100},[],{"trials":3343,"activeCount":100},[3344],{"nctId":3314,"briefTitle":3315,"status":126,"phases":3345,"primaryCompletion":3317,"completion":3318,"start":3319,"enrollment":2784,"conditions":3346,"interventions":3347},[91],[3321,3322,3323,3301,3324,3325],[3301,3327,3328,3329],{"trials":3349,"activeCount":100},[],{"intervention":3328,"totalTrials":120,"cells":3351},{"EARLY_PHASE1":3352,"PHASE1":3354,"PHASE2":3356,"PHASE3":3358,"PHASE4":3360,"NA":3366},{"trials":3353,"activeCount":100},[],{"trials":3355,"activeCount":100},[],{"trials":3357,"activeCount":100},[],{"trials":3359,"activeCount":100},[],{"trials":3361,"activeCount":100},[3362],{"nctId":3314,"briefTitle":3315,"status":126,"phases":3363,"primaryCompletion":3317,"completion":3318,"start":3319,"enrollment":2784,"conditions":3364,"interventions":3365},[91],[3321,3322,3323,3301,3324,3325],[3301,3327,3328,3329],{"trials":3367,"activeCount":100},[],{"intervention":3329,"totalTrials":120,"cells":3369},{"EARLY_PHASE1":3370,"PHASE1":3372,"PHASE2":3374,"PHASE3":3376,"PHASE4":3378,"NA":3384},{"trials":3371,"activeCount":100},[],{"trials":3373,"activeCount":100},[],{"trials":3375,"activeCount":100},[],{"trials":3377,"activeCount":100},[],{"trials":3379,"activeCount":100},[3380],{"nctId":3314,"briefTitle":3315,"status":126,"phases":3381,"primaryCompletion":3317,"completion":3318,"start":3319,"enrollment":2784,"conditions":3382,"interventions":3383},[91],[3321,3322,3323,3301,3324,3325],[3301,3327,3328,3329],{"trials":3385,"activeCount":100},[],{"intervention":3387,"totalTrials":120,"cells":3388},"Reteplase 10 Units (U) plus a second dose of reteplase 10 U",{"EARLY_PHASE1":3389,"PHASE1":3391,"PHASE2":3393,"PHASE3":3395,"PHASE4":3397,"NA":3412},{"trials":3390,"activeCount":100},[],{"trials":3392,"activeCount":100},[],{"trials":3394,"activeCount":100},[],{"trials":3396,"activeCount":100},[],{"trials":3398,"activeCount":100},[3399],{"nctId":3400,"briefTitle":3401,"status":126,"phases":3402,"primaryCompletion":3403,"completion":3403,"start":3404,"enrollment":3405,"conditions":3406,"interventions":3410},"NCT00178620","Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization",[91],"2009-12","2003-09",390,[3407,3408,3409],"Heart Disease","Myocardial Infarction","Acute Myocardial Infarction",[3387,3411],"Reteplase 10 U",{"trials":3413,"activeCount":100},[],{"intervention":3411,"totalTrials":120,"cells":3415},{"EARLY_PHASE1":3416,"PHASE1":3418,"PHASE2":3420,"PHASE3":3422,"PHASE4":3424,"NA":3430},{"trials":3417,"activeCount":100},[],{"trials":3419,"activeCount":100},[],{"trials":3421,"activeCount":100},[],{"trials":3423,"activeCount":100},[],{"trials":3425,"activeCount":100},[3426],{"nctId":3400,"briefTitle":3401,"status":126,"phases":3427,"primaryCompletion":3403,"completion":3403,"start":3404,"enrollment":3405,"conditions":3428,"interventions":3429},[91],[3407,3408,3409],[3387,3411],{"trials":3431,"activeCount":100},[],{"intervention":3433,"totalTrials":120,"cells":3434},"Pegylated Interferon",{"EARLY_PHASE1":3435,"PHASE1":3437,"PHASE2":3439,"PHASE3":3441,"PHASE4":3443,"NA":3455},{"trials":3436,"activeCount":100},[],{"trials":3438,"activeCount":100},[],{"trials":3440,"activeCount":100},[],{"trials":3442,"activeCount":100},[],{"trials":3444,"activeCount":100},[3445],{"nctId":3446,"briefTitle":3447,"status":789,"phases":3448,"primaryCompletion":3449,"completion":3449,"start":3450,"enrollment":100,"conditions":3451,"interventions":3453},"NCT00167557","Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment",[91],"2008-03","2005-01",[3452],"Hepatitis C",[3433,3454],"Ribavirin",{"trials":3456,"activeCount":100},[],{"intervention":3454,"totalTrials":120,"cells":3458},{"EARLY_PHASE1":3459,"PHASE1":3461,"PHASE2":3463,"PHASE3":3465,"PHASE4":3467,"NA":3473},{"trials":3460,"activeCount":100},[],{"trials":3462,"activeCount":100},[],{"trials":3464,"activeCount":100},[],{"trials":3466,"activeCount":100},[],{"trials":3468,"activeCount":100},[3469],{"nctId":3446,"briefTitle":3447,"status":789,"phases":3470,"primaryCompletion":3449,"completion":3449,"start":3450,"enrollment":100,"conditions":3471,"interventions":3472},[91],[3452],[3433,3454],{"trials":3474,"activeCount":100},[],{"intervention":3476,"totalTrials":120,"cells":3477},"Bupivacaine with Epinephrine",{"EARLY_PHASE1":3478,"PHASE1":3480,"PHASE2":3482,"PHASE3":3484,"PHASE4":3486,"NA":3498},{"trials":3479,"activeCount":100},[],{"trials":3481,"activeCount":100},[],{"trials":3483,"activeCount":100},[],{"trials":3485,"activeCount":100},[],{"trials":3487,"activeCount":100},[3488],{"nctId":3489,"briefTitle":3490,"status":126,"phases":3491,"primaryCompletion":3492,"completion":3492,"start":3493,"enrollment":856,"conditions":3494,"interventions":3496},"NCT05244525","Subacromial Injection of Epinephrine Improves Visualization in Shoulder Arthroscopy",[91],"2022-08-31","2022-03-14",[3495],"Shoulder Arthroscopy",[3476,3497],"Bupivacaine alone",{"trials":3499,"activeCount":100},[],{"intervention":3497,"totalTrials":120,"cells":3501},{"EARLY_PHASE1":3502,"PHASE1":3504,"PHASE2":3506,"PHASE3":3508,"PHASE4":3510,"NA":3516},{"trials":3503,"activeCount":100},[],{"trials":3505,"activeCount":100},[],{"trials":3507,"activeCount":100},[],{"trials":3509,"activeCount":100},[],{"trials":3511,"activeCount":100},[3512],{"nctId":3489,"briefTitle":3490,"status":126,"phases":3513,"primaryCompletion":3492,"completion":3492,"start":3493,"enrollment":856,"conditions":3514,"interventions":3515},[91],[3495],[3476,3497],{"trials":3517,"activeCount":100},[],{"intervention":137,"totalTrials":120,"cells":3519},{"EARLY_PHASE1":3520,"PHASE1":3522,"PHASE2":3524,"PHASE3":3526,"PHASE4":3528,"NA":3534},{"trials":3521,"activeCount":100},[],{"trials":3523,"activeCount":100},[],{"trials":3525,"activeCount":100},[],{"trials":3527,"activeCount":100},[],{"trials":3529,"activeCount":100},[3530],{"nctId":124,"briefTitle":125,"status":126,"phases":3531,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":3532,"interventions":3533},[91],[133,134,135],[137,95],{"trials":3535,"activeCount":100},[],{"intervention":3537,"totalTrials":120,"cells":3538},"Administration of antibiotics prophylactically at the time of membrane rupture",{"EARLY_PHASE1":3539,"PHASE1":3541,"PHASE2":3543,"PHASE3":3545,"PHASE4":3547,"NA":3559},{"trials":3540,"activeCount":100},[],{"trials":3542,"activeCount":100},[],{"trials":3544,"activeCount":100},[],{"trials":3546,"activeCount":100},[],{"trials":3548,"activeCount":100},[3549],{"nctId":3550,"briefTitle":3551,"status":789,"phases":3552,"primaryCompletion":3553,"completion":3554,"start":462,"enrollment":100,"conditions":3555,"interventions":3557},"NCT06917157","Latency Antibiotics for Previable Rupture Of Membranes Trial",[91],"2026-05-31","2027-05-31",[3556],"Preterm Prelabor Rupture of Membranes (PPROM)",[3537,3558],"Administration of antibiotics non-prophylactically at 22 weeks",{"trials":3560,"activeCount":100},[],{"intervention":3558,"totalTrials":120,"cells":3562},{"EARLY_PHASE1":3563,"PHASE1":3565,"PHASE2":3567,"PHASE3":3569,"PHASE4":3571,"NA":3577},{"trials":3564,"activeCount":100},[],{"trials":3566,"activeCount":100},[],{"trials":3568,"activeCount":100},[],{"trials":3570,"activeCount":100},[],{"trials":3572,"activeCount":100},[3573],{"nctId":3550,"briefTitle":3551,"status":789,"phases":3574,"primaryCompletion":3553,"completion":3554,"start":462,"enrollment":100,"conditions":3575,"interventions":3576},[91],[3556],[3537,3558],{"trials":3578,"activeCount":100},[],{"intervention":3580,"totalTrials":120,"cells":3581},"LA group",{"EARLY_PHASE1":3582,"PHASE1":3584,"PHASE2":3586,"PHASE3":3588,"PHASE4":3590,"NA":3603},{"trials":3583,"activeCount":100},[],{"trials":3585,"activeCount":100},[],{"trials":3587,"activeCount":100},[],{"trials":3589,"activeCount":100},[],{"trials":3591,"activeCount":100},[3592],{"nctId":3593,"briefTitle":3594,"status":126,"phases":3595,"primaryCompletion":3596,"completion":3596,"start":3597,"enrollment":1809,"conditions":3598,"interventions":3601},"NCT04184349","Truncal Ultrasound Guided Regional Anesthesia for Implantation and Revision of Automatic Implantable Cardioverter Defibrillators (AICDs) and Pacemakers in Pediatric Patients",[91],"2022-06-09","2020-10-01",[3599,3600],"Analgesia After Pacemaker","AICDS Implantation Pediatrics",[3580,3602],"B Group",{"trials":3604,"activeCount":100},[],{"intervention":3602,"totalTrials":120,"cells":3606},{"EARLY_PHASE1":3607,"PHASE1":3609,"PHASE2":3611,"PHASE3":3613,"PHASE4":3615,"NA":3621},{"trials":3608,"activeCount":100},[],{"trials":3610,"activeCount":100},[],{"trials":3612,"activeCount":100},[],{"trials":3614,"activeCount":100},[],{"trials":3616,"activeCount":100},[3617],{"nctId":3593,"briefTitle":3594,"status":126,"phases":3618,"primaryCompletion":3596,"completion":3596,"start":3597,"enrollment":1809,"conditions":3619,"interventions":3620},[91],[3599,3600],[3580,3602],{"trials":3622,"activeCount":100},[],{"intervention":3624,"totalTrials":120,"cells":3625},"MTPI",{"EARLY_PHASE1":3626,"PHASE1":3628,"PHASE2":3630,"PHASE3":3632,"PHASE4":3634,"NA":3645},{"trials":3627,"activeCount":100},[],{"trials":3629,"activeCount":100},[],{"trials":3631,"activeCount":100},[],{"trials":3633,"activeCount":100},[],{"trials":3635,"activeCount":100},[3636],{"nctId":3637,"briefTitle":3638,"status":126,"phases":3639,"primaryCompletion":1188,"completion":1188,"start":3640,"enrollment":3641,"conditions":3642,"interventions":3643},"NCT05509192","Intubation Conditions Achieved With Rapid Co-administration of Rocuronium and Propofol Versus Classical Induction",[91],"2022-08-17",154,[573],[3624,3644],"Classic Induction",{"trials":3646,"activeCount":100},[],{"intervention":3644,"totalTrials":120,"cells":3648},{"EARLY_PHASE1":3649,"PHASE1":3651,"PHASE2":3653,"PHASE3":3655,"PHASE4":3657,"NA":3663},{"trials":3650,"activeCount":100},[],{"trials":3652,"activeCount":100},[],{"trials":3654,"activeCount":100},[],{"trials":3656,"activeCount":100},[],{"trials":3658,"activeCount":100},[3659],{"nctId":3637,"briefTitle":3638,"status":126,"phases":3660,"primaryCompletion":1188,"completion":1188,"start":3640,"enrollment":3641,"conditions":3661,"interventions":3662},[91],[573],[3624,3644],{"trials":3664,"activeCount":100},[],{"intervention":3666,"totalTrials":120,"cells":3667},"Raltegravir and truvada",{"EARLY_PHASE1":3668,"PHASE1":3670,"PHASE2":3672,"PHASE3":3674,"PHASE4":3676,"NA":3686},{"trials":3669,"activeCount":100},[],{"trials":3671,"activeCount":100},[],{"trials":3673,"activeCount":100},[],{"trials":3675,"activeCount":100},[],{"trials":3677,"activeCount":100},[3678],{"nctId":3679,"briefTitle":3680,"status":126,"phases":3681,"primaryCompletion":3682,"completion":3079,"start":1679,"enrollment":2189,"conditions":3683,"interventions":3684},"NCT00762892","Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients",[91],"2012-12",[24],[3666,3685],"Atazanavir, Norvir and Truvada",{"trials":3687,"activeCount":100},[],{"intervention":3685,"totalTrials":120,"cells":3689},{"EARLY_PHASE1":3690,"PHASE1":3692,"PHASE2":3694,"PHASE3":3696,"PHASE4":3698,"NA":3704},{"trials":3691,"activeCount":100},[],{"trials":3693,"activeCount":100},[],{"trials":3695,"activeCount":100},[],{"trials":3697,"activeCount":100},[],{"trials":3699,"activeCount":100},[3700],{"nctId":3679,"briefTitle":3680,"status":126,"phases":3701,"primaryCompletion":3682,"completion":3079,"start":1679,"enrollment":2189,"conditions":3702,"interventions":3703},[91],[24],[3666,3685],{"trials":3705,"activeCount":100},[],{"intervention":3707,"totalTrials":120,"cells":3708},"topical irrigation with gentamicin",{"EARLY_PHASE1":3709,"PHASE1":3711,"PHASE2":3713,"PHASE3":3715,"PHASE4":3717,"NA":3730},{"trials":3710,"activeCount":100},[],{"trials":3712,"activeCount":100},[],{"trials":3714,"activeCount":100},[],{"trials":3716,"activeCount":100},[],{"trials":3718,"activeCount":100},[3719],{"nctId":3720,"briefTitle":3721,"status":141,"phases":3722,"primaryCompletion":3723,"completion":3723,"start":3724,"enrollment":3725,"conditions":3726,"interventions":3727},"NCT03483363","Topical Antibiotic Irrigation (Gentamicin) in Prophylaxis of Midfacial Fracture Surgical Wounds",[91],"2022-01-02","2018-10-09",39,[464],[3707,3728,3729],"topical irrigation with sterile normal saline","intravenous (IV) prophylactic antibiotic",{"trials":3731,"activeCount":100},[],{"intervention":3728,"totalTrials":120,"cells":3733},{"EARLY_PHASE1":3734,"PHASE1":3736,"PHASE2":3738,"PHASE3":3740,"PHASE4":3742,"NA":3748},{"trials":3735,"activeCount":100},[],{"trials":3737,"activeCount":100},[],{"trials":3739,"activeCount":100},[],{"trials":3741,"activeCount":100},[],{"trials":3743,"activeCount":100},[3744],{"nctId":3720,"briefTitle":3721,"status":141,"phases":3745,"primaryCompletion":3723,"completion":3723,"start":3724,"enrollment":3725,"conditions":3746,"interventions":3747},[91],[464],[3707,3728,3729],{"trials":3749,"activeCount":100},[],{"intervention":3729,"totalTrials":120,"cells":3751},{"EARLY_PHASE1":3752,"PHASE1":3754,"PHASE2":3756,"PHASE3":3758,"PHASE4":3760,"NA":3766},{"trials":3753,"activeCount":100},[],{"trials":3755,"activeCount":100},[],{"trials":3757,"activeCount":100},[],{"trials":3759,"activeCount":100},[],{"trials":3761,"activeCount":100},[3762],{"nctId":3720,"briefTitle":3721,"status":141,"phases":3763,"primaryCompletion":3723,"completion":3723,"start":3724,"enrollment":3725,"conditions":3764,"interventions":3765},[91],[464],[3707,3728,3729],{"trials":3767,"activeCount":100},[],{"intervention":3769,"totalTrials":120,"cells":3770},"Femoral Nerve Block",{"EARLY_PHASE1":3771,"PHASE1":3773,"PHASE2":3775,"PHASE3":3777,"PHASE4":3779,"NA":3787},{"trials":3772,"activeCount":100},[],{"trials":3774,"activeCount":100},[],{"trials":3776,"activeCount":100},[],{"trials":3778,"activeCount":100},[],{"trials":3780,"activeCount":100},[3781],{"nctId":3782,"briefTitle":3783,"status":141,"phases":3784,"primaryCompletion":1836,"completion":1836,"start":1862,"enrollment":27,"conditions":3785,"interventions":3786},"NCT02046317","Trial of Ultrasound Guided Femoral Nerve Block on Isolated Femur Fracture Using Echo Friendly Needles",[91],[134],[3769],{"trials":3788,"activeCount":100},[],{"intervention":3790,"totalTrials":120,"cells":3791},"Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum",{"EARLY_PHASE1":3792,"PHASE1":3794,"PHASE2":3796,"PHASE3":3798,"PHASE4":3800,"NA":3814},{"trials":3793,"activeCount":100},[],{"trials":3795,"activeCount":100},[],{"trials":3797,"activeCount":100},[],{"trials":3799,"activeCount":100},[],{"trials":3801,"activeCount":100},[3802],{"nctId":3803,"briefTitle":3804,"status":126,"phases":3805,"primaryCompletion":3806,"completion":3806,"start":3807,"enrollment":3274,"conditions":3808,"interventions":3812},"NCT03219840","Cetylpyridium Chloride (CPC) Based Chewing Gum and Gingivitis",[91],"2018-09-08","2017-10-18",[3809,3810,3811],"Gingivitis","Plaque, Dental","Periodontal Diseases",[3790,3813],"Xylitol only chewing gum",{"trials":3815,"activeCount":100},[],{"intervention":3813,"totalTrials":120,"cells":3817},{"EARLY_PHASE1":3818,"PHASE1":3820,"PHASE2":3822,"PHASE3":3824,"PHASE4":3826,"NA":3832},{"trials":3819,"activeCount":100},[],{"trials":3821,"activeCount":100},[],{"trials":3823,"activeCount":100},[],{"trials":3825,"activeCount":100},[],{"trials":3827,"activeCount":100},[3828],{"nctId":3803,"briefTitle":3804,"status":126,"phases":3829,"primaryCompletion":3806,"completion":3806,"start":3807,"enrollment":3274,"conditions":3830,"interventions":3831},[91],[3809,3810,3811],[3790,3813],{"trials":3833,"activeCount":100},[],{"intervention":3835,"totalTrials":120,"cells":3836},"benzocaine",{"EARLY_PHASE1":3837,"PHASE1":3839,"PHASE2":3841,"PHASE3":3843,"PHASE4":3845,"NA":3857},{"trials":3838,"activeCount":100},[],{"trials":3840,"activeCount":100},[],{"trials":3842,"activeCount":100},[],{"trials":3844,"activeCount":100},[],{"trials":3846,"activeCount":100},[3847],{"nctId":3848,"briefTitle":3849,"status":1858,"phases":3850,"primaryCompletion":3851,"completion":3852,"start":1679,"enrollment":19,"conditions":3853,"interventions":3855},"NCT00846690","Comparative Efficacy of 20% Benzocaine Versus TAC Alternate Gel",[91],"2009-03","2009-05",[3854,1865],"Dental Pain",[3835,3856],"TAC alternate gel",{"trials":3858,"activeCount":100},[],{"intervention":3856,"totalTrials":120,"cells":3860},{"EARLY_PHASE1":3861,"PHASE1":3863,"PHASE2":3865,"PHASE3":3867,"PHASE4":3869,"NA":3875},{"trials":3862,"activeCount":100},[],{"trials":3864,"activeCount":100},[],{"trials":3866,"activeCount":100},[],{"trials":3868,"activeCount":100},[],{"trials":3870,"activeCount":100},[3871],{"nctId":3848,"briefTitle":3849,"status":1858,"phases":3872,"primaryCompletion":3851,"completion":3852,"start":1679,"enrollment":19,"conditions":3873,"interventions":3874},[91],[3854,1865],[3835,3856],{"trials":3876,"activeCount":100},[],{"intervention":3878,"totalTrials":120,"cells":3879},"Losartan",{"EARLY_PHASE1":3880,"PHASE1":3882,"PHASE2":3884,"PHASE3":3886,"PHASE4":3888,"NA":3903},{"trials":3881,"activeCount":100},[],{"trials":3883,"activeCount":100},[],{"trials":3885,"activeCount":100},[],{"trials":3887,"activeCount":100},[],{"trials":3889,"activeCount":100},[3890],{"nctId":3891,"briefTitle":3892,"status":126,"phases":3893,"primaryCompletion":3894,"completion":3895,"start":215,"enrollment":3896,"conditions":3897,"interventions":3899},"NCT03461003","N-of-1 Trials In Children With Hypertension",[91],"2020-11-14","2021-05-02",49,[3898],"Pediatric Hypertension",[3900,3901,3902,3878],"Amlodipine","Lisinopril","Hydrochlorothiazide",{"trials":3904,"activeCount":100},[],{"intervention":2328,"totalTrials":120,"cells":3906},{"EARLY_PHASE1":3907,"PHASE1":3909,"PHASE2":3911,"PHASE3":3913,"PHASE4":3915,"NA":3921},{"trials":3908,"activeCount":100},[],{"trials":3910,"activeCount":100},[],{"trials":3912,"activeCount":100},[],{"trials":3914,"activeCount":100},[],{"trials":3916,"activeCount":100},[3917],{"nctId":2318,"briefTitle":2319,"status":126,"phases":3918,"primaryCompletion":2321,"completion":2321,"start":2322,"enrollment":2323,"conditions":3919,"interventions":3920},[91],[2325,2326],[2298,2328,2329,2330],{"trials":3922,"activeCount":100},[],{"intervention":2329,"totalTrials":120,"cells":3924},{"EARLY_PHASE1":3925,"PHASE1":3927,"PHASE2":3929,"PHASE3":3931,"PHASE4":3933,"NA":3939},{"trials":3926,"activeCount":100},[],{"trials":3928,"activeCount":100},[],{"trials":3930,"activeCount":100},[],{"trials":3932,"activeCount":100},[],{"trials":3934,"activeCount":100},[3935],{"nctId":2318,"briefTitle":2319,"status":126,"phases":3936,"primaryCompletion":2321,"completion":2321,"start":2322,"enrollment":2323,"conditions":3937,"interventions":3938},[91],[2325,2326],[2298,2328,2329,2330],{"trials":3940,"activeCount":100},[],{"intervention":2330,"totalTrials":120,"cells":3942},{"EARLY_PHASE1":3943,"PHASE1":3945,"PHASE2":3947,"PHASE3":3949,"PHASE4":3951,"NA":3957},{"trials":3944,"activeCount":100},[],{"trials":3946,"activeCount":100},[],{"trials":3948,"activeCount":100},[],{"trials":3950,"activeCount":100},[],{"trials":3952,"activeCount":100},[3953],{"nctId":2318,"briefTitle":2319,"status":126,"phases":3954,"primaryCompletion":2321,"completion":2321,"start":2322,"enrollment":2323,"conditions":3955,"interventions":3956},[91],[2325,2326],[2298,2328,2329,2330],{"trials":3958,"activeCount":100},[],{"intervention":220,"totalTrials":120,"cells":3960},{"EARLY_PHASE1":3961,"PHASE1":3963,"PHASE2":3965,"PHASE3":3967,"PHASE4":3969,"NA":3975},{"trials":3962,"activeCount":100},[],{"trials":3964,"activeCount":100},[],{"trials":3966,"activeCount":100},[],{"trials":3968,"activeCount":100},[],{"trials":3970,"activeCount":100},[3971],{"nctId":211,"briefTitle":212,"status":126,"phases":3972,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":3973,"interventions":3974},[91],[218],[220,221,198,222,223,224,225,226,227,228,229],{"trials":3976,"activeCount":100},[],{"intervention":221,"totalTrials":120,"cells":3978},{"EARLY_PHASE1":3979,"PHASE1":3981,"PHASE2":3983,"PHASE3":3985,"PHASE4":3987,"NA":3993},{"trials":3980,"activeCount":100},[],{"trials":3982,"activeCount":100},[],{"trials":3984,"activeCount":100},[],{"trials":3986,"activeCount":100},[],{"trials":3988,"activeCount":100},[3989],{"nctId":211,"briefTitle":212,"status":126,"phases":3990,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":3991,"interventions":3992},[91],[218],[220,221,198,222,223,224,225,226,227,228,229],{"trials":3994,"activeCount":100},[],{"intervention":222,"totalTrials":120,"cells":3996},{"EARLY_PHASE1":3997,"PHASE1":3999,"PHASE2":4001,"PHASE3":4003,"PHASE4":4005,"NA":4011},{"trials":3998,"activeCount":100},[],{"trials":4000,"activeCount":100},[],{"trials":4002,"activeCount":100},[],{"trials":4004,"activeCount":100},[],{"trials":4006,"activeCount":100},[4007],{"nctId":211,"briefTitle":212,"status":126,"phases":4008,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":4009,"interventions":4010},[91],[218],[220,221,198,222,223,224,225,226,227,228,229],{"trials":4012,"activeCount":100},[],{"intervention":224,"totalTrials":120,"cells":4014},{"EARLY_PHASE1":4015,"PHASE1":4017,"PHASE2":4019,"PHASE3":4021,"PHASE4":4023,"NA":4029},{"trials":4016,"activeCount":100},[],{"trials":4018,"activeCount":100},[],{"trials":4020,"activeCount":100},[],{"trials":4022,"activeCount":100},[],{"trials":4024,"activeCount":100},[4025],{"nctId":211,"briefTitle":212,"status":126,"phases":4026,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":4027,"interventions":4028},[91],[218],[220,221,198,222,223,224,225,226,227,228,229],{"trials":4030,"activeCount":100},[],{"intervention":225,"totalTrials":120,"cells":4032},{"EARLY_PHASE1":4033,"PHASE1":4035,"PHASE2":4037,"PHASE3":4039,"PHASE4":4041,"NA":4047},{"trials":4034,"activeCount":100},[],{"trials":4036,"activeCount":100},[],{"trials":4038,"activeCount":100},[],{"trials":4040,"activeCount":100},[],{"trials":4042,"activeCount":100},[4043],{"nctId":211,"briefTitle":212,"status":126,"phases":4044,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":4045,"interventions":4046},[91],[218],[220,221,198,222,223,224,225,226,227,228,229],{"trials":4048,"activeCount":100},[],{"intervention":226,"totalTrials":120,"cells":4050},{"EARLY_PHASE1":4051,"PHASE1":4053,"PHASE2":4055,"PHASE3":4057,"PHASE4":4059,"NA":4065},{"trials":4052,"activeCount":100},[],{"trials":4054,"activeCount":100},[],{"trials":4056,"activeCount":100},[],{"trials":4058,"activeCount":100},[],{"trials":4060,"activeCount":100},[4061],{"nctId":211,"briefTitle":212,"status":126,"phases":4062,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":4063,"interventions":4064},[91],[218],[220,221,198,222,223,224,225,226,227,228,229],{"trials":4066,"activeCount":100},[],{"intervention":228,"totalTrials":120,"cells":4068},{"EARLY_PHASE1":4069,"PHASE1":4071,"PHASE2":4073,"PHASE3":4075,"PHASE4":4077,"NA":4083},{"trials":4070,"activeCount":100},[],{"trials":4072,"activeCount":100},[],{"trials":4074,"activeCount":100},[],{"trials":4076,"activeCount":100},[],{"trials":4078,"activeCount":100},[4079],{"nctId":211,"briefTitle":212,"status":126,"phases":4080,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":4081,"interventions":4082},[91],[218],[220,221,198,222,223,224,225,226,227,228,229],{"trials":4084,"activeCount":100},[],{"intervention":229,"totalTrials":120,"cells":4086},{"EARLY_PHASE1":4087,"PHASE1":4089,"PHASE2":4091,"PHASE3":4093,"PHASE4":4095,"NA":4101},{"trials":4088,"activeCount":100},[],{"trials":4090,"activeCount":100},[],{"trials":4092,"activeCount":100},[],{"trials":4094,"activeCount":100},[],{"trials":4096,"activeCount":100},[4097],{"nctId":211,"briefTitle":212,"status":126,"phases":4098,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":4099,"interventions":4100},[91],[218],[220,221,198,222,223,224,225,226,227,228,229],{"trials":4102,"activeCount":100},[],{"intervention":1984,"totalTrials":120,"cells":4104},{"EARLY_PHASE1":4105,"PHASE1":4107,"PHASE2":4109,"PHASE3":4111,"PHASE4":4113,"NA":4119},{"trials":4106,"activeCount":100},[],{"trials":4108,"activeCount":100},[],{"trials":4110,"activeCount":100},[],{"trials":4112,"activeCount":100},[],{"trials":4114,"activeCount":100},[4115],{"nctId":1975,"briefTitle":1976,"status":126,"phases":4116,"primaryCompletion":1978,"completion":1978,"start":1979,"enrollment":1928,"conditions":4117,"interventions":4118},[91],[1981,1982],[1917,1984],{"trials":4120,"activeCount":100},[],{"intervention":4122,"totalTrials":120,"cells":4123},"Glyburide",{"EARLY_PHASE1":4124,"PHASE1":4126,"PHASE2":4128,"PHASE3":4130,"PHASE4":4132,"NA":4145},{"trials":4125,"activeCount":100},[],{"trials":4127,"activeCount":100},[],{"trials":4129,"activeCount":100},[],{"trials":4131,"activeCount":100},[],{"trials":4133,"activeCount":100},[4134],{"nctId":4135,"briefTitle":4136,"status":789,"phases":4137,"primaryCompletion":4138,"completion":4139,"start":4140,"enrollment":100,"conditions":4141,"interventions":4143},"NCT03078725","Failure Rate of GLyburide And Metformin Among Gestational Diabetics",[91],"2018-03-10","2018-05-10","2017-06-20",[4142],"Gestational Diabetes Mellitus, Class A2",[4122,4144],"Metformin",{"trials":4146,"activeCount":100},[],{"intervention":4148,"totalTrials":120,"cells":4149},"Estrogen vaginal cream",{"EARLY_PHASE1":4150,"PHASE1":4152,"PHASE2":4154,"PHASE3":4156,"PHASE4":4158,"NA":4173},{"trials":4151,"activeCount":100},[],{"trials":4153,"activeCount":100},[],{"trials":4155,"activeCount":100},[],{"trials":4157,"activeCount":100},[],{"trials":4159,"activeCount":100},[4160],{"nctId":4161,"briefTitle":4162,"status":141,"phases":4163,"primaryCompletion":4164,"completion":4165,"start":4166,"enrollment":96,"conditions":4167,"interventions":4171},"NCT03943823","Postmenopausal Pessary Users: Estrogen Versus Trimosan",[91],"2021-03-08","2021-04-08","2019-05-07",[4168,4169,4170],"Vaginosis","Vaginosis, Bacterial","Vaginal Discharge",[4148,4172],"Trimo-San vaginal gel",{"trials":4174,"activeCount":100},[],{"intervention":4172,"totalTrials":120,"cells":4176},{"EARLY_PHASE1":4177,"PHASE1":4179,"PHASE2":4181,"PHASE3":4183,"PHASE4":4185,"NA":4191},{"trials":4178,"activeCount":100},[],{"trials":4180,"activeCount":100},[],{"trials":4182,"activeCount":100},[],{"trials":4184,"activeCount":100},[],{"trials":4186,"activeCount":100},[4187],{"nctId":4161,"briefTitle":4162,"status":141,"phases":4188,"primaryCompletion":4164,"completion":4165,"start":4166,"enrollment":96,"conditions":4189,"interventions":4190},[91],[4168,4169,4170],[4148,4172],{"trials":4192,"activeCount":100},[],{"intervention":4194,"totalTrials":120,"cells":4195},"Azithromycin 500 mg",{"EARLY_PHASE1":4196,"PHASE1":4198,"PHASE2":4200,"PHASE3":4202,"PHASE4":4204,"NA":4218},{"trials":4197,"activeCount":100},[],{"trials":4199,"activeCount":100},[],{"trials":4201,"activeCount":100},[],{"trials":4203,"activeCount":100},[],{"trials":4205,"activeCount":100},[4206],{"nctId":4207,"briefTitle":4208,"status":126,"phases":4209,"primaryCompletion":4210,"completion":4210,"start":4211,"enrollment":4212,"conditions":4213,"interventions":4215},"NCT00359970","Azithromycin, With or Without Loperamide, to Treat Travelers' Diarrhea",[91],"2003-08","2002-06",176,[4214],"Diarrhea",[4194,4216,4217],"Azithromycin 1000 mg","Loperamide",{"trials":4219,"activeCount":100},[],{"intervention":4216,"totalTrials":120,"cells":4221},{"EARLY_PHASE1":4222,"PHASE1":4224,"PHASE2":4226,"PHASE3":4228,"PHASE4":4230,"NA":4236},{"trials":4223,"activeCount":100},[],{"trials":4225,"activeCount":100},[],{"trials":4227,"activeCount":100},[],{"trials":4229,"activeCount":100},[],{"trials":4231,"activeCount":100},[4232],{"nctId":4207,"briefTitle":4208,"status":126,"phases":4233,"primaryCompletion":4210,"completion":4210,"start":4211,"enrollment":4212,"conditions":4234,"interventions":4235},[91],[4214],[4194,4216,4217],{"trials":4237,"activeCount":100},[],{"intervention":4217,"totalTrials":120,"cells":4239},{"EARLY_PHASE1":4240,"PHASE1":4242,"PHASE2":4244,"PHASE3":4246,"PHASE4":4248,"NA":4254},{"trials":4241,"activeCount":100},[],{"trials":4243,"activeCount":100},[],{"trials":4245,"activeCount":100},[],{"trials":4247,"activeCount":100},[],{"trials":4249,"activeCount":100},[4250],{"nctId":4207,"briefTitle":4208,"status":126,"phases":4251,"primaryCompletion":4210,"completion":4210,"start":4211,"enrollment":4212,"conditions":4252,"interventions":4253},[91],[4214],[4194,4216,4217],{"trials":4255,"activeCount":100},[],{"intervention":1932,"totalTrials":120,"cells":4257},{"EARLY_PHASE1":4258,"PHASE1":4260,"PHASE2":4262,"PHASE3":4264,"PHASE4":4266,"NA":4272},{"trials":4259,"activeCount":100},[],{"trials":4261,"activeCount":100},[],{"trials":4263,"activeCount":100},[],{"trials":4265,"activeCount":100},[],{"trials":4267,"activeCount":100},[4268],{"nctId":1923,"briefTitle":1924,"status":126,"phases":4269,"primaryCompletion":1926,"completion":1926,"start":1927,"enrollment":1928,"conditions":4270,"interventions":4271},[91],[1930],[1932,227],{"trials":4273,"activeCount":100},[],{"intervention":4275,"totalTrials":120,"cells":4276},"Remifentanil",{"EARLY_PHASE1":4277,"PHASE1":4279,"PHASE2":4281,"PHASE3":4283,"PHASE4":4285,"NA":4297},{"trials":4278,"activeCount":100},[],{"trials":4280,"activeCount":100},[],{"trials":4282,"activeCount":100},[],{"trials":4284,"activeCount":100},[],{"trials":4286,"activeCount":100},[4287],{"nctId":4288,"briefTitle":4289,"status":126,"phases":4290,"primaryCompletion":4291,"completion":4291,"start":4292,"enrollment":258,"conditions":4293,"interventions":4295},"NCT00349245","Dexmedetomidine vs. Remifentanil for Sedation During AFI",[91],"2007-08","2006-06",[4294],"Intubation, Endotracheal",[4275,4296],"Dexmedetomidine",{"trials":4298,"activeCount":100},[],{"intervention":4300,"totalTrials":120,"cells":4301},"Truvada",{"EARLY_PHASE1":4302,"PHASE1":4304,"PHASE2":4306,"PHASE3":4308,"PHASE4":4310,"NA":4323},{"trials":4303,"activeCount":100},[],{"trials":4305,"activeCount":100},[],{"trials":4307,"activeCount":100},[],{"trials":4309,"activeCount":100},[],{"trials":4311,"activeCount":100},[4312],{"nctId":4313,"briefTitle":4314,"status":126,"phases":4315,"primaryCompletion":4316,"completion":4317,"start":1862,"enrollment":4318,"conditions":4319,"interventions":4321},"NCT01214759","Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)",[91],"2013-12","2015-08",103,[4320],"HIV",[4300,4322],"Raltegravir",{"trials":4324,"activeCount":100},[],{"intervention":2018,"totalTrials":120,"cells":4326},{"EARLY_PHASE1":4327,"PHASE1":4329,"PHASE2":4331,"PHASE3":4333,"PHASE4":4335,"NA":4341},{"trials":4328,"activeCount":100},[],{"trials":4330,"activeCount":100},[],{"trials":4332,"activeCount":100},[],{"trials":4334,"activeCount":100},[],{"trials":4336,"activeCount":100},[4337],{"nctId":2009,"briefTitle":2010,"status":126,"phases":4338,"primaryCompletion":2012,"completion":2012,"start":2013,"enrollment":2014,"conditions":4339,"interventions":4340},[91],[135,2016],[2018,1988,2019],{"trials":4342,"activeCount":100},[],{"intervention":1604,"totalTrials":120,"cells":4344},{"EARLY_PHASE1":4345,"PHASE1":4347,"PHASE2":4349,"PHASE3":4351,"PHASE4":4353,"NA":4359},{"trials":4346,"activeCount":100},[],{"trials":4348,"activeCount":100},[],{"trials":4350,"activeCount":100},[],{"trials":4352,"activeCount":100},[],{"trials":4354,"activeCount":100},[4355],{"nctId":1594,"briefTitle":1595,"status":126,"phases":4356,"completion":1597,"start":1598,"enrollment":115,"conditions":4357,"interventions":4358},[91],[1600,1601],[1603,1604],{"trials":4360,"activeCount":100},[],{"intervention":4362,"totalTrials":120,"cells":4363},"Bupivacaine liposomal injectable suspension",{"EARLY_PHASE1":4364,"PHASE1":4366,"PHASE2":4368,"PHASE3":4370,"PHASE4":4372,"NA":4383},{"trials":4365,"activeCount":100},[],{"trials":4367,"activeCount":100},[],{"trials":4369,"activeCount":100},[],{"trials":4371,"activeCount":100},[],{"trials":4373,"activeCount":100},[4374],{"nctId":4375,"briefTitle":4376,"status":126,"phases":4377,"primaryCompletion":4378,"completion":4378,"start":4379,"enrollment":19,"conditions":4380,"interventions":4381},"NCT03972397","Intercostal Nerve Cryoablation for Postoperative Pain Management",[91],"2022-09-22","2019-07-15",[2016],[4362,4382],"Patient-controlled analgesia",{"trials":4384,"activeCount":100},[],{"intervention":4382,"totalTrials":120,"cells":4386},{"EARLY_PHASE1":4387,"PHASE1":4389,"PHASE2":4391,"PHASE3":4393,"PHASE4":4395,"NA":4401},{"trials":4388,"activeCount":100},[],{"trials":4390,"activeCount":100},[],{"trials":4392,"activeCount":100},[],{"trials":4394,"activeCount":100},[],{"trials":4396,"activeCount":100},[4397],{"nctId":4375,"briefTitle":4376,"status":126,"phases":4398,"primaryCompletion":4378,"completion":4378,"start":4379,"enrollment":19,"conditions":4399,"interventions":4400},[91],[2016],[4362,4382],{"trials":4402,"activeCount":100},[],{"intervention":4404,"totalTrials":120,"cells":4405},"Imiquimod and Interferon alpha",{"EARLY_PHASE1":4406,"PHASE1":4408,"PHASE2":4410,"PHASE3":4412,"PHASE4":4414,"NA":4424},{"trials":4407,"activeCount":100},[],{"trials":4409,"activeCount":100},[],{"trials":4411,"activeCount":100},[],{"trials":4413,"activeCount":100},[],{"trials":4415,"activeCount":100},[4416],{"nctId":4417,"briefTitle":4418,"status":126,"phases":4419,"primaryCompletion":4420,"completion":4420,"start":1582,"enrollment":3896,"conditions":4421,"interventions":4423},"NCT00581425","Intron-A\u002FAldara Combination Therapy for Basal Cell Carcinoma (BCC)",[91],"2011-09",[4422],"Basal Cell Carcinoma",[4404],{"trials":4425,"activeCount":100},[],{"intervention":4427,"totalTrials":120,"cells":4428},"aerosolized 2% lidocaine",{"EARLY_PHASE1":4429,"PHASE1":4431,"PHASE2":4433,"PHASE3":4435,"PHASE4":4437,"NA":4449},{"trials":4430,"activeCount":100},[],{"trials":4432,"activeCount":100},[],{"trials":4434,"activeCount":100},[],{"trials":4436,"activeCount":100},[],{"trials":4438,"activeCount":100},[4439],{"nctId":4440,"briefTitle":4441,"status":126,"phases":4442,"primaryCompletion":4443,"completion":4443,"start":4444,"enrollment":35,"conditions":4445,"interventions":4446},"NCT05058677","Aerosolized Endotracheal Lidocaine to Avoid Intracranial Pressure Spikes in Patients With Severe Traumatic Brain Injury",[91],"2025-06-30","2021-11-09",[29],[4427,4447,4448],"instilled 0.9% sodium chloride","instilled 2% lidocaine solution",{"trials":4450,"activeCount":100},[],{"intervention":4447,"totalTrials":120,"cells":4452},{"EARLY_PHASE1":4453,"PHASE1":4455,"PHASE2":4457,"PHASE3":4459,"PHASE4":4461,"NA":4467},{"trials":4454,"activeCount":100},[],{"trials":4456,"activeCount":100},[],{"trials":4458,"activeCount":100},[],{"trials":4460,"activeCount":100},[],{"trials":4462,"activeCount":100},[4463],{"nctId":4440,"briefTitle":4441,"status":126,"phases":4464,"primaryCompletion":4443,"completion":4443,"start":4444,"enrollment":35,"conditions":4465,"interventions":4466},[91],[29],[4427,4447,4448],{"trials":4468,"activeCount":100},[],{"intervention":4448,"totalTrials":120,"cells":4470},{"EARLY_PHASE1":4471,"PHASE1":4473,"PHASE2":4475,"PHASE3":4477,"PHASE4":4479,"NA":4485},{"trials":4472,"activeCount":100},[],{"trials":4474,"activeCount":100},[],{"trials":4476,"activeCount":100},[],{"trials":4478,"activeCount":100},[],{"trials":4480,"activeCount":100},[4481],{"nctId":4440,"briefTitle":4441,"status":126,"phases":4482,"primaryCompletion":4443,"completion":4443,"start":4444,"enrollment":35,"conditions":4483,"interventions":4484},[91],[29],[4427,4447,4448],{"trials":4486,"activeCount":100},[],{"intervention":4488,"totalTrials":120,"cells":4489},"Myfortic",{"EARLY_PHASE1":4490,"PHASE1":4492,"PHASE2":4494,"PHASE3":4496,"PHASE4":4498,"NA":4507},{"trials":4491,"activeCount":100},[],{"trials":4493,"activeCount":100},[],{"trials":4495,"activeCount":100},[],{"trials":4497,"activeCount":100},[],{"trials":4499,"activeCount":100},[4500],{"nctId":4501,"briefTitle":4502,"status":789,"phases":4503,"primaryCompletion":4504,"completion":4504,"start":2892,"enrollment":100,"conditions":4505,"interventions":4506},"NCT00167492","Enteric Coated Myfortic for Liver Transplant Recipients",[91],"2009-02",[2894],[4488],{"trials":4508,"activeCount":100},[],{"intervention":4510,"totalTrials":120,"cells":4511},"Nifedipine",{"EARLY_PHASE1":4512,"PHASE1":4514,"PHASE2":4516,"PHASE3":4518,"PHASE4":4520,"NA":4532},{"trials":4513,"activeCount":100},[],{"trials":4515,"activeCount":100},[],{"trials":4517,"activeCount":100},[],{"trials":4519,"activeCount":100},[],{"trials":4521,"activeCount":100},[4522],{"nctId":4523,"briefTitle":4524,"status":141,"phases":4525,"primaryCompletion":4526,"completion":4526,"start":4527,"enrollment":3896,"conditions":4528,"interventions":4530},"NCT02438371","Nifedipine or Nifedipine Plus Indomethacin for Treatment of Acute Preterm Labor",[91],"2019-10-10","2015-05",[4529],"Preterm Labor",[4510,4531],"Indomethacin",{"trials":4533,"activeCount":100},[],{"intervention":4531,"totalTrials":120,"cells":4535},{"EARLY_PHASE1":4536,"PHASE1":4538,"PHASE2":4540,"PHASE3":4542,"PHASE4":4544,"NA":4550},{"trials":4537,"activeCount":100},[],{"trials":4539,"activeCount":100},[],{"trials":4541,"activeCount":100},[],{"trials":4543,"activeCount":100},[],{"trials":4545,"activeCount":100},[4546],{"nctId":4523,"briefTitle":4524,"status":141,"phases":4547,"primaryCompletion":4526,"completion":4526,"start":4527,"enrollment":3896,"conditions":4548,"interventions":4549},[91],[4529],[4510,4531],{"trials":4551,"activeCount":100},[],{"intervention":2060,"totalTrials":120,"cells":4553},{"EARLY_PHASE1":4554,"PHASE1":4556,"PHASE2":4558,"PHASE3":4560,"PHASE4":4562,"NA":4568},{"trials":4555,"activeCount":100},[],{"trials":4557,"activeCount":100},[],{"trials":4559,"activeCount":100},[],{"trials":4561,"activeCount":100},[],{"trials":4563,"activeCount":100},[4564],{"nctId":2049,"briefTitle":2050,"status":126,"phases":4565,"primaryCompletion":2052,"completion":2052,"start":2053,"enrollment":2054,"conditions":4566,"interventions":4567},[91],[2056,2057],[2059,2060],{"trials":4569,"activeCount":100},[],{"intervention":4571,"totalTrials":120,"cells":4572},"Toradol",{"EARLY_PHASE1":4573,"PHASE1":4575,"PHASE2":4577,"PHASE3":4579,"PHASE4":4581,"NA":4593},{"trials":4574,"activeCount":100},[],{"trials":4576,"activeCount":100},[],{"trials":4578,"activeCount":100},[],{"trials":4580,"activeCount":100},[],{"trials":4582,"activeCount":100},[4583],{"nctId":4584,"briefTitle":4585,"status":789,"phases":4586,"primaryCompletion":4587,"completion":4587,"start":4588,"enrollment":100,"conditions":4589,"interventions":4591},"NCT02966288","A Trial to Assess the Pain-control Efficacy of Intra-articular Toradol Compared to Oral NSAIDs",[91],"2019-01","2017-01",[4590],"Arthritic Knee Pain",[4571,4592],"Oral NSAID",{"trials":4594,"activeCount":100},[],{"intervention":4592,"totalTrials":120,"cells":4596},{"EARLY_PHASE1":4597,"PHASE1":4599,"PHASE2":4601,"PHASE3":4603,"PHASE4":4605,"NA":4611},{"trials":4598,"activeCount":100},[],{"trials":4600,"activeCount":100},[],{"trials":4602,"activeCount":100},[],{"trials":4604,"activeCount":100},[],{"trials":4606,"activeCount":100},[4607],{"nctId":4584,"briefTitle":4585,"status":789,"phases":4608,"primaryCompletion":4587,"completion":4587,"start":4588,"enrollment":100,"conditions":4609,"interventions":4610},[91],[4590],[4571,4592],{"trials":4612,"activeCount":100},[],{"intervention":2096,"totalTrials":120,"cells":4614},{"EARLY_PHASE1":4615,"PHASE1":4617,"PHASE2":4619,"PHASE3":4621,"PHASE4":4623,"NA":4629},{"trials":4616,"activeCount":100},[],{"trials":4618,"activeCount":100},[],{"trials":4620,"activeCount":100},[],{"trials":4622,"activeCount":100},[],{"trials":4624,"activeCount":100},[4625],{"nctId":2089,"briefTitle":2090,"status":141,"phases":4626,"primaryCompletion":2092,"completion":2092,"start":2093,"enrollment":1620,"conditions":4627,"interventions":4628},[91],[2016],[2096,2064,2097],{"trials":4630,"activeCount":100},[],{"intervention":2097,"totalTrials":120,"cells":4632},{"EARLY_PHASE1":4633,"PHASE1":4635,"PHASE2":4637,"PHASE3":4639,"PHASE4":4641,"NA":4647},{"trials":4634,"activeCount":100},[],{"trials":4636,"activeCount":100},[],{"trials":4638,"activeCount":100},[],{"trials":4640,"activeCount":100},[],{"trials":4642,"activeCount":100},[4643],{"nctId":2089,"briefTitle":2090,"status":141,"phases":4644,"primaryCompletion":2092,"completion":2092,"start":2093,"enrollment":1620,"conditions":4645,"interventions":4646},[91],[2016],[2096,2064,2097],{"trials":4648,"activeCount":100},[],{"intervention":4650,"totalTrials":120,"cells":4651},"CCK",{"EARLY_PHASE1":4652,"PHASE1":4654,"PHASE2":4656,"PHASE3":4658,"PHASE4":4660,"NA":4671},{"trials":4653,"activeCount":100},[],{"trials":4655,"activeCount":100},[],{"trials":4657,"activeCount":100},[],{"trials":4659,"activeCount":100},[],{"trials":4661,"activeCount":100},[4662],{"nctId":4663,"briefTitle":4664,"status":126,"phases":4665,"primaryCompletion":4666,"completion":4666,"start":4667,"enrollment":1889,"conditions":4668,"interventions":4670},"NCT02748525","Evaluation of Gallbladder Contractility Using Both CCK and Milk Consecutively",[91],"2018-06-14","2016-05-03",[4669],"Abdominal Pain",[4650],{"trials":4672,"activeCount":100},[],{"intervention":1853,"totalTrials":120,"cells":4674},{"EARLY_PHASE1":4675,"PHASE1":4677,"PHASE2":4679,"PHASE3":4681,"PHASE4":4683,"NA":4689},{"trials":4676,"activeCount":100},[],{"trials":4678,"activeCount":100},[],{"trials":4680,"activeCount":100},[],{"trials":4682,"activeCount":100},[],{"trials":4684,"activeCount":100},[4685],{"nctId":1845,"briefTitle":1846,"status":789,"phases":4686,"primaryCompletion":1848,"completion":1848,"start":1849,"enrollment":100,"conditions":4687,"interventions":4688},[91],[1851],[1853,1854],{"trials":4690,"activeCount":100},[],{"intervention":4692,"totalTrials":120,"cells":4693},"Crofelemer",{"EARLY_PHASE1":4694,"PHASE1":4696,"PHASE2":4698,"PHASE3":4700,"PHASE4":4702,"NA":4714},{"trials":4695,"activeCount":100},[],{"trials":4697,"activeCount":100},[],{"trials":4699,"activeCount":100},[],{"trials":4701,"activeCount":100},[],{"trials":4703,"activeCount":100},[4704],{"nctId":4705,"briefTitle":4706,"status":126,"phases":4707,"primaryCompletion":4708,"completion":4708,"start":4709,"enrollment":4710,"conditions":4711,"interventions":4713},"NCT03898856","Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients",[91],"2025-01-30","2019-04-01",93,[4712],"Chronic Diarrhea of Unknown Origin",[4692],{"trials":4715,"activeCount":100},[],{"intervention":4717,"totalTrials":120,"cells":4718},"ritonavir-boosted atazanavir",{"EARLY_PHASE1":4719,"PHASE1":4721,"PHASE2":4723,"PHASE3":4725,"PHASE4":4727,"NA":4737},{"trials":4720,"activeCount":100},[],{"trials":4722,"activeCount":100},[],{"trials":4724,"activeCount":100},[],{"trials":4726,"activeCount":100},[],{"trials":4728,"activeCount":100},[4729],{"nctId":4730,"briefTitle":4731,"status":126,"phases":4732,"primaryCompletion":2187,"completion":2187,"start":4733,"enrollment":1913,"conditions":4734,"interventions":4735},"NCT00242216","\"The Once A Day Protease Inhibitor Regimens\"",[91],"2004-05",[24],[4717,4736],"ritonavir-boosted fosamprenavir",{"trials":4738,"activeCount":100},[],{"intervention":4736,"totalTrials":120,"cells":4740},{"EARLY_PHASE1":4741,"PHASE1":4743,"PHASE2":4745,"PHASE3":4747,"PHASE4":4749,"NA":4755},{"trials":4742,"activeCount":100},[],{"trials":4744,"activeCount":100},[],{"trials":4746,"activeCount":100},[],{"trials":4748,"activeCount":100},[],{"trials":4750,"activeCount":100},[4751],{"nctId":4730,"briefTitle":4731,"status":126,"phases":4752,"primaryCompletion":2187,"completion":2187,"start":4733,"enrollment":1913,"conditions":4753,"interventions":4754},[91],[24],[4717,4736],{"trials":4756,"activeCount":100},[],{"intervention":149,"totalTrials":120,"cells":4758},{"EARLY_PHASE1":4759,"PHASE1":4761,"PHASE2":4763,"PHASE3":4765,"PHASE4":4767,"NA":4773},{"trials":4760,"activeCount":100},[],{"trials":4762,"activeCount":100},[],{"trials":4764,"activeCount":100},[],{"trials":4766,"activeCount":100},[],{"trials":4768,"activeCount":100},[4769],{"nctId":139,"briefTitle":140,"status":141,"phases":4770,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":4771,"interventions":4772},[91],[147],[149,150],{"trials":4774,"activeCount":100},[],{"intervention":4776,"totalTrials":120,"cells":4777},"H.P. Acthar Gel",{"EARLY_PHASE1":4778,"PHASE1":4780,"PHASE2":4782,"PHASE3":4784,"PHASE4":4786,"NA":4796},{"trials":4779,"activeCount":100},[],{"trials":4781,"activeCount":100},[],{"trials":4783,"activeCount":100},[],{"trials":4785,"activeCount":100},[],{"trials":4787,"activeCount":100},[4788],{"nctId":4789,"briefTitle":4790,"status":126,"phases":4791,"primaryCompletion":1912,"completion":1912,"start":4792,"enrollment":9,"conditions":4793,"interventions":4795},"NCT01888354","Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations",[91],"2013-04",[4794],"Multiple Sclerosis (MS)",[4776],{"trials":4797,"activeCount":100},[],{"intervention":4799,"totalTrials":120,"cells":4800},"Vaginal Misoprostol",{"EARLY_PHASE1":4801,"PHASE1":4803,"PHASE2":4805,"PHASE3":4807,"PHASE4":4809,"NA":4822},{"trials":4802,"activeCount":100},[],{"trials":4804,"activeCount":100},[],{"trials":4806,"activeCount":100},[],{"trials":4808,"activeCount":100},[],{"trials":4810,"activeCount":100},[4811],{"nctId":4812,"briefTitle":4813,"status":126,"phases":4814,"primaryCompletion":4815,"completion":4815,"start":4816,"enrollment":4817,"conditions":4818,"interventions":4821},"NCT02639429","Cervical Ripening for Obese Women: A Randomized, Comparative Effectiveness Trial",[91],"2018-06-24","2016-01",236,[18,4819,4820],"Labor Induction","Cesarean Delivery",[4799],{"trials":4823,"activeCount":100},[],{"intervention":4825,"totalTrials":120,"cells":4826},"Haloperidol",{"EARLY_PHASE1":4827,"PHASE1":4829,"PHASE2":4831,"PHASE3":4833,"PHASE4":4835,"NA":4846},{"trials":4828,"activeCount":100},[],{"trials":4830,"activeCount":100},[],{"trials":4832,"activeCount":100},[],{"trials":4834,"activeCount":100},[],{"trials":4836,"activeCount":100},[4837],{"nctId":4838,"briefTitle":4839,"status":141,"phases":4840,"primaryCompletion":1836,"completion":1836,"start":3195,"enrollment":4841,"conditions":4842,"interventions":4844},"NCT02057549","Haloperidol vs Conventional Therapy for Gastroparesis",[91],36,[4843],"Gastroparesis",[4825,4845],"Conventional Therapy",{"trials":4847,"activeCount":100},[],{"intervention":4845,"totalTrials":120,"cells":4849},{"EARLY_PHASE1":4850,"PHASE1":4852,"PHASE2":4854,"PHASE3":4856,"PHASE4":4858,"NA":4864},{"trials":4851,"activeCount":100},[],{"trials":4853,"activeCount":100},[],{"trials":4855,"activeCount":100},[],{"trials":4857,"activeCount":100},[],{"trials":4859,"activeCount":100},[4860],{"nctId":4838,"briefTitle":4839,"status":141,"phases":4861,"primaryCompletion":1836,"completion":1836,"start":3195,"enrollment":4841,"conditions":4862,"interventions":4863},[91],[4843],[4825,4845],{"trials":4865,"activeCount":100},[],{"intervention":4867,"totalTrials":120,"cells":4868},"Oxymetazoline",{"EARLY_PHASE1":4869,"PHASE1":4871,"PHASE2":4873,"PHASE3":4875,"PHASE4":4877,"NA":4889},{"trials":4870,"activeCount":100},[],{"trials":4872,"activeCount":100},[],{"trials":4874,"activeCount":100},[],{"trials":4876,"activeCount":100},[],{"trials":4878,"activeCount":100},[4879],{"nctId":4880,"briefTitle":4881,"status":126,"phases":4882,"primaryCompletion":4883,"completion":4883,"start":4666,"enrollment":19,"conditions":4884,"interventions":4887},"NCT03228914","Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery",[91],"2018-08-29",[4885,4886],"Endoscopic Sinus Surgery","Nasal Polyps",[4867,4888],"Epinephrine",{"trials":4890,"activeCount":100},[],{"intervention":4888,"totalTrials":120,"cells":4892},{"EARLY_PHASE1":4893,"PHASE1":4895,"PHASE2":4897,"PHASE3":4899,"PHASE4":4901,"NA":4907},{"trials":4894,"activeCount":100},[],{"trials":4896,"activeCount":100},[],{"trials":4898,"activeCount":100},[],{"trials":4900,"activeCount":100},[],{"trials":4902,"activeCount":100},[4903],{"nctId":4880,"briefTitle":4881,"status":126,"phases":4904,"primaryCompletion":4883,"completion":4883,"start":4666,"enrollment":19,"conditions":4905,"interventions":4906},[91],[4885,4886],[4867,4888],{"trials":4908,"activeCount":100},[],{"intervention":4910,"totalTrials":120,"cells":4911},"Papaverine",{"EARLY_PHASE1":4912,"PHASE1":4914,"PHASE2":4916,"PHASE3":4918,"PHASE4":4920,"NA":4933},{"trials":4913,"activeCount":100},[],{"trials":4915,"activeCount":100},[],{"trials":4917,"activeCount":100},[],{"trials":4919,"activeCount":100},[],{"trials":4921,"activeCount":100},[4922],{"nctId":4923,"briefTitle":4924,"status":126,"phases":4925,"primaryCompletion":4926,"completion":4926,"start":4709,"enrollment":728,"conditions":4927,"interventions":4930},"NCT03894904","Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric Patients",[91],"2020-10-10",[4928,573,4929],"Pediatrics","Vasospasm",[4910,4931,4932],"Heparin","Rescue papaverine, as needed",{"trials":4934,"activeCount":100},[],{"intervention":4931,"totalTrials":120,"cells":4936},{"EARLY_PHASE1":4937,"PHASE1":4939,"PHASE2":4941,"PHASE3":4943,"PHASE4":4945,"NA":4951},{"trials":4938,"activeCount":100},[],{"trials":4940,"activeCount":100},[],{"trials":4942,"activeCount":100},[],{"trials":4944,"activeCount":100},[],{"trials":4946,"activeCount":100},[4947],{"nctId":4923,"briefTitle":4924,"status":126,"phases":4948,"primaryCompletion":4926,"completion":4926,"start":4709,"enrollment":728,"conditions":4949,"interventions":4950},[91],[4928,573,4929],[4910,4931,4932],{"trials":4952,"activeCount":100},[],{"intervention":4932,"totalTrials":120,"cells":4954},{"EARLY_PHASE1":4955,"PHASE1":4957,"PHASE2":4959,"PHASE3":4961,"PHASE4":4963,"NA":4969},{"trials":4956,"activeCount":100},[],{"trials":4958,"activeCount":100},[],{"trials":4960,"activeCount":100},[],{"trials":4962,"activeCount":100},[],{"trials":4964,"activeCount":100},[4965],{"nctId":4923,"briefTitle":4924,"status":126,"phases":4966,"primaryCompletion":4926,"completion":4926,"start":4709,"enrollment":728,"conditions":4967,"interventions":4968},[91],[4928,573,4929],[4910,4931,4932],{"trials":4970,"activeCount":100},[],{"intervention":2358,"totalTrials":120,"cells":4972},{"EARLY_PHASE1":4973,"PHASE1":4975,"PHASE2":4977,"PHASE3":4979,"PHASE4":4981,"NA":4987},{"trials":4974,"activeCount":100},[],{"trials":4976,"activeCount":100},[],{"trials":4978,"activeCount":100},[],{"trials":4980,"activeCount":100},[],{"trials":4982,"activeCount":100},[4983],{"nctId":2350,"briefTitle":2351,"status":126,"phases":4984,"primaryCompletion":130,"completion":2353,"start":2354,"enrollment":728,"conditions":4985,"interventions":4986},[91],[2356],[2358,2019],{"trials":4988,"activeCount":100},[],{"intervention":4990,"totalTrials":120,"cells":4991},"Hydrogen Peroxide",{"EARLY_PHASE1":4992,"PHASE1":4994,"PHASE2":4996,"PHASE3":4998,"PHASE4":5000,"NA":5012},{"trials":4993,"activeCount":100},[],{"trials":4995,"activeCount":100},[],{"trials":4997,"activeCount":100},[],{"trials":4999,"activeCount":100},[],{"trials":5001,"activeCount":100},[5002],{"nctId":5003,"briefTitle":5004,"status":126,"phases":5005,"primaryCompletion":5006,"completion":5006,"start":5007,"enrollment":5008,"conditions":5009,"interventions":5011},"NCT04659928","Evaluation of Aerosol in a Dental Clinic",[91],"2024-05-02","2021-07-21",41,[5010],"Covid19",[4990],{"trials":5013,"activeCount":100},[],{"intervention":5015,"totalTrials":120,"cells":5016},"Group A",{"EARLY_PHASE1":5017,"PHASE1":5019,"PHASE2":5021,"PHASE3":5023,"PHASE4":5025,"NA":5037},{"trials":5018,"activeCount":100},[],{"trials":5020,"activeCount":100},[],{"trials":5022,"activeCount":100},[],{"trials":5024,"activeCount":100},[],{"trials":5026,"activeCount":100},[5027],{"nctId":5028,"briefTitle":5029,"status":789,"phases":5030,"primaryCompletion":5031,"completion":5031,"start":5032,"enrollment":100,"conditions":5033,"interventions":5034},"NCT04540848","Post Operative Pain Control for Distal Radius Surgery: Does Exparel Injected at the Surgery Site Improve Postoperative Pain Scores at 24 and 48 Hours ?",[91],"2021-11-20","2021-03-01",[1904],[5015,5035,5036],"Group B","Group C",{"trials":5038,"activeCount":100},[],{"intervention":5035,"totalTrials":120,"cells":5040},{"EARLY_PHASE1":5041,"PHASE1":5043,"PHASE2":5045,"PHASE3":5047,"PHASE4":5049,"NA":5055},{"trials":5042,"activeCount":100},[],{"trials":5044,"activeCount":100},[],{"trials":5046,"activeCount":100},[],{"trials":5048,"activeCount":100},[],{"trials":5050,"activeCount":100},[5051],{"nctId":5028,"briefTitle":5029,"status":789,"phases":5052,"primaryCompletion":5031,"completion":5031,"start":5032,"enrollment":100,"conditions":5053,"interventions":5054},[91],[1904],[5015,5035,5036],{"trials":5056,"activeCount":100},[],{"intervention":5036,"totalTrials":120,"cells":5058},{"EARLY_PHASE1":5059,"PHASE1":5061,"PHASE2":5063,"PHASE3":5065,"PHASE4":5067,"NA":5073},{"trials":5060,"activeCount":100},[],{"trials":5062,"activeCount":100},[],{"trials":5064,"activeCount":100},[],{"trials":5066,"activeCount":100},[],{"trials":5068,"activeCount":100},[5069],{"nctId":5028,"briefTitle":5029,"status":789,"phases":5070,"primaryCompletion":5031,"completion":5031,"start":5032,"enrollment":100,"conditions":5071,"interventions":5072},[91],[1904],[5015,5035,5036],{"trials":5074,"activeCount":100},[],{"intervention":5076,"totalTrials":120,"cells":5077},"Epidural anesthesia",{"EARLY_PHASE1":5078,"PHASE1":5080,"PHASE2":5082,"PHASE3":5084,"PHASE4":5086,"NA":5099},{"trials":5079,"activeCount":100},[],{"trials":5081,"activeCount":100},[],{"trials":5083,"activeCount":100},[],{"trials":5085,"activeCount":100},[],{"trials":5087,"activeCount":100},[5088],{"nctId":5089,"briefTitle":5090,"status":126,"phases":5091,"primaryCompletion":5092,"completion":5092,"start":2128,"enrollment":2784,"conditions":5093,"interventions":5097},"NCT02105558","Outcomes of Neuraxial Anesthetic Technique on the Trial of Labor After Cesarean (TOLAC)",[91],"2017-04-13",[5094,5095,5096],"Labor Pain","Complications; Cesarean Section","Pregnancy",[5076,5098],"Combined spinal and epidural anesthesia",{"trials":5100,"activeCount":100},[],{"intervention":5098,"totalTrials":120,"cells":5102},{"EARLY_PHASE1":5103,"PHASE1":5105,"PHASE2":5107,"PHASE3":5109,"PHASE4":5111,"NA":5117},{"trials":5104,"activeCount":100},[],{"trials":5106,"activeCount":100},[],{"trials":5108,"activeCount":100},[],{"trials":5110,"activeCount":100},[],{"trials":5112,"activeCount":100},[5113],{"nctId":5089,"briefTitle":5090,"status":126,"phases":5114,"primaryCompletion":5092,"completion":5092,"start":2128,"enrollment":2784,"conditions":5115,"interventions":5116},[91],[5094,5095,5096],[5076,5098],{"trials":5118,"activeCount":100},[],{"intervention":5120,"totalTrials":120,"cells":5121},"Transfusion of blood products",{"EARLY_PHASE1":5122,"PHASE1":5124,"PHASE2":5126,"PHASE3":5128,"PHASE4":5130,"NA":5141},{"trials":5123,"activeCount":100},[],{"trials":5125,"activeCount":100},[],{"trials":5127,"activeCount":100},[],{"trials":5129,"activeCount":100},[],{"trials":5131,"activeCount":100},[5132],{"nctId":5133,"briefTitle":5134,"status":126,"phases":5135,"primaryCompletion":5136,"completion":3682,"start":1862,"enrollment":5137,"conditions":5138,"interventions":5140},"NCT01227005","Early Whole Blood in Patients Requiring Transfusion After Major Trauma",[91],"2012-08",107,[5139],"Trauma\u002FInjury Problem",[5120],{"trials":5142,"activeCount":100},[],{"intervention":5144,"totalTrials":120,"cells":5145},"Estradiol",{"EARLY_PHASE1":5146,"PHASE1":5148,"PHASE2":5150,"PHASE3":5152,"PHASE4":5165,"NA":5167},{"trials":5147,"activeCount":100},[],{"trials":5149,"activeCount":100},[],{"trials":5151,"activeCount":100},[],{"trials":5153,"activeCount":100},[5154],{"nctId":5155,"briefTitle":5156,"status":126,"phases":5157,"primaryCompletion":5158,"completion":5159,"start":5160,"enrollment":5161,"conditions":5162,"interventions":5164},"NCT04192266","Estrogen and Fear in PTSD",[90],"2024-05-29","2024-12-02","2020-06-24",83,[5163],"PTSD",[5144],{"trials":5166,"activeCount":100},[],{"trials":5168,"activeCount":100},[],{"intervention":5170,"totalTrials":120,"cells":5171},"Cyclophosphamide",{"EARLY_PHASE1":5172,"PHASE1":5174,"PHASE2":5176,"PHASE3":5178,"PHASE4":5193,"NA":5195},{"trials":5173,"activeCount":100},[],{"trials":5175,"activeCount":100},[],{"trials":5177,"activeCount":100},[],{"trials":5179,"activeCount":100},[5180],{"nctId":5181,"briefTitle":5182,"status":126,"phases":5183,"primaryCompletion":5184,"completion":5184,"start":5185,"enrollment":5186,"conditions":5187,"interventions":5192},"NCT00004563","Scleroderma Lung Disease",[90],"2013-05","1999-08",158,[5188,5189,5190,5191],"Lung Diseases","Pulmonary Fibrosis","Systemic Scleroderma","Scleroderma, Systemic",[5170],{"trials":5194,"activeCount":100},[],{"trials":5196,"activeCount":100},[],{"intervention":5198,"totalTrials":120,"cells":5199},"Methylphenidate-extended release",{"EARLY_PHASE1":5200,"PHASE1":5202,"PHASE2":5204,"PHASE3":5206,"PHASE4":5217,"NA":5219},{"trials":5201,"activeCount":100},[],{"trials":5203,"activeCount":100},[],{"trials":5205,"activeCount":100},[],{"trials":5207,"activeCount":100},[5208],{"nctId":5209,"briefTitle":5210,"status":126,"phases":5211,"primaryCompletion":1862,"completion":1862,"start":2892,"enrollment":845,"conditions":5212,"interventions":5215},"NCT00178503","Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children",[89,90],[5213,5214],"Autism","Attention Deficit Disorder With Hyperactivity",[5198,5216],"Methylphenidate-immediate release",{"trials":5218,"activeCount":100},[],{"trials":5220,"activeCount":100},[],{"intervention":5216,"totalTrials":120,"cells":5222},{"EARLY_PHASE1":5223,"PHASE1":5225,"PHASE2":5227,"PHASE3":5229,"PHASE4":5235,"NA":5237},{"trials":5224,"activeCount":100},[],{"trials":5226,"activeCount":100},[],{"trials":5228,"activeCount":100},[],{"trials":5230,"activeCount":100},[5231],{"nctId":5209,"briefTitle":5210,"status":126,"phases":5232,"primaryCompletion":1862,"completion":1862,"start":2892,"enrollment":845,"conditions":5233,"interventions":5234},[89,90],[5213,5214],[5198,5216],{"trials":5236,"activeCount":100},[],{"trials":5238,"activeCount":100},[],{"intervention":5240,"totalTrials":120,"cells":5241},"Dextromethorphan\u002Fquinidine 20mg\u002F10mg",{"EARLY_PHASE1":5242,"PHASE1":5244,"PHASE2":5246,"PHASE3":5248,"PHASE4":5260,"NA":5262},{"trials":5243,"activeCount":100},[],{"trials":5245,"activeCount":100},[],{"trials":5247,"activeCount":100},[],{"trials":5249,"activeCount":100},[5250],{"nctId":5251,"briefTitle":5252,"status":126,"phases":5253,"primaryCompletion":5254,"completion":5254,"start":5255,"enrollment":19,"conditions":5256,"interventions":5259},"NCT03854019","Evaluating the Efficacy of Dextromethorphan\u002FQuinidine in Treating Irritability in Huntington's Disease",[90],"2022-11-11","2019-08-05",[5257,5258],"Huntington Disease","Irritability",[5240],{"trials":5261,"activeCount":100},[],{"trials":5263,"activeCount":100},[],{"intervention":5265,"totalTrials":120,"cells":5266},"Aspirin 81 mg",{"EARLY_PHASE1":5267,"PHASE1":5269,"PHASE2":5271,"PHASE3":5273,"PHASE4":5285,"NA":5287},{"trials":5268,"activeCount":100},[],{"trials":5270,"activeCount":100},[],{"trials":5272,"activeCount":100},[],{"trials":5274,"activeCount":100},[5275],{"nctId":5276,"briefTitle":5277,"status":126,"phases":5278,"primaryCompletion":5279,"completion":5279,"start":5280,"enrollment":5281,"conditions":5282,"interventions":5283},"NCT03961360","Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida",[89,90],"2023-04-10","2019-05-06",220,[508,3276,18],[5265,5284],"Aspirin 162 mg",{"trials":5286,"activeCount":100},[],{"trials":5288,"activeCount":100},[],{"intervention":5284,"totalTrials":120,"cells":5290},{"EARLY_PHASE1":5291,"PHASE1":5293,"PHASE2":5295,"PHASE3":5297,"PHASE4":5303,"NA":5305},{"trials":5292,"activeCount":100},[],{"trials":5294,"activeCount":100},[],{"trials":5296,"activeCount":100},[],{"trials":5298,"activeCount":100},[5299],{"nctId":5276,"briefTitle":5277,"status":126,"phases":5300,"primaryCompletion":5279,"completion":5279,"start":5280,"enrollment":5281,"conditions":5301,"interventions":5302},[89,90],[508,3276,18],[5265,5284],{"trials":5304,"activeCount":100},[],{"trials":5306,"activeCount":100},[],{"intervention":5308,"totalTrials":120,"cells":5309},"Intranasal ketamine",{"EARLY_PHASE1":5310,"PHASE1":5312,"PHASE2":5314,"PHASE3":5316,"PHASE4":5329,"NA":5331},{"trials":5311,"activeCount":100},[],{"trials":5313,"activeCount":100},[],{"trials":5315,"activeCount":100},[],{"trials":5317,"activeCount":100},[5318],{"nctId":5319,"briefTitle":5320,"status":126,"phases":5321,"primaryCompletion":5322,"completion":5322,"start":5323,"enrollment":2189,"conditions":5324,"interventions":5328},"NCT03539887","Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse",[90],"2022-01-15","2018-05-01",[5325,5326,5327],"Suicidal Ideation","Depression","Alcohol Abuse",[5308],{"trials":5330,"activeCount":100},[],{"trials":5332,"activeCount":100},[],{"intervention":1322,"totalTrials":120,"cells":5334},{"EARLY_PHASE1":5335,"PHASE1":5337,"PHASE2":5339,"PHASE3":5341,"PHASE4":5347,"NA":5349},{"trials":5336,"activeCount":100},[],{"trials":5338,"activeCount":100},[],{"trials":5340,"activeCount":100},[],{"trials":5342,"activeCount":100},[5343],{"nctId":1313,"briefTitle":1314,"status":126,"phases":5344,"primaryCompletion":1316,"completion":1316,"start":1317,"enrollment":1318,"conditions":5345,"interventions":5346},[90],[1320],[1283,1322],{"trials":5348,"activeCount":100},[],{"trials":5350,"activeCount":100},[],{"intervention":5352,"totalTrials":120,"cells":5353},"Metaclopramide",{"EARLY_PHASE1":5354,"PHASE1":5356,"PHASE2":5358,"PHASE3":5360,"PHASE4":5372,"NA":5374},{"trials":5355,"activeCount":100},[],{"trials":5357,"activeCount":100},[],{"trials":5359,"activeCount":100},[],{"trials":5361,"activeCount":100},[5362],{"nctId":5363,"briefTitle":5364,"status":126,"phases":5365,"primaryCompletion":3449,"completion":3449,"start":5366,"enrollment":5367,"conditions":5368,"interventions":5370},"NCT00131248","Medical Treatment for Gastroesophageal Reflux Disease (GERD) in Preterm Infants",[90],"2004-04",18,[5369],"Gastroesophageal Reflux",[5352,5371],"Ranitidine",{"trials":5373,"activeCount":100},[],{"trials":5375,"activeCount":100},[],{"intervention":5371,"totalTrials":120,"cells":5377},{"EARLY_PHASE1":5378,"PHASE1":5380,"PHASE2":5382,"PHASE3":5384,"PHASE4":5390,"NA":5392},{"trials":5379,"activeCount":100},[],{"trials":5381,"activeCount":100},[],{"trials":5383,"activeCount":100},[],{"trials":5385,"activeCount":100},[5386],{"nctId":5363,"briefTitle":5364,"status":126,"phases":5387,"primaryCompletion":3449,"completion":3449,"start":5366,"enrollment":5367,"conditions":5388,"interventions":5389},[90],[5369],[5352,5371],{"trials":5391,"activeCount":100},[],{"trials":5393,"activeCount":100},[],{"intervention":5395,"totalTrials":120,"cells":5396},"Sildenafil",{"EARLY_PHASE1":5397,"PHASE1":5399,"PHASE2":5401,"PHASE3":5403,"PHASE4":5413,"NA":5415},{"trials":5398,"activeCount":100},[],{"trials":5400,"activeCount":100},[],{"trials":5402,"activeCount":100},[],{"trials":5404,"activeCount":100},[5405],{"nctId":5406,"briefTitle":5407,"status":789,"phases":5408,"primaryCompletion":5409,"completion":5409,"start":2114,"enrollment":100,"conditions":5410,"interventions":5412},"NCT02782559","Efficacy of Sildenafil in Preterm Preeclampsia",[89,90],"2017-07",[5411],"Preterm Preeclampsia",[5395],{"trials":5414,"activeCount":100},[],{"trials":5416,"activeCount":100},[],{"intervention":5418,"totalTrials":120,"cells":5419},"Iron Supplement",{"EARLY_PHASE1":5420,"PHASE1":5422,"PHASE2":5424,"PHASE3":5426,"PHASE4":5439,"NA":5441},{"trials":5421,"activeCount":100},[],{"trials":5423,"activeCount":100},[],{"trials":5425,"activeCount":100},[],{"trials":5427,"activeCount":100},[5428],{"nctId":5429,"briefTitle":5430,"status":126,"phases":5431,"primaryCompletion":5432,"completion":5432,"start":5433,"enrollment":5434,"conditions":5435,"interventions":5437},"NCT01224236","Randomized Trial of Iron Supplementation to Prevent Anemia in Very-low-birth-weight Infants",[89,90],"2012-02","2010-07",150,[5436],"Anemia",[5418,5438],"control",{"trials":5440,"activeCount":100},[],{"trials":5442,"activeCount":100},[],{"intervention":5438,"totalTrials":120,"cells":5444},{"EARLY_PHASE1":5445,"PHASE1":5447,"PHASE2":5449,"PHASE3":5451,"PHASE4":5457,"NA":5459},{"trials":5446,"activeCount":100},[],{"trials":5448,"activeCount":100},[],{"trials":5450,"activeCount":100},[],{"trials":5452,"activeCount":100},[5453],{"nctId":5429,"briefTitle":5430,"status":126,"phases":5454,"primaryCompletion":5432,"completion":5432,"start":5433,"enrollment":5434,"conditions":5455,"interventions":5456},[89,90],[5436],[5418,5438],{"trials":5458,"activeCount":100},[],{"trials":5460,"activeCount":100},[],{"intervention":5462,"totalTrials":120,"cells":5463},"Itraconazole",{"EARLY_PHASE1":5464,"PHASE1":5466,"PHASE2":5468,"PHASE3":5470,"PHASE4":5480,"NA":5482},{"trials":5465,"activeCount":100},[],{"trials":5467,"activeCount":100},[],{"trials":5469,"activeCount":100},[],{"trials":5471,"activeCount":100},[5472],{"nctId":5473,"briefTitle":5474,"status":141,"phases":5475,"primaryCompletion":768,"completion":768,"start":5476,"enrollment":781,"conditions":5477,"interventions":5479},"NCT02285283","Itraconazole for Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps",[89,90],"2014-11",[5478],"Chronic Rhinosinusitis",[5462],{"trials":5481,"activeCount":100},[],{"trials":5483,"activeCount":100},[],{"intervention":5485,"totalTrials":120,"cells":5486},"Postoperative methadone",{"EARLY_PHASE1":5487,"PHASE1":5489,"PHASE2":5491,"PHASE3":5493,"PHASE4":5506,"NA":5508},{"trials":5488,"activeCount":100},[],{"trials":5490,"activeCount":100},[],{"trials":5492,"activeCount":100},[],{"trials":5494,"activeCount":100},[5495],{"nctId":5496,"briefTitle":5497,"status":789,"phases":5498,"primaryCompletion":5499,"completion":5499,"start":5500,"enrollment":100,"conditions":5501,"interventions":5503},"NCT05693675","Postoperative Oral Methadone After Major Spine Surgery; Safety, Feasibility and Efficacy in Prevention of Progression to Chronic Opioid Usage at 3 Months",[89,90],"2024-07-01","2023-10-01",[5502],"Spine Surgery",[5485,5504,5505],"Postoperative placebo","Rescue Analgesia",{"trials":5507,"activeCount":100},[],{"trials":5509,"activeCount":100},[],{"intervention":5504,"totalTrials":120,"cells":5511},{"EARLY_PHASE1":5512,"PHASE1":5514,"PHASE2":5516,"PHASE3":5518,"PHASE4":5524,"NA":5526},{"trials":5513,"activeCount":100},[],{"trials":5515,"activeCount":100},[],{"trials":5517,"activeCount":100},[],{"trials":5519,"activeCount":100},[5520],{"nctId":5496,"briefTitle":5497,"status":789,"phases":5521,"primaryCompletion":5499,"completion":5499,"start":5500,"enrollment":100,"conditions":5522,"interventions":5523},[89,90],[5502],[5485,5504,5505],{"trials":5525,"activeCount":100},[],{"trials":5527,"activeCount":100},[],{"intervention":5505,"totalTrials":120,"cells":5529},{"EARLY_PHASE1":5530,"PHASE1":5532,"PHASE2":5534,"PHASE3":5536,"PHASE4":5542,"NA":5544},{"trials":5531,"activeCount":100},[],{"trials":5533,"activeCount":100},[],{"trials":5535,"activeCount":100},[],{"trials":5537,"activeCount":100},[5538],{"nctId":5496,"briefTitle":5497,"status":789,"phases":5539,"primaryCompletion":5499,"completion":5499,"start":5500,"enrollment":100,"conditions":5540,"interventions":5541},[89,90],[5502],[5485,5504,5505],{"trials":5543,"activeCount":100},[],{"trials":5545,"activeCount":100},[],{"intervention":5547,"totalTrials":120,"cells":5548},"1:1:1 Blood Transfusion Ratio",{"EARLY_PHASE1":5549,"PHASE1":5551,"PHASE2":5553,"PHASE3":5555,"PHASE4":5566,"NA":5568},{"trials":5550,"activeCount":100},[],{"trials":5552,"activeCount":100},[],{"trials":5554,"activeCount":100},[],{"trials":5556,"activeCount":100},[5557],{"nctId":5558,"briefTitle":5559,"status":126,"phases":5560,"primaryCompletion":4316,"completion":4316,"start":5136,"enrollment":5561,"conditions":5562,"interventions":5564},"NCT01545232","Pragmatic, Randomized Optimal Platelet and Plasma Ratios",[90],680,[5563],"Trauma",[5547,5565],"1:1:2 Blood Transfusion Ratio",{"trials":5567,"activeCount":100},[],{"trials":5569,"activeCount":100},[],{"intervention":5565,"totalTrials":120,"cells":5571},{"EARLY_PHASE1":5572,"PHASE1":5574,"PHASE2":5576,"PHASE3":5578,"PHASE4":5584,"NA":5586},{"trials":5573,"activeCount":100},[],{"trials":5575,"activeCount":100},[],{"trials":5577,"activeCount":100},[],{"trials":5579,"activeCount":100},[5580],{"nctId":5558,"briefTitle":5559,"status":126,"phases":5581,"primaryCompletion":4316,"completion":4316,"start":5136,"enrollment":5561,"conditions":5582,"interventions":5583},[90],[5563],[5547,5565],{"trials":5585,"activeCount":100},[],{"trials":5587,"activeCount":100},[],{"intervention":5589,"totalTrials":120,"cells":5590},"Quadruple sequential Helicobacter pylori eradication + iron sulfate",{"EARLY_PHASE1":5591,"PHASE1":5593,"PHASE2":5595,"PHASE3":5597,"PHASE4":5610,"NA":5612},{"trials":5592,"activeCount":100},[],{"trials":5594,"activeCount":100},[],{"trials":5596,"activeCount":100},[],{"trials":5598,"activeCount":100},[5599],{"nctId":5600,"briefTitle":5601,"status":126,"phases":5602,"primaryCompletion":5603,"completion":5603,"start":5604,"enrollment":2614,"conditions":5605,"interventions":5607},"NCT00364104","Helicobacter Pylori Eradication Trial to Reduce Iron Deficiency in Children",[90],"2008-12","2007-03",[5606],"Iron Deficiency",[5589,5608,5609],"Quadruple sequential Helicobacter pylori eradication therapy","Ferrous sulfate",{"trials":5611,"activeCount":100},[],{"trials":5613,"activeCount":100},[],{"intervention":5608,"totalTrials":120,"cells":5615},{"EARLY_PHASE1":5616,"PHASE1":5618,"PHASE2":5620,"PHASE3":5622,"PHASE4":5628,"NA":5630},{"trials":5617,"activeCount":100},[],{"trials":5619,"activeCount":100},[],{"trials":5621,"activeCount":100},[],{"trials":5623,"activeCount":100},[5624],{"nctId":5600,"briefTitle":5601,"status":126,"phases":5625,"primaryCompletion":5603,"completion":5603,"start":5604,"enrollment":2614,"conditions":5626,"interventions":5627},[90],[5606],[5589,5608,5609],{"trials":5629,"activeCount":100},[],{"trials":5631,"activeCount":100},[],{"intervention":5609,"totalTrials":120,"cells":5633},{"EARLY_PHASE1":5634,"PHASE1":5636,"PHASE2":5638,"PHASE3":5640,"PHASE4":5646,"NA":5648},{"trials":5635,"activeCount":100},[],{"trials":5637,"activeCount":100},[],{"trials":5639,"activeCount":100},[],{"trials":5641,"activeCount":100},[5642],{"nctId":5600,"briefTitle":5601,"status":126,"phases":5643,"primaryCompletion":5603,"completion":5603,"start":5604,"enrollment":2614,"conditions":5644,"interventions":5645},[90],[5606],[5589,5608,5609],{"trials":5647,"activeCount":100},[],{"trials":5649,"activeCount":100},[],{"intervention":5651,"totalTrials":1797,"cells":5652},"Pioglitazone",{"EARLY_PHASE1":5653,"PHASE1":5655,"PHASE2":5657,"PHASE3":5699,"PHASE4":5701,"NA":5703},{"trials":5654,"activeCount":100},[],{"trials":5656,"activeCount":100},[],{"trials":5658,"activeCount":100},[5659,5669,5678,5686,5693],{"nctId":5660,"briefTitle":5661,"status":126,"phases":5662,"primaryCompletion":5663,"completion":5664,"start":5665,"enrollment":5666,"conditions":5667,"interventions":5668},"NCT04843046","Pioglitazone as an Adjunct to Cognitive-Behavioral Therapy for Cocaine Relapse Prevention",[89],"2025-09-26","2025-10-15","2021-08-23",61,[179],[5651],{"nctId":5670,"briefTitle":5671,"status":126,"phases":5672,"primaryCompletion":5673,"completion":5673,"start":5674,"enrollment":11,"conditions":5675,"interventions":5677},"NCT05107765","Effects of Pioglitazone on Stress Reactivity and Alcohol Craving",[88,89],"2024-08-16","2022-05-12",[5676],"Alcohol Use Disorder",[5651],{"nctId":5679,"briefTitle":5680,"status":141,"phases":5681,"primaryCompletion":5682,"completion":5682,"start":5683,"enrollment":96,"conditions":5684,"interventions":5685},"NCT03860753","Effects of Pioglitazone on Stress Reactivity and Alcohol Craving (Pilot)",[88,89],"2019-08-23","2019-03-01",[5676],[5651],{"nctId":5687,"briefTitle":5688,"status":126,"phases":5689,"primaryCompletion":4792,"completion":1948,"start":3851,"enrollment":2115,"conditions":5690,"interventions":5692},"NCT00827892","Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage",[89],[5691],"Intracerebral Hemorrhage",[5651],{"nctId":5694,"briefTitle":5695,"status":126,"phases":5696,"primaryCompletion":2321,"completion":2321,"start":5136,"enrollment":258,"conditions":5697,"interventions":5698},"NCT02774343","PPARγ Agonist Treatment for Cocaine Dependence",[88,89],[179,5676],[5651],{"trials":5700,"activeCount":100},[],{"trials":5702,"activeCount":100},[],{"trials":5704,"activeCount":100},[],{"intervention":5706,"totalTrials":96,"cells":5707},"Docetaxel",{"EARLY_PHASE1":5708,"PHASE1":5710,"PHASE2":5712,"PHASE3":5750,"PHASE4":5752,"NA":5754},{"trials":5709,"activeCount":100},[],{"trials":5711,"activeCount":100},[],{"trials":5713,"activeCount":100},[5714,5726,5735,5741],{"nctId":5715,"briefTitle":5716,"status":141,"phases":5717,"primaryCompletion":5718,"completion":5718,"start":5719,"enrollment":96,"conditions":5720,"interventions":5721},"NCT02494713","Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer",[89],"2017-09-14","2015-10",[2170],[5722,5723,5724,5706,5725],"Degarelix","Doxorubicin","Ketoconazole","Estramustine",{"nctId":5727,"briefTitle":5728,"status":789,"phases":5729,"primaryCompletion":5730,"completion":5731,"start":1860,"enrollment":100,"conditions":5732,"interventions":5733},"NCT02793765","Docetaxel Followed by Provenge in Metastatic Prostate Cancer",[89],"2018-07","2021-07",[2170],[5706,5734],"Sipuleucel-T",{"nctId":5736,"briefTitle":5737,"status":789,"phases":5738,"primaryCompletion":5730,"completion":5731,"start":1860,"enrollment":100,"conditions":5739,"interventions":5740},"NCT02793219","Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer",[89],[2170],[5734,5706],{"nctId":5742,"briefTitle":5743,"status":141,"phases":5744,"primaryCompletion":5745,"completion":5718,"start":5746,"enrollment":1809,"conditions":5747,"interventions":5749},"NCT02560051","Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer",[89],"2017-09-12","2015-11",[5748],"Prostatic Neoplasms",[5723,5724,5706,5725,5722],{"trials":5751,"activeCount":100},[],{"trials":5753,"activeCount":100},[],{"trials":5755,"activeCount":100},[],{"intervention":5757,"totalTrials":1620,"cells":5758},"autologous bone marrow mononuclear cells",{"EARLY_PHASE1":5759,"PHASE1":5761,"PHASE2":5771,"PHASE3":5790,"PHASE4":5792,"NA":5794},{"trials":5760,"activeCount":100},[],{"trials":5762,"activeCount":100},[5763],{"nctId":5764,"briefTitle":5765,"status":126,"phases":5766,"primaryCompletion":1948,"completion":1948,"start":1679,"enrollment":9,"conditions":5767,"interventions":5769},"NCT00859014","Safety\u002FFeasibility of Autologous Mononuclear Bone Marrow Cells in Stroke Patients",[88],[5768],"Ischemic Stroke",[5770],"Autologous Bone Marrow Mononuclear Cells",{"trials":5772,"activeCount":100},[5773,5780],{"nctId":5774,"briefTitle":5775,"status":126,"phases":5776,"primaryCompletion":4527,"completion":4527,"start":5777,"enrollment":9,"conditions":5778,"interventions":5779},"NCT01575470","Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells",[88,89],"2012-03",[29],[5757],{"nctId":5781,"briefTitle":5782,"status":126,"phases":5783,"primaryCompletion":5784,"completion":5785,"start":5786,"enrollment":5787,"conditions":5788,"interventions":5789},"NCT01851083","Pediatric Autologous Bone Marrow Mononuclear Cells for Severe Traumatic Brain Injury",[89],"2020-09-16","2020-10-12","2013-08",47,[29],[5757],{"trials":5791,"activeCount":100},[],{"trials":5793,"activeCount":100},[],{"trials":5795,"activeCount":100},[],{"intervention":5797,"totalTrials":1620,"cells":5798},"cisplatin",{"EARLY_PHASE1":5799,"PHASE1":5801,"PHASE2":5803,"PHASE3":5834,"PHASE4":5836,"NA":5838},{"trials":5800,"activeCount":100},[],{"trials":5802,"activeCount":100},[],{"trials":5804,"activeCount":100},[5805,5815,5825],{"nctId":5806,"briefTitle":5807,"status":1858,"phases":5808,"primaryCompletion":5809,"start":5185,"enrollment":258,"conditions":5810,"interventions":5812},"NCT00004063","Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer",[88,89],"2011-11",[5811],"Unspecified Adult Solid Tumor, Protocol Specific",[5813,5797,5814],"recombinant interferon alfa","gemcitabine hydrochloride",{"nctId":5816,"briefTitle":5817,"status":141,"phases":5818,"primaryCompletion":5718,"completion":5718,"start":5719,"enrollment":1620,"conditions":5819,"interventions":5821},"NCT02560038","Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer",[89],[5820],"Urinary Bladder Neoplasms",[5822,5823,5824],"Gemcitabine","Paclitaxel","Cisplatin",{"nctId":5826,"briefTitle":5827,"status":1858,"phases":5828,"primaryCompletion":3195,"start":5829,"enrollment":5830,"conditions":5831,"interventions":5833},"NCT00082862","Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer",[89],"2002-07",48,[5832],"Pancreatic Cancer",[5813,5797,5814],{"trials":5835,"activeCount":100},[],{"trials":5837,"activeCount":100},[],{"trials":5839,"activeCount":100},[],{"intervention":5841,"totalTrials":1620,"cells":5842},"Ketamine",{"EARLY_PHASE1":5843,"PHASE1":5845,"PHASE2":5847,"PHASE3":5875,"PHASE4":5877,"NA":5879},{"trials":5844,"activeCount":100},[],{"trials":5846,"activeCount":100},[],{"trials":5848,"activeCount":100},[5849,5857,5867],{"nctId":5850,"briefTitle":5851,"status":789,"phases":5852,"primaryCompletion":5853,"completion":5853,"start":1967,"enrollment":100,"conditions":5854,"interventions":5856},"NCT04061330","Comparison of Low-dose Ketamine to Opioids in the Management of Acute Pain in Patients Presenting to the Emergency Department With Long Bone Fractures",[89],"2022-12-31",[5855],"Pain, Acute",[5841,1969],{"nctId":5858,"briefTitle":5859,"status":126,"phases":5860,"primaryCompletion":5861,"completion":5861,"start":5862,"enrollment":5863,"conditions":5864,"interventions":5866},"NCT02935595","Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients",[89],"2017-08-16","2016-10-14",9,[5865],"Treatment Resistant Depression",[5841],{"nctId":5868,"briefTitle":5869,"status":141,"phases":5870,"primaryCompletion":5861,"completion":5861,"start":5871,"enrollment":35,"conditions":5872,"interventions":5874},"NCT02882711","The UTHealth Ketamine Project",[89],"2016-11-07",[5865,1811,5873],"Bipolar Disorder",[5841],{"trials":5876,"activeCount":100},[],{"trials":5878,"activeCount":100},[],{"trials":5880,"activeCount":100},[],{"intervention":5882,"totalTrials":1620,"cells":5883},"Adult stem cells",{"EARLY_PHASE1":5884,"PHASE1":5886,"PHASE2":5888,"PHASE3":5916,"PHASE4":5918,"NA":5920},{"trials":5885,"activeCount":100},[],{"trials":5887,"activeCount":100},[],{"trials":5889,"activeCount":100},[5890,5902,5909],{"nctId":5891,"briefTitle":5892,"status":126,"phases":5893,"primaryCompletion":5809,"completion":5894,"start":3851,"enrollment":5895,"conditions":5896,"interventions":5901},"NCT00824005","Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)",[89],"2012-05",92,[5897,5898,5899,5900],"Chronic Ischemic Heart Disease","Left Ventricular Dysfunction","Angina","Ischemic Cardiomyopathy",[5882],{"nctId":5903,"briefTitle":5904,"status":126,"phases":5905,"primaryCompletion":2676,"completion":5432,"start":5906,"enrollment":1584,"conditions":5907,"interventions":5908},"NCT00684060","Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)",[89],"2008-07",[5898],[5882],{"nctId":5910,"briefTitle":5911,"status":126,"phases":5912,"primaryCompletion":5894,"completion":3195,"start":5906,"enrollment":5913,"conditions":5914,"interventions":5915},"NCT00684021","Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)",[89],120,[5898],[5882],{"trials":5917,"activeCount":100},[],{"trials":5919,"activeCount":100},[],{"trials":5921,"activeCount":100},[],{"intervention":5923,"totalTrials":145,"cells":5924},"levodopa\u002Fcarbidopa",{"EARLY_PHASE1":5925,"PHASE1":5927,"PHASE2":5929,"PHASE3":5945,"PHASE4":5947,"NA":5949},{"trials":5926,"activeCount":100},[],{"trials":5928,"activeCount":100},[],{"trials":5930,"activeCount":100},[5931,5941],{"nctId":5932,"briefTitle":5933,"status":126,"phases":5934,"primaryCompletion":5935,"completion":5935,"start":2675,"enrollment":5936,"conditions":5937,"interventions":5938},"NCT01393457","Cognitive Remediation for Cocaine Dependence",[89],"2017-02",119,[1587],[5923,5939,5940],"Ropinirole 2 mg\u002Fd","Ropinirole 4 mg\u002Fd",{"nctId":1629,"briefTitle":1630,"status":126,"phases":5942,"primaryCompletion":1632,"completion":1632,"start":1633,"enrollment":1634,"conditions":5943,"interventions":5944},[89],[1612,1636],[1619,1638,1639],{"trials":5946,"activeCount":100},[],{"trials":5948,"activeCount":100},[],{"trials":5950,"activeCount":100},[],{"intervention":5952,"totalTrials":145,"cells":5953},"Modafinil 200mg",{"EARLY_PHASE1":5954,"PHASE1":5956,"PHASE2":5958,"PHASE3":5982,"PHASE4":5984,"NA":5986},{"trials":5955,"activeCount":100},[],{"trials":5957,"activeCount":100},[],{"trials":5959,"activeCount":100},[5960,5972],{"nctId":5961,"briefTitle":5962,"status":141,"phases":5963,"primaryCompletion":5964,"completion":5964,"start":5965,"enrollment":5966,"conditions":5967,"interventions":5968},"NCT00218036","Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8",[89],"2010-02","2006-07",54,[1612,1613],[5952,5969,5970,5971],"Modafinil 400mg","Citalopram 20mg","Citalopram 40mg",{"nctId":5973,"briefTitle":5974,"status":126,"phases":5975,"primaryCompletion":5976,"completion":5976,"start":1633,"enrollment":5977,"conditions":5978,"interventions":5979},"NCT00218062","Effectiveness of Modafinil and D-amphetamine in Treating Cocaine Dependent Individuals",[89],"2012-01",73,[1636],[5980,5981,5952,5969],"D-Amphetamine 30mg","D-Amphetamine 60mg",{"trials":5983,"activeCount":100},[],{"trials":5985,"activeCount":100},[],{"trials":5987,"activeCount":100},[],{"intervention":5969,"totalTrials":145,"cells":5989},{"EARLY_PHASE1":5990,"PHASE1":5992,"PHASE2":5994,"PHASE3":6004,"PHASE4":6006,"NA":6008},{"trials":5991,"activeCount":100},[],{"trials":5993,"activeCount":100},[],{"trials":5995,"activeCount":100},[5996,6000],{"nctId":5961,"briefTitle":5962,"status":141,"phases":5997,"primaryCompletion":5964,"completion":5964,"start":5965,"enrollment":5966,"conditions":5998,"interventions":5999},[89],[1612,1613],[5952,5969,5970,5971],{"nctId":5973,"briefTitle":5974,"status":126,"phases":6001,"primaryCompletion":5976,"completion":5976,"start":1633,"enrollment":5977,"conditions":6002,"interventions":6003},[89],[1636],[5980,5981,5952,5969],{"trials":6005,"activeCount":100},[],{"trials":6007,"activeCount":100},[],{"trials":6009,"activeCount":100},[],{"intervention":6011,"totalTrials":145,"cells":6012},"Mesenchymal Stem Cells",{"EARLY_PHASE1":6013,"PHASE1":6015,"PHASE2":6017,"PHASE3":6036,"PHASE4":6038,"NA":6040},{"trials":6014,"activeCount":100},[],{"trials":6016,"activeCount":100},[],{"trials":6018,"activeCount":100},[6019,6027],{"nctId":6020,"briefTitle":6021,"status":126,"phases":6022,"primaryCompletion":2209,"completion":6023,"start":5719,"enrollment":2614,"conditions":6024,"interventions":6025},"NCT02501811","Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure",[89],"2020-07-22",[5900],[6011,6026],"c-kit+ cells",{"nctId":6028,"briefTitle":6029,"status":126,"phases":6030,"primaryCompletion":6031,"completion":6031,"start":6032,"enrollment":6033,"conditions":6034,"interventions":6035},"NCT04506073","Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease",[89],"2023-07-30","2020-11-09",45,[803],[6011],{"trials":6037,"activeCount":100},[],{"trials":6039,"activeCount":100},[],{"trials":6041,"activeCount":100},[],{"intervention":5813,"totalTrials":145,"cells":6043},{"EARLY_PHASE1":6044,"PHASE1":6046,"PHASE2":6048,"PHASE3":6058,"PHASE4":6060,"NA":6062},{"trials":6045,"activeCount":100},[],{"trials":6047,"activeCount":100},[],{"trials":6049,"activeCount":100},[6050,6054],{"nctId":5806,"briefTitle":5807,"status":1858,"phases":6051,"primaryCompletion":5809,"start":5185,"enrollment":258,"conditions":6052,"interventions":6053},[88,89],[5811],[5813,5797,5814],{"nctId":5826,"briefTitle":5827,"status":1858,"phases":6055,"primaryCompletion":3195,"start":5829,"enrollment":5830,"conditions":6056,"interventions":6057},[89],[5832],[5813,5797,5814],{"trials":6059,"activeCount":100},[],{"trials":6061,"activeCount":100},[],{"trials":6063,"activeCount":100},[],{"intervention":5814,"totalTrials":145,"cells":6065},{"EARLY_PHASE1":6066,"PHASE1":6068,"PHASE2":6070,"PHASE3":6080,"PHASE4":6082,"NA":6084},{"trials":6067,"activeCount":100},[],{"trials":6069,"activeCount":100},[],{"trials":6071,"activeCount":100},[6072,6076],{"nctId":5806,"briefTitle":5807,"status":1858,"phases":6073,"primaryCompletion":5809,"start":5185,"enrollment":258,"conditions":6074,"interventions":6075},[88,89],[5811],[5813,5797,5814],{"nctId":5826,"briefTitle":5827,"status":1858,"phases":6077,"primaryCompletion":3195,"start":5829,"enrollment":5830,"conditions":6078,"interventions":6079},[89],[5832],[5813,5797,5814],{"trials":6081,"activeCount":100},[],{"trials":6083,"activeCount":100},[],{"trials":6085,"activeCount":100},[],{"intervention":6087,"totalTrials":145,"cells":6088},"suvorexant",{"EARLY_PHASE1":6089,"PHASE1":6091,"PHASE2":6093,"PHASE3":6113,"PHASE4":6115,"NA":6117},{"trials":6090,"activeCount":100},[],{"trials":6092,"activeCount":100},[],{"trials":6094,"activeCount":100},[6095,6105],{"nctId":6096,"briefTitle":6097,"status":141,"phases":6098,"primaryCompletion":6099,"completion":6099,"start":6100,"enrollment":6101,"conditions":6102,"interventions":6104},"NCT05711862","The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder",[89],"2024-03-28","2023-03-09",7,[6103],"Methamphetamine Use Disorder",[6087],{"nctId":6106,"briefTitle":6107,"status":126,"phases":6108,"primaryCompletion":6109,"completion":6109,"start":6110,"enrollment":19,"conditions":6111,"interventions":6112},"NCT02785406","Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use",[89],"2018-11-15","2016-05",[179,1128],[6087],{"trials":6114,"activeCount":100},[],{"trials":6116,"activeCount":100},[],{"trials":6118,"activeCount":100},[],{"intervention":6120,"totalTrials":145,"cells":6121},"Argatroban",{"EARLY_PHASE1":6122,"PHASE1":6124,"PHASE2":6126,"PHASE3":6144,"PHASE4":6146,"NA":6148},{"trials":6123,"activeCount":100},[],{"trials":6125,"activeCount":100},[],{"trials":6127,"activeCount":100},[6128,6135],{"nctId":6129,"briefTitle":6130,"status":126,"phases":6131,"primaryCompletion":3194,"completion":3194,"start":4527,"enrollment":35,"conditions":6132,"interventions":6134},"NCT02448069","Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke",[89],[15,6133],"Cerebral Ischemia",[6120],{"nctId":6136,"briefTitle":6137,"status":126,"phases":6138,"primaryCompletion":6139,"completion":6139,"start":6140,"enrollment":2026,"conditions":6141,"interventions":6142},"NCT00268762","Argatroban Stroke Treatment - A Pilot Safety Study",[88,89],"2010-08","2003-02",[5768],[6143],"argatroban",{"trials":6145,"activeCount":100},[],{"trials":6147,"activeCount":100},[],{"trials":6149,"activeCount":100},[],{"intervention":5822,"totalTrials":145,"cells":6151},{"EARLY_PHASE1":6152,"PHASE1":6154,"PHASE2":6167,"PHASE3":6173,"PHASE4":6175,"NA":6177},{"trials":6153,"activeCount":100},[],{"trials":6155,"activeCount":100},[6156],{"nctId":6157,"briefTitle":6158,"status":126,"phases":6159,"primaryCompletion":6160,"completion":6160,"start":6161,"enrollment":756,"conditions":6162,"interventions":6164},"NCT02514421","Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma",[88],"2017-04-18","2015-07",[6163],"Pancreatic Adenocarcinoma",[6165,6166],"gemcitabine","nab-paclitaxel",{"trials":6168,"activeCount":100},[6169],{"nctId":5816,"briefTitle":5817,"status":141,"phases":6170,"primaryCompletion":5718,"completion":5718,"start":5719,"enrollment":1620,"conditions":6171,"interventions":6172},[89],[5820],[5822,5823,5824],{"trials":6174,"activeCount":100},[],{"trials":6176,"activeCount":100},[],{"trials":6178,"activeCount":100},[],{"intervention":5722,"totalTrials":145,"cells":6180},{"EARLY_PHASE1":6181,"PHASE1":6183,"PHASE2":6185,"PHASE3":6195,"PHASE4":6197,"NA":6199},{"trials":6182,"activeCount":100},[],{"trials":6184,"activeCount":100},[],{"trials":6186,"activeCount":100},[6187,6191],{"nctId":5715,"briefTitle":5716,"status":141,"phases":6188,"primaryCompletion":5718,"completion":5718,"start":5719,"enrollment":96,"conditions":6189,"interventions":6190},[89],[2170],[5722,5723,5724,5706,5725],{"nctId":5742,"briefTitle":5743,"status":141,"phases":6192,"primaryCompletion":5745,"completion":5718,"start":5746,"enrollment":1809,"conditions":6193,"interventions":6194},[89],[5748],[5723,5724,5706,5725,5722],{"trials":6196,"activeCount":100},[],{"trials":6198,"activeCount":100},[],{"trials":6200,"activeCount":100},[],{"intervention":5723,"totalTrials":145,"cells":6202},{"EARLY_PHASE1":6203,"PHASE1":6205,"PHASE2":6207,"PHASE3":6217,"PHASE4":6219,"NA":6221},{"trials":6204,"activeCount":100},[],{"trials":6206,"activeCount":100},[],{"trials":6208,"activeCount":100},[6209,6213],{"nctId":5715,"briefTitle":5716,"status":141,"phases":6210,"primaryCompletion":5718,"completion":5718,"start":5719,"enrollment":96,"conditions":6211,"interventions":6212},[89],[2170],[5722,5723,5724,5706,5725],{"nctId":5742,"briefTitle":5743,"status":141,"phases":6214,"primaryCompletion":5745,"completion":5718,"start":5746,"enrollment":1809,"conditions":6215,"interventions":6216},[89],[5748],[5723,5724,5706,5725,5722],{"trials":6218,"activeCount":100},[],{"trials":6220,"activeCount":100},[],{"trials":6222,"activeCount":100},[],{"intervention":5724,"totalTrials":145,"cells":6224},{"EARLY_PHASE1":6225,"PHASE1":6227,"PHASE2":6229,"PHASE3":6239,"PHASE4":6241,"NA":6243},{"trials":6226,"activeCount":100},[],{"trials":6228,"activeCount":100},[],{"trials":6230,"activeCount":100},[6231,6235],{"nctId":5715,"briefTitle":5716,"status":141,"phases":6232,"primaryCompletion":5718,"completion":5718,"start":5719,"enrollment":96,"conditions":6233,"interventions":6234},[89],[2170],[5722,5723,5724,5706,5725],{"nctId":5742,"briefTitle":5743,"status":141,"phases":6236,"primaryCompletion":5745,"completion":5718,"start":5746,"enrollment":1809,"conditions":6237,"interventions":6238},[89],[5748],[5723,5724,5706,5725,5722],{"trials":6240,"activeCount":100},[],{"trials":6242,"activeCount":100},[],{"trials":6244,"activeCount":100},[],{"intervention":5725,"totalTrials":145,"cells":6246},{"EARLY_PHASE1":6247,"PHASE1":6249,"PHASE2":6251,"PHASE3":6261,"PHASE4":6263,"NA":6265},{"trials":6248,"activeCount":100},[],{"trials":6250,"activeCount":100},[],{"trials":6252,"activeCount":100},[6253,6257],{"nctId":5715,"briefTitle":5716,"status":141,"phases":6254,"primaryCompletion":5718,"completion":5718,"start":5719,"enrollment":96,"conditions":6255,"interventions":6256},[89],[2170],[5722,5723,5724,5706,5725],{"nctId":5742,"briefTitle":5743,"status":141,"phases":6258,"primaryCompletion":5745,"completion":5718,"start":5746,"enrollment":1809,"conditions":6259,"interventions":6260},[89],[5748],[5723,5724,5706,5725,5722],{"trials":6262,"activeCount":100},[],{"trials":6264,"activeCount":100},[],{"trials":6266,"activeCount":100},[],{"intervention":6268,"totalTrials":145,"cells":6269},"Levodopa",{"EARLY_PHASE1":6270,"PHASE1":6272,"PHASE2":6274,"PHASE3":6295,"PHASE4":6297,"NA":6299},{"trials":6271,"activeCount":100},[],{"trials":6273,"activeCount":100},[],{"trials":6275,"activeCount":100},[6276,6285],{"nctId":6277,"briefTitle":6278,"status":126,"phases":6279,"primaryCompletion":6280,"completion":6280,"start":6281,"enrollment":115,"conditions":6282,"interventions":6283},"NCT00218075","Behavioral Therapy Combined With Carbidopa\u002FLevodopa for the Treatment of Cocaine Dependence",[89],"2007-10","2000-03",[1612,1636],[6268,6284],"Carbidopa",{"nctId":6286,"briefTitle":6287,"status":126,"phases":6288,"primaryCompletion":6289,"completion":6289,"start":6290,"enrollment":6291,"conditions":6292,"interventions":6293},"NCT00713583","Carbidopa\u002FLevodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence",[89],"2011-12","2008-01",85,[1587],[6294],"levodopa",{"trials":6296,"activeCount":100},[],{"trials":6298,"activeCount":100},[],{"trials":6300,"activeCount":100},[],{"intervention":6302,"totalTrials":145,"cells":6303},"Bevacizumab",{"EARLY_PHASE1":6304,"PHASE1":6306,"PHASE2":6308,"PHASE3":6327,"PHASE4":6329,"NA":6331},{"trials":6305,"activeCount":100},[],{"trials":6307,"activeCount":100},[],{"trials":6309,"activeCount":100},[6310,6318],{"nctId":6311,"briefTitle":6312,"status":1858,"phases":6313,"primaryCompletion":6139,"completion":6314,"start":3449,"enrollment":5434,"conditions":6315,"interventions":6317},"NCT00622726","Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity",[89],"2020-08",[6316],"Retinopathy of Prematurity",[6302],{"nctId":6319,"briefTitle":6320,"status":126,"phases":6321,"primaryCompletion":6161,"completion":6161,"start":6322,"enrollment":1838,"conditions":6323,"interventions":6325},"NCT01115517","Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery",[89],"2010-10",[6324],"Pterygium",[6302,6326],"Mitomycin C",{"trials":6328,"activeCount":100},[],{"trials":6330,"activeCount":100},[],{"trials":6332,"activeCount":100},[],{"intervention":5734,"totalTrials":145,"cells":6334},{"EARLY_PHASE1":6335,"PHASE1":6337,"PHASE2":6339,"PHASE3":6349,"PHASE4":6351,"NA":6353},{"trials":6336,"activeCount":100},[],{"trials":6338,"activeCount":100},[],{"trials":6340,"activeCount":100},[6341,6345],{"nctId":5727,"briefTitle":5728,"status":789,"phases":6342,"primaryCompletion":5730,"completion":5731,"start":1860,"enrollment":100,"conditions":6343,"interventions":6344},[89],[2170],[5706,5734],{"nctId":5736,"briefTitle":5737,"status":789,"phases":6346,"primaryCompletion":5730,"completion":5731,"start":1860,"enrollment":100,"conditions":6347,"interventions":6348},[89],[2170],[5734,5706],{"trials":6350,"activeCount":100},[],{"trials":6352,"activeCount":100},[],{"trials":6354,"activeCount":100},[],{"intervention":2312,"totalTrials":145,"cells":6356},{"EARLY_PHASE1":6357,"PHASE1":6359,"PHASE2":6361,"PHASE3":6376,"PHASE4":6378,"NA":6380},{"trials":6358,"activeCount":100},[],{"trials":6360,"activeCount":100},[],{"trials":6362,"activeCount":100},[6363,6372],{"nctId":6364,"briefTitle":6365,"status":126,"phases":6366,"primaryCompletion":6367,"completion":6367,"start":6368,"enrollment":6033,"conditions":6369,"interventions":6371},"NCT02132832","Buspirone, Stress, and Attentional Bias to Marijuana Cues",[89],"2016-03","2013-06",[6370],"Cannabis Use Disorder",[2312],{"nctId":2307,"briefTitle":2308,"status":126,"phases":6373,"primaryCompletion":1821,"completion":1821,"start":2168,"enrollment":1889,"conditions":6374,"interventions":6375},[89],[1587],[2312,2298],{"trials":6377,"activeCount":100},[],{"trials":6379,"activeCount":100},[],{"trials":6381,"activeCount":100},[],{"intervention":6383,"totalTrials":145,"cells":6384},"Everolimus",{"EARLY_PHASE1":6385,"PHASE1":6387,"PHASE2":6389,"PHASE3":6413,"PHASE4":6415,"NA":6417},{"trials":6386,"activeCount":100},[],{"trials":6388,"activeCount":100},[],{"trials":6390,"activeCount":100},[6391,6405],{"nctId":6392,"briefTitle":6393,"status":141,"phases":6394,"primaryCompletion":6395,"completion":6395,"start":6396,"enrollment":96,"conditions":6397,"interventions":6399},"NCT02560012","Personalized Targeted Inhibitors Treatment in Renal Cell Cancer",[89],"2017-07-27","2016-01-04",[6398],"Carcinoma, Renal Cell",[6400,6401,6402,6403,6383,6404],"Sunitinib","Temsirolimus","Sorafenib","Pazopanib","Axitinib",{"nctId":6406,"briefTitle":6407,"status":126,"phases":6408,"primaryCompletion":6367,"completion":6367,"start":6409,"enrollment":845,"conditions":6410,"interventions":6412},"NCT02332902","Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T",[89],"2015-02",[6411],"Neurofibromatosis 1",[6383],{"trials":6414,"activeCount":100},[],{"trials":6416,"activeCount":100},[],{"trials":6418,"activeCount":100},[],{"intervention":6420,"totalTrials":120,"cells":6421},"Acetazolamide",{"EARLY_PHASE1":6422,"PHASE1":6424,"PHASE2":6426,"PHASE3":6437,"PHASE4":6439,"NA":6441},{"trials":6423,"activeCount":100},[],{"trials":6425,"activeCount":100},[],{"trials":6427,"activeCount":100},[6428],{"nctId":6429,"briefTitle":6430,"status":141,"phases":6431,"primaryCompletion":6432,"completion":6432,"start":6433,"enrollment":1797,"conditions":6434,"interventions":6436},"NCT02466074","Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis",[89],"2022-02-07","2016-08-17",[6435],"Multiple Sclerosis",[6420],{"trials":6438,"activeCount":100},[],{"trials":6440,"activeCount":100},[],{"trials":6442,"activeCount":100},[],{"intervention":5939,"totalTrials":120,"cells":6444},{"EARLY_PHASE1":6445,"PHASE1":6447,"PHASE2":6449,"PHASE3":6455,"PHASE4":6457,"NA":6459},{"trials":6446,"activeCount":100},[],{"trials":6448,"activeCount":100},[],{"trials":6450,"activeCount":100},[6451],{"nctId":5932,"briefTitle":5933,"status":126,"phases":6452,"primaryCompletion":5935,"completion":5935,"start":2675,"enrollment":5936,"conditions":6453,"interventions":6454},[89],[1587],[5923,5939,5940],{"trials":6456,"activeCount":100},[],{"trials":6458,"activeCount":100},[],{"trials":6460,"activeCount":100},[],{"intervention":5940,"totalTrials":120,"cells":6462},{"EARLY_PHASE1":6463,"PHASE1":6465,"PHASE2":6467,"PHASE3":6473,"PHASE4":6475,"NA":6477},{"trials":6464,"activeCount":100},[],{"trials":6466,"activeCount":100},[],{"trials":6468,"activeCount":100},[6469],{"nctId":5932,"briefTitle":5933,"status":126,"phases":6470,"primaryCompletion":5935,"completion":5935,"start":2675,"enrollment":5936,"conditions":6471,"interventions":6472},[89],[1587],[5923,5939,5940],{"trials":6474,"activeCount":100},[],{"trials":6476,"activeCount":100},[],{"trials":6478,"activeCount":100},[],{"intervention":5970,"totalTrials":120,"cells":6480},{"EARLY_PHASE1":6481,"PHASE1":6483,"PHASE2":6485,"PHASE3":6491,"PHASE4":6493,"NA":6495},{"trials":6482,"activeCount":100},[],{"trials":6484,"activeCount":100},[],{"trials":6486,"activeCount":100},[6487],{"nctId":5961,"briefTitle":5962,"status":141,"phases":6488,"primaryCompletion":5964,"completion":5964,"start":5965,"enrollment":5966,"conditions":6489,"interventions":6490},[89],[1612,1613],[5952,5969,5970,5971],{"trials":6492,"activeCount":100},[],{"trials":6494,"activeCount":100},[],{"trials":6496,"activeCount":100},[],{"intervention":5971,"totalTrials":120,"cells":6498},{"EARLY_PHASE1":6499,"PHASE1":6501,"PHASE2":6503,"PHASE3":6509,"PHASE4":6511,"NA":6513},{"trials":6500,"activeCount":100},[],{"trials":6502,"activeCount":100},[],{"trials":6504,"activeCount":100},[6505],{"nctId":5961,"briefTitle":5962,"status":141,"phases":6506,"primaryCompletion":5964,"completion":5964,"start":5965,"enrollment":5966,"conditions":6507,"interventions":6508},[89],[1612,1613],[5952,5969,5970,5971],{"trials":6510,"activeCount":100},[],{"trials":6512,"activeCount":100},[],{"trials":6514,"activeCount":100},[],{"intervention":5980,"totalTrials":120,"cells":6516},{"EARLY_PHASE1":6517,"PHASE1":6519,"PHASE2":6521,"PHASE3":6527,"PHASE4":6529,"NA":6531},{"trials":6518,"activeCount":100},[],{"trials":6520,"activeCount":100},[],{"trials":6522,"activeCount":100},[6523],{"nctId":5973,"briefTitle":5974,"status":126,"phases":6524,"primaryCompletion":5976,"completion":5976,"start":1633,"enrollment":5977,"conditions":6525,"interventions":6526},[89],[1636],[5980,5981,5952,5969],{"trials":6528,"activeCount":100},[],{"trials":6530,"activeCount":100},[],{"trials":6532,"activeCount":100},[],{"intervention":5981,"totalTrials":120,"cells":6534},{"EARLY_PHASE1":6535,"PHASE1":6537,"PHASE2":6539,"PHASE3":6545,"PHASE4":6547,"NA":6549},{"trials":6536,"activeCount":100},[],{"trials":6538,"activeCount":100},[],{"trials":6540,"activeCount":100},[6541],{"nctId":5973,"briefTitle":5974,"status":126,"phases":6542,"primaryCompletion":5976,"completion":5976,"start":1633,"enrollment":5977,"conditions":6543,"interventions":6544},[89],[1636],[5980,5981,5952,5969],{"trials":6546,"activeCount":100},[],{"trials":6548,"activeCount":100},[],{"trials":6550,"activeCount":100},[],{"intervention":6026,"totalTrials":120,"cells":6552},{"EARLY_PHASE1":6553,"PHASE1":6555,"PHASE2":6557,"PHASE3":6563,"PHASE4":6565,"NA":6567},{"trials":6554,"activeCount":100},[],{"trials":6556,"activeCount":100},[],{"trials":6558,"activeCount":100},[6559],{"nctId":6020,"briefTitle":6021,"status":126,"phases":6560,"primaryCompletion":2209,"completion":6023,"start":5719,"enrollment":2614,"conditions":6561,"interventions":6562},[89],[5900],[6011,6026],{"trials":6564,"activeCount":100},[],{"trials":6566,"activeCount":100},[],{"trials":6568,"activeCount":100},[],{"intervention":6570,"totalTrials":120,"cells":6571},"Pantoprazole",{"EARLY_PHASE1":6572,"PHASE1":6574,"PHASE2":6576,"PHASE3":6588,"PHASE4":6590,"NA":6592},{"trials":6573,"activeCount":100},[],{"trials":6575,"activeCount":100},[],{"trials":6577,"activeCount":100},[6578],{"nctId":6579,"briefTitle":6580,"status":126,"phases":6581,"primaryCompletion":6582,"completion":6583,"start":6584,"enrollment":728,"conditions":6585,"interventions":6586},"NCT06154226","Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor",[89],"2024-09-17","2024-10-10","2024-01-10",[730],[6570,6587],"Famotidine",{"trials":6589,"activeCount":100},[],{"trials":6591,"activeCount":100},[],{"trials":6593,"activeCount":100},[],{"intervention":6587,"totalTrials":120,"cells":6595},{"EARLY_PHASE1":6596,"PHASE1":6598,"PHASE2":6600,"PHASE3":6606,"PHASE4":6608,"NA":6610},{"trials":6597,"activeCount":100},[],{"trials":6599,"activeCount":100},[],{"trials":6601,"activeCount":100},[6602],{"nctId":6579,"briefTitle":6580,"status":126,"phases":6603,"primaryCompletion":6582,"completion":6583,"start":6584,"enrollment":728,"conditions":6604,"interventions":6605},[89],[730],[6570,6587],{"trials":6607,"activeCount":100},[],{"trials":6609,"activeCount":100},[],{"trials":6611,"activeCount":100},[],{"intervention":6613,"totalTrials":120,"cells":6614},"Cisplatin, Gemcitabine, Interferon-a",{"EARLY_PHASE1":6615,"PHASE1":6617,"PHASE2":6619,"PHASE3":6632,"PHASE4":6634,"NA":6636},{"trials":6616,"activeCount":100},[],{"trials":6618,"activeCount":100},[],{"trials":6620,"activeCount":100},[6621],{"nctId":6622,"briefTitle":6623,"status":1858,"phases":6624,"primaryCompletion":6368,"completion":6625,"start":5829,"enrollment":4841,"conditions":6626,"interventions":6631},"NCT00178698","Hyperthermia\u002FThermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors",[89],"2014-06",[6627,6628,6629,6630],"Neuroendocrine Cancer","Small Cell Lung Cancer","Non-Small Cell Lung Cancer","Gastric Cancer",[6613],{"trials":6633,"activeCount":100},[],{"trials":6635,"activeCount":100},[],{"trials":6637,"activeCount":100},[],{"intervention":6639,"totalTrials":120,"cells":6640},"Isosorbide Mononitrate",{"EARLY_PHASE1":6641,"PHASE1":6643,"PHASE2":6645,"PHASE3":6658,"PHASE4":6660,"NA":6662},{"trials":6642,"activeCount":100},[],{"trials":6644,"activeCount":100},[],{"trials":6646,"activeCount":100},[6647],{"nctId":6648,"briefTitle":6649,"status":141,"phases":6650,"primaryCompletion":6651,"completion":6651,"start":6652,"enrollment":5863,"conditions":6653,"interventions":6657},"NCT04051957","Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury",[89],"2021-02-12","2019-09-26",[6654,6655,6656],"Kidney Injury","Proteinuria","Hypertension",[6639],{"trials":6659,"activeCount":100},[],{"trials":6661,"activeCount":100},[],{"trials":6663,"activeCount":100},[],{"intervention":6665,"totalTrials":120,"cells":6666},"Caffeine",{"EARLY_PHASE1":6667,"PHASE1":6669,"PHASE2":6671,"PHASE3":6684,"PHASE4":6686,"NA":6688},{"trials":6668,"activeCount":100},[],{"trials":6670,"activeCount":100},[],{"trials":6672,"activeCount":100},[6673],{"nctId":6674,"briefTitle":6675,"status":126,"phases":6676,"primaryCompletion":6677,"completion":6677,"start":3404,"enrollment":237,"conditions":6678,"interventions":6683},"NCT00273754","The Effect of Caffeine on Postextubation Adverse Respiratory Events in Children With Obstructive Sleep Apnea (OSA).",[89],"2008-05",[6679,6680,6681,6682],"Sleep Apnea, Obstructive","Tonsillectomy","Adenoidectomy","Postoperative Complications",[6665],{"trials":6685,"activeCount":100},[],{"trials":6687,"activeCount":100},[],{"trials":6689,"activeCount":100},[],{"intervention":6691,"totalTrials":120,"cells":6692},"Nelfinavir",{"EARLY_PHASE1":6693,"PHASE1":6695,"PHASE2":6697,"PHASE3":6708,"PHASE4":6710,"NA":6712},{"trials":6694,"activeCount":100},[],{"trials":6696,"activeCount":100},[],{"trials":6698,"activeCount":100},[6699],{"nctId":6700,"briefTitle":6701,"status":789,"phases":6702,"primaryCompletion":6703,"completion":6703,"start":6704,"enrollment":100,"conditions":6705,"interventions":6707},"NCT01925378","A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2\u002F3 or 3 Cervical Intraepithelial Neoplasia",[89],"2022-12","2018-11-07",[6706],"Cervical Dysplasia",[6691],{"trials":6709,"activeCount":100},[],{"trials":6711,"activeCount":100},[],{"trials":6713,"activeCount":100},[],{"intervention":1969,"totalTrials":120,"cells":6715},{"EARLY_PHASE1":6716,"PHASE1":6718,"PHASE2":6720,"PHASE3":6726,"PHASE4":6728,"NA":6730},{"trials":6717,"activeCount":100},[],{"trials":6719,"activeCount":100},[],{"trials":6721,"activeCount":100},[6722],{"nctId":5850,"briefTitle":5851,"status":789,"phases":6723,"primaryCompletion":5853,"completion":5853,"start":1967,"enrollment":100,"conditions":6724,"interventions":6725},[89],[5855],[5841,1969],{"trials":6727,"activeCount":100},[],{"trials":6729,"activeCount":100},[],{"trials":6731,"activeCount":100},[],{"intervention":6733,"totalTrials":120,"cells":6734},"Fecal Microbiota",{"EARLY_PHASE1":6735,"PHASE1":6737,"PHASE2":6739,"PHASE3":6750,"PHASE4":6752,"NA":6754},{"trials":6736,"activeCount":100},[],{"trials":6738,"activeCount":100},[],{"trials":6740,"activeCount":100},[6741],{"nctId":6742,"briefTitle":6743,"status":126,"phases":6744,"primaryCompletion":6745,"completion":6745,"start":5786,"enrollment":6746,"conditions":6747,"interventions":6749},"NCT02318992","Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea",[88,89],"2018-04",79,[6748],"Recurrent C. Difficile Associated Diarrhea",[6733],{"trials":6751,"activeCount":100},[],{"trials":6753,"activeCount":100},[],{"trials":6755,"activeCount":100},[],{"intervention":6757,"totalTrials":120,"cells":6758},"Misoprostol",{"EARLY_PHASE1":6759,"PHASE1":6761,"PHASE2":6763,"PHASE3":6775,"PHASE4":6777,"NA":6779},{"trials":6760,"activeCount":100},[],{"trials":6762,"activeCount":100},[],{"trials":6764,"activeCount":100},[6765],{"nctId":6766,"briefTitle":6767,"status":126,"phases":6768,"primaryCompletion":4291,"completion":4291,"start":6769,"enrollment":6770,"conditions":6771,"interventions":6773},"NCT00393731","A Randomized, Control Trial for Preinduction Cervical Ripening",[89],"2004-01",540,[6772],"Labor, Induced",[6757,6774],"oxytocin",{"trials":6776,"activeCount":100},[],{"trials":6778,"activeCount":100},[],{"trials":6780,"activeCount":100},[],{"intervention":6774,"totalTrials":120,"cells":6782},{"EARLY_PHASE1":6783,"PHASE1":6785,"PHASE2":6787,"PHASE3":6793,"PHASE4":6795,"NA":6797},{"trials":6784,"activeCount":100},[],{"trials":6786,"activeCount":100},[],{"trials":6788,"activeCount":100},[6789],{"nctId":6766,"briefTitle":6767,"status":126,"phases":6790,"primaryCompletion":4291,"completion":4291,"start":6769,"enrollment":6770,"conditions":6791,"interventions":6792},[89],[6772],[6757,6774],{"trials":6794,"activeCount":100},[],{"trials":6796,"activeCount":100},[],{"trials":6798,"activeCount":100},[],{"intervention":6800,"totalTrials":120,"cells":6801},"Caffeinol",{"EARLY_PHASE1":6802,"PHASE1":6804,"PHASE2":6806,"PHASE3":6816,"PHASE4":6818,"NA":6820},{"trials":6803,"activeCount":100},[],{"trials":6805,"activeCount":100},[],{"trials":6807,"activeCount":100},[6808],{"nctId":6809,"briefTitle":6810,"status":126,"phases":6811,"primaryCompletion":1679,"completion":6812,"start":6140,"enrollment":258,"conditions":6813,"interventions":6815},"NCT00299416","Caffeinol Hypothermia Protocol",[88,89],"2009-08",[6814],"Acute Ischemic Stroke",[6800],{"trials":6817,"activeCount":100},[],{"trials":6819,"activeCount":100},[],{"trials":6821,"activeCount":100},[],{"intervention":6823,"totalTrials":120,"cells":6824},"Rapamycin",{"EARLY_PHASE1":6825,"PHASE1":6827,"PHASE2":6829,"PHASE3":6840,"PHASE4":6842,"NA":6844},{"trials":6826,"activeCount":100},[],{"trials":6828,"activeCount":100},[],{"trials":6830,"activeCount":100},[6831],{"nctId":6832,"briefTitle":6833,"status":126,"phases":6834,"primaryCompletion":1912,"completion":1912,"start":5894,"enrollment":6835,"conditions":6836,"interventions":6839},"NCT01526356","Topical Rapamycin to Erase Angiofibromas in TSC",[89],179,[6837,6838],"Angiofibromas","Tuberous Sclerosis",[6823,6823],{"trials":6841,"activeCount":100},[],{"trials":6843,"activeCount":100},[],{"trials":6845,"activeCount":100},[],{"intervention":6847,"totalTrials":120,"cells":6848},"Nabilone",{"EARLY_PHASE1":6849,"PHASE1":6851,"PHASE2":6853,"PHASE3":6863,"PHASE4":6865,"NA":6867},{"trials":6850,"activeCount":100},[],{"trials":6852,"activeCount":100},[],{"trials":6854,"activeCount":100},[6855],{"nctId":6856,"briefTitle":6857,"status":789,"phases":6858,"primaryCompletion":6859,"completion":6859,"start":6860,"enrollment":100,"conditions":6861,"interventions":6862},"NCT04807829","Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation",[89],"2022-04","2021-04",[5325],[6847],{"trials":6864,"activeCount":100},[],{"trials":6866,"activeCount":100},[],{"trials":6868,"activeCount":100},[],{"intervention":6870,"totalTrials":120,"cells":6871},"fluorouracil",{"EARLY_PHASE1":6872,"PHASE1":6874,"PHASE2":6876,"PHASE3":6890,"PHASE4":6892,"NA":6894},{"trials":6873,"activeCount":100},[],{"trials":6875,"activeCount":100},[],{"trials":6877,"activeCount":100},[6878],{"nctId":6879,"briefTitle":6880,"status":1858,"phases":6881,"primaryCompletion":6882,"start":6883,"enrollment":1229,"conditions":6884,"interventions":6888},"NCT00003135","Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer",[89],"2009-09","1997-11",[1901,6885,6886,6887],"Cervical Cancer","Endometrial Cancer","Ovarian Cancer",[6870,6889],"pegylated liposomal doxorubicin hydrochloride",{"trials":6891,"activeCount":100},[],{"trials":6893,"activeCount":100},[],{"trials":6895,"activeCount":100},[],{"intervention":6889,"totalTrials":120,"cells":6897},{"EARLY_PHASE1":6898,"PHASE1":6900,"PHASE2":6902,"PHASE3":6908,"PHASE4":6910,"NA":6912},{"trials":6899,"activeCount":100},[],{"trials":6901,"activeCount":100},[],{"trials":6903,"activeCount":100},[6904],{"nctId":6879,"briefTitle":6880,"status":1858,"phases":6905,"primaryCompletion":6882,"start":6883,"enrollment":1229,"conditions":6906,"interventions":6907},[89],[1901,6885,6886,6887],[6870,6889],{"trials":6909,"activeCount":100},[],{"trials":6911,"activeCount":100},[],{"trials":6913,"activeCount":100},[],{"intervention":2118,"totalTrials":120,"cells":6915},{"EARLY_PHASE1":6916,"PHASE1":6918,"PHASE2":6920,"PHASE3":6926,"PHASE4":6928,"NA":6930},{"trials":6917,"activeCount":100},[],{"trials":6919,"activeCount":100},[],{"trials":6921,"activeCount":100},[6922],{"nctId":2110,"briefTitle":2111,"status":126,"phases":6923,"primaryCompletion":2113,"completion":2113,"start":2114,"enrollment":2115,"conditions":6924,"interventions":6925},[88,89],[32],[2101,2118],{"trials":6927,"activeCount":100},[],{"trials":6929,"activeCount":100},[],{"trials":6931,"activeCount":100},[],{"intervention":6933,"totalTrials":120,"cells":6934},"ALD-301",{"EARLY_PHASE1":6935,"PHASE1":6937,"PHASE2":6939,"PHASE3":6950,"PHASE4":6952,"NA":6954},{"trials":6936,"activeCount":100},[],{"trials":6938,"activeCount":100},[],{"trials":6940,"activeCount":100},[6941],{"nctId":6942,"briefTitle":6943,"status":126,"phases":6944,"primaryCompletion":3194,"completion":2127,"start":6368,"enrollment":6945,"conditions":6946,"interventions":6949},"NCT01774097","Patients With Intermittent Claudication Injected With ALDH Bright Cells",[89],82,[6947,6948],"Peripheral Artery Disease","Intermittent Claudication",[6933],{"trials":6951,"activeCount":100},[],{"trials":6953,"activeCount":100},[],{"trials":6955,"activeCount":100},[],{"intervention":6957,"totalTrials":120,"cells":6958},"Dextroamphetamine SR",{"EARLY_PHASE1":6959,"PHASE1":6961,"PHASE2":6963,"PHASE3":6973,"PHASE4":6975,"NA":6977},{"trials":6960,"activeCount":100},[],{"trials":6962,"activeCount":100},[],{"trials":6964,"activeCount":100},[6965],{"nctId":6966,"briefTitle":6967,"status":141,"phases":6968,"primaryCompletion":6969,"completion":6969,"start":4291,"enrollment":1797,"conditions":6970,"interventions":6972},"NCT00514202","Pilot Study Examining Effect for Dextroamphetamine to Treat Cocaine Dependence Plus Attention-deficit Hyperactivity Disorder (ADHD)",[89],"2008-10",[5214,1636,6971],"Substance-Related Disorders",[6957],{"trials":6974,"activeCount":100},[],{"trials":6976,"activeCount":100},[],{"trials":6978,"activeCount":100},[],{"intervention":6980,"totalTrials":120,"cells":6981},"Frozen Microbiota",{"EARLY_PHASE1":6982,"PHASE1":6984,"PHASE2":6986,"PHASE3":6998,"PHASE4":7000,"NA":7002},{"trials":6983,"activeCount":100},[],{"trials":6985,"activeCount":100},[],{"trials":6987,"activeCount":100},[6988],{"nctId":6989,"briefTitle":6990,"status":126,"phases":6991,"primaryCompletion":1861,"completion":1899,"start":6992,"enrollment":6993,"conditions":6994,"interventions":6996},"NCT02449174","Fecal Microbiota Transplantation to Treat Recurrent C. Difficile Associated Diarrhea Via Retention Enema or Oral Route",[88,89],"2015-03-17",69,[6995],"C. Difficile",[6980,6997],"Lyophilized Microbiota",{"trials":6999,"activeCount":100},[],{"trials":7001,"activeCount":100},[],{"trials":7003,"activeCount":100},[],{"intervention":6997,"totalTrials":120,"cells":7005},{"EARLY_PHASE1":7006,"PHASE1":7008,"PHASE2":7010,"PHASE3":7016,"PHASE4":7018,"NA":7020},{"trials":7007,"activeCount":100},[],{"trials":7009,"activeCount":100},[],{"trials":7011,"activeCount":100},[7012],{"nctId":6989,"briefTitle":6990,"status":126,"phases":7013,"primaryCompletion":1861,"completion":1899,"start":6992,"enrollment":6993,"conditions":7014,"interventions":7015},[88,89],[6995],[6980,6997],{"trials":7017,"activeCount":100},[],{"trials":7019,"activeCount":100},[],{"trials":7021,"activeCount":100},[],{"intervention":7023,"totalTrials":120,"cells":7024},"Povidone-iodine irrigation",{"EARLY_PHASE1":7025,"PHASE1":7027,"PHASE2":7029,"PHASE3":7039,"PHASE4":7041,"NA":7043},{"trials":7026,"activeCount":100},[],{"trials":7028,"activeCount":100},[],{"trials":7030,"activeCount":100},[7031],{"nctId":7032,"briefTitle":7033,"status":126,"phases":7034,"primaryCompletion":7035,"completion":7035,"start":7036,"enrollment":728,"conditions":7037,"interventions":7038},"NCT02664220","Dilute Povidone-iodine Irrigation vs No Irrigation for Children With Acute, Perforated Appendicitis",[89],"2018-03","2016-04",[331],[7023],{"trials":7040,"activeCount":100},[],{"trials":7042,"activeCount":100},[],{"trials":7044,"activeCount":100},[],{"intervention":7046,"totalTrials":120,"cells":7047},"FX006",{"EARLY_PHASE1":7048,"PHASE1":7050,"PHASE2":7052,"PHASE3":7064,"PHASE4":7066,"NA":7068},{"trials":7049,"activeCount":100},[],{"trials":7051,"activeCount":100},[],{"trials":7053,"activeCount":100},[7054],{"nctId":7055,"briefTitle":7056,"status":126,"phases":7057,"primaryCompletion":7058,"completion":7058,"start":7059,"enrollment":7060,"conditions":7061,"interventions":7063},"NCT04182672","Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis",[89],"2022-12-14","2020-08-12",22,[7062],"Trochanteric Bursitis",[7046],{"trials":7065,"activeCount":100},[],{"trials":7067,"activeCount":100},[],{"trials":7069,"activeCount":100},[],{"intervention":7071,"totalTrials":120,"cells":7072},"Plasma",{"EARLY_PHASE1":7073,"PHASE1":7075,"PHASE2":7077,"PHASE3":7091,"PHASE4":7093,"NA":7095},{"trials":7074,"activeCount":100},[],{"trials":7076,"activeCount":100},[],{"trials":7078,"activeCount":100},[7079],{"nctId":7080,"briefTitle":7081,"status":141,"phases":7082,"primaryCompletion":7083,"completion":7084,"start":7085,"enrollment":7086,"conditions":7087,"interventions":7089},"NCT03366220","Resuscitation With Plasma in Surgical and Trauma Patients With Septic Shock",[89],"2019-09-17","2019-10-16","2018-03-26",16,[7088],"Septic Shock",[7071,7090],"Balanced crystalloids",{"trials":7092,"activeCount":100},[],{"trials":7094,"activeCount":100},[],{"trials":7096,"activeCount":100},[],{"intervention":7090,"totalTrials":120,"cells":7098},{"EARLY_PHASE1":7099,"PHASE1":7101,"PHASE2":7103,"PHASE3":7109,"PHASE4":7111,"NA":7113},{"trials":7100,"activeCount":100},[],{"trials":7102,"activeCount":100},[],{"trials":7104,"activeCount":100},[7105],{"nctId":7080,"briefTitle":7081,"status":141,"phases":7106,"primaryCompletion":7083,"completion":7084,"start":7085,"enrollment":7086,"conditions":7107,"interventions":7108},[89],[7088],[7071,7090],{"trials":7110,"activeCount":100},[],{"trials":7112,"activeCount":100},[],{"trials":7114,"activeCount":100},[],{"intervention":5823,"totalTrials":120,"cells":7116},{"EARLY_PHASE1":7117,"PHASE1":7119,"PHASE2":7121,"PHASE3":7127,"PHASE4":7129,"NA":7131},{"trials":7118,"activeCount":100},[],{"trials":7120,"activeCount":100},[],{"trials":7122,"activeCount":100},[7123],{"nctId":5816,"briefTitle":5817,"status":141,"phases":7124,"primaryCompletion":5718,"completion":5718,"start":5719,"enrollment":1620,"conditions":7125,"interventions":7126},[89],[5820],[5822,5823,5824],{"trials":7128,"activeCount":100},[],{"trials":7130,"activeCount":100},[],{"trials":7132,"activeCount":100},[],{"intervention":2214,"totalTrials":120,"cells":7134},{"EARLY_PHASE1":7135,"PHASE1":7137,"PHASE2":7139,"PHASE3":7145,"PHASE4":7147,"NA":7149},{"trials":7136,"activeCount":100},[],{"trials":7138,"activeCount":100},[],{"trials":7140,"activeCount":100},[7141],{"nctId":2205,"briefTitle":2206,"status":141,"phases":7142,"primaryCompletion":2208,"completion":2208,"start":2209,"enrollment":2210,"conditions":7143,"interventions":7144},[89],[2212],[2029,223,2214],{"trials":7146,"activeCount":100},[],{"trials":7148,"activeCount":100},[],{"trials":7150,"activeCount":100},[],{"intervention":7152,"totalTrials":120,"cells":7153},"BB-12 with LGG",{"EARLY_PHASE1":7154,"PHASE1":7156,"PHASE2":7158,"PHASE3":7170,"PHASE4":7172,"NA":7174},{"trials":7155,"activeCount":100},[],{"trials":7157,"activeCount":100},[],{"trials":7159,"activeCount":100},[7160],{"nctId":7161,"briefTitle":7162,"status":126,"phases":7163,"primaryCompletion":7164,"completion":7164,"start":6110,"enrollment":7165,"conditions":7166,"interventions":7169},"NCT03514784","Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder",[88,89],"2025-07-30",123,[7167,7168],"Autism Spectrum Disorder","Gastrointestinal Symptoms",[7152,7152],{"trials":7171,"activeCount":100},[],{"trials":7173,"activeCount":100},[],{"trials":7175,"activeCount":100},[],{"intervention":7177,"totalTrials":120,"cells":7178},"Ketamine 0.5 mg\u002Fkg",{"EARLY_PHASE1":7179,"PHASE1":7181,"PHASE2":7183,"PHASE3":7195,"PHASE4":7197,"NA":7199},{"trials":7180,"activeCount":100},[],{"trials":7182,"activeCount":100},[],{"trials":7184,"activeCount":100},[7185],{"nctId":7186,"briefTitle":7187,"status":141,"phases":7188,"primaryCompletion":7189,"completion":7189,"start":7190,"enrollment":120,"conditions":7191,"interventions":7193},"NCT04011592","Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression",[89],"2019-09-09","2019-03-04",[7192],"Post Partum Depression",[7177,7194],"Ketamine 0.2 mg\u002Fkg",{"trials":7196,"activeCount":100},[],{"trials":7198,"activeCount":100},[],{"trials":7200,"activeCount":100},[],{"intervention":7194,"totalTrials":120,"cells":7202},{"EARLY_PHASE1":7203,"PHASE1":7205,"PHASE2":7207,"PHASE3":7213,"PHASE4":7215,"NA":7217},{"trials":7204,"activeCount":100},[],{"trials":7206,"activeCount":100},[],{"trials":7208,"activeCount":100},[7209],{"nctId":7186,"briefTitle":7187,"status":141,"phases":7210,"primaryCompletion":7189,"completion":7189,"start":7190,"enrollment":120,"conditions":7211,"interventions":7212},[89],[7192],[7177,7194],{"trials":7214,"activeCount":100},[],{"trials":7216,"activeCount":100},[],{"trials":7218,"activeCount":100},[],{"intervention":7220,"totalTrials":120,"cells":7221},"Meclofenamic acid",{"EARLY_PHASE1":7222,"PHASE1":7224,"PHASE2":7226,"PHASE3":7241,"PHASE4":7243,"NA":7245},{"trials":7223,"activeCount":100},[],{"trials":7225,"activeCount":100},[],{"trials":7227,"activeCount":100},[7228],{"nctId":7229,"briefTitle":7230,"status":126,"phases":7231,"primaryCompletion":7232,"completion":7232,"start":7233,"enrollment":7234,"conditions":7235,"interventions":7239},"NCT02930005","Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders",[89],"2016-10-06","2015-08-07",8,[7236,7237,7238,5873],"Psychotic Disorders","Schizophrenia","Schizoaffective Disorder",[7220,7240],"Pentosan polysulfate sodium",{"trials":7242,"activeCount":100},[],{"trials":7244,"activeCount":100},[],{"trials":7246,"activeCount":100},[],{"intervention":7240,"totalTrials":120,"cells":7248},{"EARLY_PHASE1":7249,"PHASE1":7251,"PHASE2":7253,"PHASE3":7259,"PHASE4":7261,"NA":7263},{"trials":7250,"activeCount":100},[],{"trials":7252,"activeCount":100},[],{"trials":7254,"activeCount":100},[7255],{"nctId":7229,"briefTitle":7230,"status":126,"phases":7256,"primaryCompletion":7232,"completion":7232,"start":7233,"enrollment":7234,"conditions":7257,"interventions":7258},[89],[7236,7237,7238,5873],[7220,7240],{"trials":7260,"activeCount":100},[],{"trials":7262,"activeCount":100},[],{"trials":7264,"activeCount":100},[],{"intervention":6284,"totalTrials":120,"cells":7266},{"EARLY_PHASE1":7267,"PHASE1":7269,"PHASE2":7271,"PHASE3":7277,"PHASE4":7279,"NA":7281},{"trials":7268,"activeCount":100},[],{"trials":7270,"activeCount":100},[],{"trials":7272,"activeCount":100},[7273],{"nctId":6277,"briefTitle":6278,"status":126,"phases":7274,"primaryCompletion":6280,"completion":6280,"start":6281,"enrollment":115,"conditions":7275,"interventions":7276},[89],[1612,1636],[6268,6284],{"trials":7278,"activeCount":100},[],{"trials":7280,"activeCount":100},[],{"trials":7282,"activeCount":100},[],{"intervention":1639,"totalTrials":120,"cells":7284},{"EARLY_PHASE1":7285,"PHASE1":7287,"PHASE2":7289,"PHASE3":7295,"PHASE4":7297,"NA":7299},{"trials":7286,"activeCount":100},[],{"trials":7288,"activeCount":100},[],{"trials":7290,"activeCount":100},[7291],{"nctId":1629,"briefTitle":1630,"status":126,"phases":7292,"primaryCompletion":1632,"completion":1632,"start":1633,"enrollment":1634,"conditions":7293,"interventions":7294},[89],[1612,1636],[1619,1638,1639],{"trials":7296,"activeCount":100},[],{"trials":7298,"activeCount":100},[],{"trials":7300,"activeCount":100},[],{"intervention":7302,"totalTrials":120,"cells":7303},"8mg galantamine twice daily",{"EARLY_PHASE1":7304,"PHASE1":7306,"PHASE2":7308,"PHASE3":7320,"PHASE4":7322,"NA":7324},{"trials":7305,"activeCount":100},[],{"trials":7307,"activeCount":100},[],{"trials":7309,"activeCount":100},[7310],{"nctId":7311,"briefTitle":7312,"status":126,"phases":7313,"primaryCompletion":7314,"completion":7314,"start":7315,"enrollment":856,"conditions":7316,"interventions":7318},"NCT02872857","Subarachnoid Hemorrhage Recovery And Galantamine",[88,89],"2019-07-20","2016-09",[7317],"Subarachnoid Hemorrhage",[7302,7319],"12mg galantamine twice daily",{"trials":7321,"activeCount":100},[],{"trials":7323,"activeCount":100},[],{"trials":7325,"activeCount":100},[],{"intervention":7319,"totalTrials":120,"cells":7327},{"EARLY_PHASE1":7328,"PHASE1":7330,"PHASE2":7332,"PHASE3":7338,"PHASE4":7340,"NA":7342},{"trials":7329,"activeCount":100},[],{"trials":7331,"activeCount":100},[],{"trials":7333,"activeCount":100},[7334],{"nctId":7311,"briefTitle":7312,"status":126,"phases":7335,"primaryCompletion":7314,"completion":7314,"start":7315,"enrollment":856,"conditions":7336,"interventions":7337},[88,89],[7317],[7302,7319],{"trials":7339,"activeCount":100},[],{"trials":7341,"activeCount":100},[],{"trials":7343,"activeCount":100},[],{"intervention":7345,"totalTrials":120,"cells":7346},"Exenatide 2 milligram (mg)",{"EARLY_PHASE1":7347,"PHASE1":7349,"PHASE2":7351,"PHASE3":7364,"PHASE4":7366,"NA":7368},{"trials":7348,"activeCount":100},[],{"trials":7350,"activeCount":100},[],{"trials":7352,"activeCount":100},[7353],{"nctId":7354,"briefTitle":7355,"status":126,"phases":7356,"primaryCompletion":7357,"completion":7358,"start":7359,"enrollment":7360,"conditions":7361,"interventions":7362},"NCT05610800","Exenatide for Smoking Cessation and Prevention of Weight Gain",[89],"2025-11-07","2026-03-10","2022-12-07",140,[32,1090],[7345,7363],"Nicotine patch",{"trials":7365,"activeCount":100},[],{"trials":7367,"activeCount":100},[],{"trials":7369,"activeCount":100},[],{"intervention":6326,"totalTrials":120,"cells":7371},{"EARLY_PHASE1":7372,"PHASE1":7374,"PHASE2":7376,"PHASE3":7382,"PHASE4":7384,"NA":7386},{"trials":7373,"activeCount":100},[],{"trials":7375,"activeCount":100},[],{"trials":7377,"activeCount":100},[7378],{"nctId":6319,"briefTitle":6320,"status":126,"phases":7379,"primaryCompletion":6161,"completion":6161,"start":6322,"enrollment":1838,"conditions":7380,"interventions":7381},[89],[6324],[6302,6326],{"trials":7383,"activeCount":100},[],{"trials":7385,"activeCount":100},[],{"trials":7387,"activeCount":100},[],{"intervention":1952,"totalTrials":120,"cells":7389},{"EARLY_PHASE1":7390,"PHASE1":7392,"PHASE2":7394,"PHASE3":7400,"PHASE4":7402,"NA":7404},{"trials":7391,"activeCount":100},[],{"trials":7393,"activeCount":100},[],{"trials":7395,"activeCount":100},[7396],{"nctId":1944,"briefTitle":1945,"status":126,"phases":7397,"primaryCompletion":1947,"completion":1947,"start":1948,"enrollment":19,"conditions":7398,"interventions":7399},[89],[1950],[1952,1917,1953],{"trials":7401,"activeCount":100},[],{"trials":7403,"activeCount":100},[],{"trials":7405,"activeCount":100},[],{"intervention":1953,"totalTrials":120,"cells":7407},{"EARLY_PHASE1":7408,"PHASE1":7410,"PHASE2":7412,"PHASE3":7418,"PHASE4":7420,"NA":7422},{"trials":7409,"activeCount":100},[],{"trials":7411,"activeCount":100},[],{"trials":7413,"activeCount":100},[7414],{"nctId":1944,"briefTitle":1945,"status":126,"phases":7415,"primaryCompletion":1947,"completion":1947,"start":1948,"enrollment":19,"conditions":7416,"interventions":7417},[89],[1950],[1952,1917,1953],{"trials":7419,"activeCount":100},[],{"trials":7421,"activeCount":100},[],{"trials":7423,"activeCount":100},[],{"intervention":7425,"totalTrials":120,"cells":7426},"Capsaicin",{"EARLY_PHASE1":7427,"PHASE1":7429,"PHASE2":7431,"PHASE3":7442,"PHASE4":7444,"NA":7446},{"trials":7428,"activeCount":100},[],{"trials":7430,"activeCount":100},[],{"trials":7432,"activeCount":100},[7433],{"nctId":7434,"briefTitle":7435,"status":126,"phases":7436,"primaryCompletion":7437,"completion":7437,"start":7438,"enrollment":7060,"conditions":7439,"interventions":7441},"NCT02493257","Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis",[89],"2019-08-02","2014-10",[7440],"Nonallergic Irritant Rhinitis",[7425],{"trials":7443,"activeCount":100},[],{"trials":7445,"activeCount":100},[],{"trials":7447,"activeCount":100},[],{"intervention":7449,"totalTrials":120,"cells":7450},"Bupropion SR",{"EARLY_PHASE1":7451,"PHASE1":7453,"PHASE2":7455,"PHASE3":7464,"PHASE4":7466,"NA":7468},{"trials":7452,"activeCount":100},[],{"trials":7454,"activeCount":100},[],{"trials":7456,"activeCount":100},[7457],{"nctId":7458,"briefTitle":7459,"status":126,"phases":7460,"primaryCompletion":3078,"completion":5184,"start":7461,"enrollment":30,"conditions":7462,"interventions":7463},"NCT01286402","Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy",[89],"2011-04",[32],[7449],{"trials":7465,"activeCount":100},[],{"trials":7467,"activeCount":100},[],{"trials":7469,"activeCount":100},[],{"intervention":7471,"totalTrials":120,"cells":7472},"Budesonide",{"EARLY_PHASE1":7473,"PHASE1":7475,"PHASE2":7477,"PHASE3":7488,"PHASE4":7490,"NA":7492},{"trials":7474,"activeCount":100},[],{"trials":7476,"activeCount":100},[],{"trials":7478,"activeCount":100},[7479],{"nctId":7480,"briefTitle":7481,"status":141,"phases":7482,"primaryCompletion":7483,"completion":7483,"start":7484,"enrollment":145,"conditions":7485,"interventions":7487},"NCT04064684","Inhaled Steroids for the Treatment of Early Pediatric Acute Respiratory Distress Syndrome",[89],"2020-03-30","2020-02-04",[7486],"Acute Respiratory Distress Syndrome",[7471],{"trials":7489,"activeCount":100},[],{"trials":7491,"activeCount":100},[],{"trials":7493,"activeCount":100},[],{"intervention":7495,"totalTrials":120,"cells":7496},"resveratrol",{"EARLY_PHASE1":7497,"PHASE1":7499,"PHASE2":7501,"PHASE3":7512,"PHASE4":7514,"NA":7516},{"trials":7498,"activeCount":100},[],{"trials":7500,"activeCount":100},[],{"trials":7502,"activeCount":100},[7503],{"nctId":7504,"briefTitle":7505,"status":141,"phases":7506,"primaryCompletion":7507,"completion":7507,"start":7508,"enrollment":756,"conditions":7509,"interventions":7511},"NCT03866200","Resveratrol Trial for Relief of Pain in Pseudoachondroplasia",[89],"2020-10-28","2019-06-29",[7510],"Pseudoachondroplasia",[7495],{"trials":7513,"activeCount":100},[],{"trials":7515,"activeCount":100},[],{"trials":7517,"activeCount":100},[],{"intervention":7519,"totalTrials":120,"cells":7520},"Exenatide 2 mg [Bydureon]",{"EARLY_PHASE1":7521,"PHASE1":7523,"PHASE2":7525,"PHASE3":7535,"PHASE4":7537,"NA":7539},{"trials":7522,"activeCount":100},[],{"trials":7524,"activeCount":100},[],{"trials":7526,"activeCount":100},[7527],{"nctId":7528,"briefTitle":7529,"status":126,"phases":7530,"primaryCompletion":7531,"completion":7531,"start":7532,"enrollment":1620,"conditions":7533,"interventions":7534},"NCT04941521","Exenatide for Treating Cocaine Use Disorder",[88,89],"2021-11-17","2021-06-24",[179],[7519],{"trials":7536,"activeCount":100},[],{"trials":7538,"activeCount":100},[],{"trials":7540,"activeCount":100},[],{"intervention":7542,"totalTrials":120,"cells":7543},"Alteplase",{"EARLY_PHASE1":7544,"PHASE1":7546,"PHASE2":7548,"PHASE3":7558,"PHASE4":7560,"NA":7562},{"trials":7545,"activeCount":100},[],{"trials":7547,"activeCount":100},[],{"trials":7549,"activeCount":100},[7550],{"nctId":7551,"briefTitle":7552,"status":126,"phases":7553,"primaryCompletion":7554,"completion":7555,"start":5433,"enrollment":421,"conditions":7556,"interventions":7557},"NCT01183533","Safety of Intravenous Thrombolysis for Wake-up Stroke",[89],"2013-10","2014-01",[5768],[7542],{"trials":7559,"activeCount":100},[],{"trials":7561,"activeCount":100},[],{"trials":7563,"activeCount":100},[],{"intervention":7565,"totalTrials":120,"cells":7566},"vadadustat",{"EARLY_PHASE1":7567,"PHASE1":7569,"PHASE2":7571,"PHASE3":7584,"PHASE4":7586,"NA":7588},{"trials":7568,"activeCount":100},[],{"trials":7570,"activeCount":100},[],{"trials":7572,"activeCount":100},[7573],{"nctId":7574,"briefTitle":7575,"status":126,"phases":7576,"primaryCompletion":7577,"completion":7578,"start":7579,"enrollment":7580,"conditions":7581,"interventions":7583},"NCT04478071","Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)",[89],"2022-03-07","2022-03-25","2020-08-22",448,[7486,7582],"Coronavirus Infection",[7565],{"trials":7585,"activeCount":100},[],{"trials":7587,"activeCount":100},[],{"trials":7589,"activeCount":100},[],{"intervention":7591,"totalTrials":120,"cells":7592},"Low fecal microbiota dose",{"EARLY_PHASE1":7593,"PHASE1":7595,"PHASE2":7597,"PHASE3":7611,"PHASE4":7613,"NA":7615},{"trials":7594,"activeCount":100},[],{"trials":7596,"activeCount":100},[],{"trials":7598,"activeCount":100},[7599],{"nctId":7600,"briefTitle":7601,"status":141,"phases":7602,"primaryCompletion":7603,"completion":7604,"start":7605,"enrollment":2725,"conditions":7606,"interventions":7608},"NCT03298048","Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI)",[89],"2019-03-30","2019-06-30","2017-12-21",[7607],"Recurrent C. Difficile Infection",[7591,7609,7610],"Mid fecal microbiota dose","High fecal microbiota dose",{"trials":7612,"activeCount":100},[],{"trials":7614,"activeCount":100},[],{"trials":7616,"activeCount":100},[],{"intervention":7609,"totalTrials":120,"cells":7618},{"EARLY_PHASE1":7619,"PHASE1":7621,"PHASE2":7623,"PHASE3":7629,"PHASE4":7631,"NA":7633},{"trials":7620,"activeCount":100},[],{"trials":7622,"activeCount":100},[],{"trials":7624,"activeCount":100},[7625],{"nctId":7600,"briefTitle":7601,"status":141,"phases":7626,"primaryCompletion":7603,"completion":7604,"start":7605,"enrollment":2725,"conditions":7627,"interventions":7628},[89],[7607],[7591,7609,7610],{"trials":7630,"activeCount":100},[],{"trials":7632,"activeCount":100},[],{"trials":7634,"activeCount":100},[],{"intervention":7610,"totalTrials":120,"cells":7636},{"EARLY_PHASE1":7637,"PHASE1":7639,"PHASE2":7641,"PHASE3":7647,"PHASE4":7649,"NA":7651},{"trials":7638,"activeCount":100},[],{"trials":7640,"activeCount":100},[],{"trials":7642,"activeCount":100},[7643],{"nctId":7600,"briefTitle":7601,"status":141,"phases":7644,"primaryCompletion":7603,"completion":7604,"start":7605,"enrollment":2725,"conditions":7645,"interventions":7646},[89],[7607],[7591,7609,7610],{"trials":7648,"activeCount":100},[],{"trials":7650,"activeCount":100},[],{"trials":7652,"activeCount":100},[],{"intervention":7654,"totalTrials":120,"cells":7655},"30,000 units hrINF-alpha",{"EARLY_PHASE1":7656,"PHASE1":7658,"PHASE2":7660,"PHASE3":7673,"PHASE4":7675,"NA":7677},{"trials":7657,"activeCount":100},[],{"trials":7659,"activeCount":100},[],{"trials":7661,"activeCount":100},[7662],{"nctId":7663,"briefTitle":7664,"status":126,"phases":7665,"primaryCompletion":7666,"completion":7666,"start":7667,"enrollment":7668,"conditions":7669,"interventions":7671},"NCT00024518","Interferon-Alpha for Diabetes Mellitus Type 1",[89],"2008-09","2001-09",57,[7670],"Insulin-Dependent Diabetes Mellitus",[7654,7672],"5,000 hrINF-alpha",{"trials":7674,"activeCount":100},[],{"trials":7676,"activeCount":100},[],{"trials":7678,"activeCount":100},[],{"intervention":7672,"totalTrials":120,"cells":7680},{"EARLY_PHASE1":7681,"PHASE1":7683,"PHASE2":7685,"PHASE3":7691,"PHASE4":7693,"NA":7695},{"trials":7682,"activeCount":100},[],{"trials":7684,"activeCount":100},[],{"trials":7686,"activeCount":100},[7687],{"nctId":7663,"briefTitle":7664,"status":126,"phases":7688,"primaryCompletion":7666,"completion":7666,"start":7667,"enrollment":7668,"conditions":7689,"interventions":7690},[89],[7670],[7654,7672],{"trials":7692,"activeCount":100},[],{"trials":7694,"activeCount":100},[],{"trials":7696,"activeCount":100},[],{"intervention":7698,"totalTrials":120,"cells":7699},"Dexedrine",{"EARLY_PHASE1":7700,"PHASE1":7702,"PHASE2":7704,"PHASE3":7713,"PHASE4":7715,"NA":7717},{"trials":7701,"activeCount":100},[],{"trials":7703,"activeCount":100},[],{"trials":7705,"activeCount":100},[7706],{"nctId":7707,"briefTitle":7708,"status":126,"phases":7709,"primaryCompletion":1821,"completion":1821,"start":7710,"enrollment":35,"conditions":7711,"interventions":7712},"NCT02514044","Dextroamphetamine and tDCS to Improve the Fluency",[89],"2015-03",[15],[7698],{"trials":7714,"activeCount":100},[],{"trials":7716,"activeCount":100},[],{"trials":7718,"activeCount":100},[],{"intervention":6400,"totalTrials":120,"cells":7720},{"EARLY_PHASE1":7721,"PHASE1":7723,"PHASE2":7725,"PHASE3":7731,"PHASE4":7733,"NA":7735},{"trials":7722,"activeCount":100},[],{"trials":7724,"activeCount":100},[],{"trials":7726,"activeCount":100},[7727],{"nctId":6392,"briefTitle":6393,"status":141,"phases":7728,"primaryCompletion":6395,"completion":6395,"start":6396,"enrollment":96,"conditions":7729,"interventions":7730},[89],[6398],[6400,6401,6402,6403,6383,6404],{"trials":7732,"activeCount":100},[],{"trials":7734,"activeCount":100},[],{"trials":7736,"activeCount":100},[],{"intervention":6401,"totalTrials":120,"cells":7738},{"EARLY_PHASE1":7739,"PHASE1":7741,"PHASE2":7743,"PHASE3":7749,"PHASE4":7751,"NA":7753},{"trials":7740,"activeCount":100},[],{"trials":7742,"activeCount":100},[],{"trials":7744,"activeCount":100},[7745],{"nctId":6392,"briefTitle":6393,"status":141,"phases":7746,"primaryCompletion":6395,"completion":6395,"start":6396,"enrollment":96,"conditions":7747,"interventions":7748},[89],[6398],[6400,6401,6402,6403,6383,6404],{"trials":7750,"activeCount":100},[],{"trials":7752,"activeCount":100},[],{"trials":7754,"activeCount":100},[],{"intervention":6402,"totalTrials":120,"cells":7756},{"EARLY_PHASE1":7757,"PHASE1":7759,"PHASE2":7761,"PHASE3":7767,"PHASE4":7769,"NA":7771},{"trials":7758,"activeCount":100},[],{"trials":7760,"activeCount":100},[],{"trials":7762,"activeCount":100},[7763],{"nctId":6392,"briefTitle":6393,"status":141,"phases":7764,"primaryCompletion":6395,"completion":6395,"start":6396,"enrollment":96,"conditions":7765,"interventions":7766},[89],[6398],[6400,6401,6402,6403,6383,6404],{"trials":7768,"activeCount":100},[],{"trials":7770,"activeCount":100},[],{"trials":7772,"activeCount":100},[],{"intervention":6403,"totalTrials":120,"cells":7774},{"EARLY_PHASE1":7775,"PHASE1":7777,"PHASE2":7779,"PHASE3":7785,"PHASE4":7787,"NA":7789},{"trials":7776,"activeCount":100},[],{"trials":7778,"activeCount":100},[],{"trials":7780,"activeCount":100},[7781],{"nctId":6392,"briefTitle":6393,"status":141,"phases":7782,"primaryCompletion":6395,"completion":6395,"start":6396,"enrollment":96,"conditions":7783,"interventions":7784},[89],[6398],[6400,6401,6402,6403,6383,6404],{"trials":7786,"activeCount":100},[],{"trials":7788,"activeCount":100},[],{"trials":7790,"activeCount":100},[],{"intervention":6404,"totalTrials":120,"cells":7792},{"EARLY_PHASE1":7793,"PHASE1":7795,"PHASE2":7797,"PHASE3":7803,"PHASE4":7805,"NA":7807},{"trials":7794,"activeCount":100},[],{"trials":7796,"activeCount":100},[],{"trials":7798,"activeCount":100},[7799],{"nctId":6392,"briefTitle":6393,"status":141,"phases":7800,"primaryCompletion":6395,"completion":6395,"start":6396,"enrollment":96,"conditions":7801,"interventions":7802},[89],[6398],[6400,6401,6402,6403,6383,6404],{"trials":7804,"activeCount":100},[],{"trials":7806,"activeCount":100},[],{"trials":7808,"activeCount":100},[],{"intervention":7810,"totalTrials":120,"cells":7811},"Apalutamide",{"EARLY_PHASE1":7812,"PHASE1":7814,"PHASE2":7816,"PHASE3":7827,"PHASE4":7829,"NA":7831},{"trials":7813,"activeCount":100},[],{"trials":7815,"activeCount":100},[],{"trials":7817,"activeCount":100},[7818],{"nctId":7819,"briefTitle":7820,"status":789,"phases":7821,"primaryCompletion":7822,"completion":50,"start":7823,"enrollment":100,"conditions":7824,"interventions":7825},"NCT02811809","Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer",[89],"2024-12","2020-12",[2170],[7810,7826],"IHT",{"trials":7828,"activeCount":100},[],{"trials":7830,"activeCount":100},[],{"trials":7832,"activeCount":100},[],{"intervention":7826,"totalTrials":120,"cells":7834},{"EARLY_PHASE1":7835,"PHASE1":7837,"PHASE2":7839,"PHASE3":7845,"PHASE4":7847,"NA":7849},{"trials":7836,"activeCount":100},[],{"trials":7838,"activeCount":100},[],{"trials":7840,"activeCount":100},[7841],{"nctId":7819,"briefTitle":7820,"status":789,"phases":7842,"primaryCompletion":7822,"completion":50,"start":7823,"enrollment":100,"conditions":7843,"interventions":7844},[89],[2170],[7810,7826],{"trials":7846,"activeCount":100},[],{"trials":7848,"activeCount":100},[],{"trials":7850,"activeCount":100},[],{"intervention":7852,"totalTrials":120,"cells":7853},"Torsemide",{"EARLY_PHASE1":7854,"PHASE1":7856,"PHASE2":7858,"PHASE3":7869,"PHASE4":7871,"NA":7873},{"trials":7855,"activeCount":100},[],{"trials":7857,"activeCount":100},[],{"trials":7859,"activeCount":100},[7860],{"nctId":7861,"briefTitle":7862,"status":126,"phases":7863,"primaryCompletion":7864,"completion":7865,"start":3194,"enrollment":1646,"conditions":7866,"interventions":7868},"NCT02813551","ToRsemide for pOstpartum HYpertension",[89],"2017-07-28","2017-09-09",[7867],"Preeclampsia",[7852],{"trials":7870,"activeCount":100},[],{"trials":7872,"activeCount":100},[],{"trials":7874,"activeCount":100},[],{"intervention":7876,"totalTrials":120,"cells":7877},"Aspirin",{"EARLY_PHASE1":7878,"PHASE1":7880,"PHASE2":7882,"PHASE3":7892,"PHASE4":7894,"NA":7896},{"trials":7879,"activeCount":100},[],{"trials":7881,"activeCount":100},[],{"trials":7883,"activeCount":100},[7884],{"nctId":7885,"briefTitle":7886,"status":126,"phases":7887,"primaryCompletion":7888,"completion":7888,"start":3079,"enrollment":3245,"conditions":7889,"interventions":7890},"NCT01797575","N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder",[89],"2017-02-01",[5873],[7876,7891],"Sugar Pill",{"trials":7893,"activeCount":100},[],{"trials":7895,"activeCount":100},[],{"trials":7897,"activeCount":100},[],{"intervention":7891,"totalTrials":120,"cells":7899},{"EARLY_PHASE1":7900,"PHASE1":7902,"PHASE2":7904,"PHASE3":7910,"PHASE4":7912,"NA":7914},{"trials":7901,"activeCount":100},[],{"trials":7903,"activeCount":100},[],{"trials":7905,"activeCount":100},[7906],{"nctId":7885,"briefTitle":7886,"status":126,"phases":7907,"primaryCompletion":7888,"completion":7888,"start":3079,"enrollment":3245,"conditions":7908,"interventions":7909},[89],[5873],[7876,7891],{"trials":7911,"activeCount":100},[],{"trials":7913,"activeCount":100},[],{"trials":7915,"activeCount":100},[],{"intervention":7917,"totalTrials":120,"cells":7918},"Dextro-Amphetamine Sulfate",{"EARLY_PHASE1":7919,"PHASE1":7921,"PHASE2":7923,"PHASE3":7933,"PHASE4":7935,"NA":7937},{"trials":7920,"activeCount":100},[],{"trials":7922,"activeCount":100},[],{"trials":7924,"activeCount":100},[7925],{"nctId":7926,"briefTitle":7927,"status":126,"phases":7928,"primaryCompletion":7929,"completion":7929,"start":3404,"enrollment":7930,"conditions":7931,"interventions":7932},"NCT00218348","Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo",[89],"2007-11",186,[1636],[7917],{"trials":7934,"activeCount":100},[],{"trials":7936,"activeCount":100},[],{"trials":7938,"activeCount":100},[],{"intervention":7940,"totalTrials":120,"cells":7941},"Suvorexant 20 mg",{"EARLY_PHASE1":7942,"PHASE1":7944,"PHASE2":7946,"PHASE3":7956,"PHASE4":7958,"NA":7960},{"trials":7943,"activeCount":100},[],{"trials":7945,"activeCount":100},[],{"trials":7947,"activeCount":100},[7948],{"nctId":7949,"briefTitle":7950,"status":126,"phases":7951,"primaryCompletion":7952,"completion":7952,"start":5665,"enrollment":2054,"conditions":7953,"interventions":7954},"NCT04234997","Suvorexant to Reduce Symptoms of Nicotine Use",[89],"2024-08-22",[32],[7940,7955],"Suvorexant 0mg",{"trials":7957,"activeCount":100},[],{"trials":7959,"activeCount":100},[],{"trials":7961,"activeCount":100},[],{"intervention":7955,"totalTrials":120,"cells":7963},{"EARLY_PHASE1":7964,"PHASE1":7966,"PHASE2":7968,"PHASE3":7974,"PHASE4":7976,"NA":7978},{"trials":7965,"activeCount":100},[],{"trials":7967,"activeCount":100},[],{"trials":7969,"activeCount":100},[7970],{"nctId":7949,"briefTitle":7950,"status":126,"phases":7971,"primaryCompletion":7952,"completion":7952,"start":5665,"enrollment":2054,"conditions":7972,"interventions":7973},[89],[32],[7940,7955],{"trials":7975,"activeCount":100},[],{"trials":7977,"activeCount":100},[],{"trials":7979,"activeCount":100},[],{"intervention":7981,"totalTrials":120,"cells":7982},"Autologous BMMNC",{"EARLY_PHASE1":7983,"PHASE1":7985,"PHASE2":7987,"PHASE3":8002,"PHASE4":8004,"NA":8006},{"trials":7984,"activeCount":100},[],{"trials":7986,"activeCount":100},[],{"trials":7988,"activeCount":100},[7989],{"nctId":7990,"briefTitle":7991,"status":1858,"phases":7992,"primaryCompletion":7993,"completion":7994,"start":7995,"enrollment":7996,"conditions":7997,"interventions":8001},"NCT02525432","Autologous Stem Cell Study for Adult TBI (Phase 2b)",[89],"2024-07","2025-01","2016-11-21",37,[7998,7999,8000],"Brain Injuries, Traumatic","Brain Injuries, Acute","TBI (Traumatic Brain Injury)",[7981],{"trials":8003,"activeCount":100},[],{"trials":8005,"activeCount":100},[],{"trials":8007,"activeCount":100},[],{"intervention":8009,"totalTrials":120,"cells":8010},"Palmitoylethanolamide",{"EARLY_PHASE1":8011,"PHASE1":8013,"PHASE2":8015,"PHASE3":8027,"PHASE4":8029,"NA":8031},{"trials":8012,"activeCount":100},[],{"trials":8014,"activeCount":100},[],{"trials":8016,"activeCount":100},[8017],{"nctId":8018,"briefTitle":8019,"status":126,"phases":8020,"primaryCompletion":8021,"completion":8021,"start":8022,"enrollment":1229,"conditions":8023,"interventions":8025},"NCT06229977","A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression",[89],"2025-07-17","2023-05-17",[8024],"Bipolar Depression",[8009,8026],"Treatment as Usual",{"trials":8028,"activeCount":100},[],{"trials":8030,"activeCount":100},[],{"trials":8032,"activeCount":100},[],{"intervention":8026,"totalTrials":120,"cells":8034},{"EARLY_PHASE1":8035,"PHASE1":8037,"PHASE2":8039,"PHASE3":8045,"PHASE4":8047,"NA":8049},{"trials":8036,"activeCount":100},[],{"trials":8038,"activeCount":100},[],{"trials":8040,"activeCount":100},[8041],{"nctId":8018,"briefTitle":8019,"status":126,"phases":8042,"primaryCompletion":8021,"completion":8021,"start":8022,"enrollment":1229,"conditions":8043,"interventions":8044},[89],[8024],[8009,8026],{"trials":8046,"activeCount":100},[],{"trials":8048,"activeCount":100},[],{"trials":8050,"activeCount":100},[],{"intervention":8052,"totalTrials":145,"cells":8053},"Methotrexate",{"EARLY_PHASE1":8054,"PHASE1":8066,"PHASE2":8077,"PHASE3":8079,"PHASE4":8081,"NA":8083},{"trials":8055,"activeCount":100},[8056],{"nctId":8057,"briefTitle":8058,"status":126,"phases":8059,"primaryCompletion":8060,"completion":8060,"start":8061,"enrollment":1620,"conditions":8062,"interventions":8064},"NCT02905110","Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children with Recurrent Posterior Fossa Brain Tumors",[87],"2022-03-04","2017-10-12",[8063],"Brain Tumor Recurrent",[8052,8065],"Etoposide",{"trials":8067,"activeCount":100},[8068],{"nctId":8069,"briefTitle":8070,"status":126,"phases":8071,"primaryCompletion":5683,"completion":5683,"start":8072,"enrollment":6101,"conditions":8073,"interventions":8076},"NCT02458339","Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors",[88],"2015-06-15",[8074,8075],"Brain Tumor, Recurrent","Malignant Neoplasm of Fourth Ventricle of Brain",[8052],{"trials":8078,"activeCount":100},[],{"trials":8080,"activeCount":100},[],{"trials":8082,"activeCount":100},[],{"trials":8084,"activeCount":100},[],{"intervention":1813,"totalTrials":120,"cells":8086},{"EARLY_PHASE1":8087,"PHASE1":8089,"PHASE2":8095,"PHASE3":8097,"PHASE4":8099,"NA":8101},{"trials":8088,"activeCount":100},[],{"trials":8090,"activeCount":100},[8091],{"nctId":1804,"briefTitle":1805,"status":141,"phases":8092,"primaryCompletion":1807,"completion":1807,"start":1808,"enrollment":1809,"conditions":8093,"interventions":8094},[88],[1811],[1813,1796],{"trials":8096,"activeCount":100},[],{"trials":8098,"activeCount":100},[],{"trials":8100,"activeCount":100},[],{"trials":8102,"activeCount":100},[],{"intervention":8104,"totalTrials":120,"cells":8105},"Doxazosin XL",{"EARLY_PHASE1":8106,"PHASE1":8108,"PHASE2":8116,"PHASE3":8118,"PHASE4":8120,"NA":8122},{"trials":8107,"activeCount":100},[],{"trials":8109,"activeCount":100},[8110],{"nctId":8111,"briefTitle":8112,"status":789,"phases":8113,"primaryCompletion":5500,"completion":5500,"start":5674,"enrollment":100,"conditions":8114,"interventions":8115},"NCT03398252","Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL",[88],[5676],[8104],{"trials":8117,"activeCount":100},[],{"trials":8119,"activeCount":100},[],{"trials":8121,"activeCount":100},[],{"trials":8123,"activeCount":100},[],{"intervention":8125,"totalTrials":120,"cells":8126},"10 mg d-amphetamine",{"EARLY_PHASE1":8127,"PHASE1":8129,"PHASE2":8142,"PHASE3":8144,"PHASE4":8146,"NA":8148},{"trials":8128,"activeCount":100},[],{"trials":8130,"activeCount":100},[8131],{"nctId":8132,"briefTitle":8133,"status":126,"phases":8134,"primaryCompletion":8135,"completion":8135,"start":8136,"enrollment":8137,"conditions":8138,"interventions":8140},"NCT03369015","Effect of D-amphetamine on Reward Functioning",[88],"2019-05-23","2018-01-24",68,[8139],"Anhedonia",[8125,8141],"20mg d-amphetamine",{"trials":8143,"activeCount":100},[],{"trials":8145,"activeCount":100},[],{"trials":8147,"activeCount":100},[],{"trials":8149,"activeCount":100},[],{"intervention":8141,"totalTrials":120,"cells":8151},{"EARLY_PHASE1":8152,"PHASE1":8154,"PHASE2":8160,"PHASE3":8162,"PHASE4":8164,"NA":8166},{"trials":8153,"activeCount":100},[],{"trials":8155,"activeCount":100},[8156],{"nctId":8132,"briefTitle":8133,"status":126,"phases":8157,"primaryCompletion":8135,"completion":8135,"start":8136,"enrollment":8137,"conditions":8158,"interventions":8159},[88],[8139],[8125,8141],{"trials":8161,"activeCount":100},[],{"trials":8163,"activeCount":100},[],{"trials":8165,"activeCount":100},[],{"trials":8167,"activeCount":100},[],{"intervention":8169,"totalTrials":120,"cells":8170},"5-Azacytidine (5-AZA) group 1",{"EARLY_PHASE1":8171,"PHASE1":8173,"PHASE2":8186,"PHASE3":8188,"PHASE4":8190,"NA":8192},{"trials":8172,"activeCount":100},[],{"trials":8174,"activeCount":100},[8175],{"nctId":8176,"briefTitle":8177,"status":126,"phases":8178,"primaryCompletion":8179,"completion":8179,"start":8180,"enrollment":1620,"conditions":8181,"interventions":8183},"NCT03572530","Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma",[88],"2020-11-24","2019-02-08",[8182],"Recurrent Ependymoma",[8169,8184,8185],"5-Azacytidine (5-AZA) group 2","5-Azacytidine (5-AZA) group 3",{"trials":8187,"activeCount":100},[],{"trials":8189,"activeCount":100},[],{"trials":8191,"activeCount":100},[],{"trials":8193,"activeCount":100},[],{"intervention":8184,"totalTrials":120,"cells":8195},{"EARLY_PHASE1":8196,"PHASE1":8198,"PHASE2":8204,"PHASE3":8206,"PHASE4":8208,"NA":8210},{"trials":8197,"activeCount":100},[],{"trials":8199,"activeCount":100},[8200],{"nctId":8176,"briefTitle":8177,"status":126,"phases":8201,"primaryCompletion":8179,"completion":8179,"start":8180,"enrollment":1620,"conditions":8202,"interventions":8203},[88],[8182],[8169,8184,8185],{"trials":8205,"activeCount":100},[],{"trials":8207,"activeCount":100},[],{"trials":8209,"activeCount":100},[],{"trials":8211,"activeCount":100},[],{"intervention":8185,"totalTrials":120,"cells":8213},{"EARLY_PHASE1":8214,"PHASE1":8216,"PHASE2":8222,"PHASE3":8224,"PHASE4":8226,"NA":8228},{"trials":8215,"activeCount":100},[],{"trials":8217,"activeCount":100},[8218],{"nctId":8176,"briefTitle":8177,"status":126,"phases":8219,"primaryCompletion":8179,"completion":8179,"start":8180,"enrollment":1620,"conditions":8220,"interventions":8221},[88],[8182],[8169,8184,8185],{"trials":8223,"activeCount":100},[],{"trials":8225,"activeCount":100},[],{"trials":8227,"activeCount":100},[],{"trials":8229,"activeCount":100},[],{"intervention":8231,"totalTrials":120,"cells":8232},"Lactobacillus reuteri",{"EARLY_PHASE1":8233,"PHASE1":8235,"PHASE2":8246,"PHASE3":8248,"PHASE4":8250,"NA":8252},{"trials":8234,"activeCount":100},[],{"trials":8236,"activeCount":100},[8237],{"nctId":8238,"briefTitle":8239,"status":126,"phases":8240,"primaryCompletion":7036,"completion":7036,"start":8241,"enrollment":16,"conditions":8242,"interventions":8245},"NCT01849991","Safety and Effect of L. Reuteri on Biomarkers of Inflammation in Healthy Infants With Colic",[88],"2013-09",[8243,8244],"Gastrointestinal","Colic",[8231],{"trials":8247,"activeCount":100},[],{"trials":8249,"activeCount":100},[],{"trials":8251,"activeCount":100},[],{"trials":8253,"activeCount":100},[],{"intervention":8255,"totalTrials":120,"cells":8256},"Autologous umbilical cord blood",{"EARLY_PHASE1":8257,"PHASE1":8259,"PHASE2":8268,"PHASE3":8270,"PHASE4":8272,"NA":8274},{"trials":8258,"activeCount":100},[],{"trials":8260,"activeCount":100},[8261],{"nctId":8262,"briefTitle":8263,"status":141,"phases":8264,"primaryCompletion":8265,"completion":5499,"start":2354,"enrollment":1620,"conditions":8266,"interventions":8267},"NCT03526588","Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH)",[88],"2022-07-01",[357],[8255],{"trials":8269,"activeCount":100},[],{"trials":8271,"activeCount":100},[],{"trials":8273,"activeCount":100},[],{"trials":8275,"activeCount":100},[],{"intervention":8277,"totalTrials":120,"cells":8278},"Dextroamphetamine",{"EARLY_PHASE1":8279,"PHASE1":8281,"PHASE2":8289,"PHASE3":8291,"PHASE4":8293,"NA":8295},{"trials":8280,"activeCount":100},[],{"trials":8282,"activeCount":100},[8283],{"nctId":8284,"briefTitle":8285,"status":141,"phases":8286,"enrollment":100,"conditions":8287,"interventions":8288},"NCT00000305","Amphetamine Cocaine Interaction Study - 2",[88],[1636],[8277],{"trials":8290,"activeCount":100},[],{"trials":8292,"activeCount":100},[],{"trials":8294,"activeCount":100},[],{"trials":8296,"activeCount":100},[],{"intervention":8298,"totalTrials":120,"cells":8299},"Glutamine",{"EARLY_PHASE1":8300,"PHASE1":8302,"PHASE2":8314,"PHASE3":8316,"PHASE4":8318,"NA":8320},{"trials":8301,"activeCount":100},[],{"trials":8303,"activeCount":100},[8304],{"nctId":8305,"briefTitle":8306,"status":141,"phases":8307,"completion":8308,"start":8309,"enrollment":19,"conditions":8310,"interventions":8313},"NCT00178581","Enteral Glutamine Supplementation for the Patient With Major Torso Trauma",[88],"2006-09","2005-06",[5563,8311,8312],"Critical Illness","Shock",[8298],{"trials":8315,"activeCount":100},[],{"trials":8317,"activeCount":100},[],{"trials":8319,"activeCount":100},[],{"trials":8321,"activeCount":100},[],{"intervention":8323,"totalTrials":120,"cells":8324},"FOLFIRINOX",{"EARLY_PHASE1":8325,"PHASE1":8327,"PHASE2":8336,"PHASE3":8338,"PHASE4":8340,"NA":8342},{"trials":8326,"activeCount":100},[],{"trials":8328,"activeCount":100},[8329],{"nctId":8330,"briefTitle":8331,"status":789,"phases":8332,"primaryCompletion":8333,"completion":8333,"start":5719,"enrollment":100,"conditions":8334,"interventions":8335},"NCT02592395","Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma",[88],"2017-10",[6163],[8323],{"trials":8337,"activeCount":100},[],{"trials":8339,"activeCount":100},[],{"trials":8341,"activeCount":100},[],{"trials":8343,"activeCount":100},[],{"intervention":8345,"totalTrials":120,"cells":8346},"Allogeneic bone marrow-derived MSCs",{"EARLY_PHASE1":8347,"PHASE1":8349,"PHASE2":8359,"PHASE3":8361,"PHASE4":8363,"NA":8365},{"trials":8348,"activeCount":100},[],{"trials":8350,"activeCount":100},[8351],{"nctId":8352,"briefTitle":8353,"status":126,"phases":8354,"primaryCompletion":8355,"completion":8355,"start":8356,"enrollment":19,"conditions":8357,"interventions":8358},"NCT02611167","Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease",[88],"2019-09-18","2017-11-01",[803],[8345,8345,8345,8345],{"trials":8360,"activeCount":100},[],{"trials":8362,"activeCount":100},[],{"trials":8364,"activeCount":100},[],{"trials":8366,"activeCount":100},[],{"intervention":8368,"totalTrials":120,"cells":8369},"Autologous bone marrow precursor cell harvest and transplant",{"EARLY_PHASE1":8370,"PHASE1":8372,"PHASE2":8383,"PHASE3":8385,"PHASE4":8387,"NA":8389},{"trials":8371,"activeCount":100},[],{"trials":8373,"activeCount":100},[8374],{"nctId":8375,"briefTitle":8376,"status":126,"phases":8377,"primaryCompletion":8378,"completion":8379,"start":8380,"enrollment":35,"conditions":8381,"interventions":8382},"NCT00254722","Safety of Autologous Stem Cell Treatment for Traumatic Brain Injury in Children",[88],"2008-11","2009-10","2006-04",[29],[8368],{"trials":8384,"activeCount":100},[],{"trials":8386,"activeCount":100},[],{"trials":8388,"activeCount":100},[],{"trials":8390,"activeCount":100},[],{"intervention":8392,"totalTrials":120,"cells":8393},"N-acetylcysteine",{"EARLY_PHASE1":8394,"PHASE1":8396,"PHASE2":8406,"PHASE3":8408,"PHASE4":8410,"NA":8412},{"trials":8395,"activeCount":100},[],{"trials":8397,"activeCount":100},[8398],{"nctId":8399,"briefTitle":8400,"status":126,"phases":8401,"primaryCompletion":8402,"completion":8402,"start":5976,"enrollment":2210,"conditions":8403,"interventions":8405},"NCT01537926","Hypertrophic Regression With N-Acetylcysteine in HCM",[88],"2016-12-31",[8404],"Hypertrophic Cardiomyopathy",[8392],{"trials":8407,"activeCount":100},[],{"trials":8409,"activeCount":100},[],{"trials":8411,"activeCount":100},[],{"trials":8413,"activeCount":100},[],{"intervention":8415,"totalTrials":120,"cells":8416},"2% Chlorohexidine Gluconate soap",{"EARLY_PHASE1":8417,"PHASE1":8419,"PHASE2":8431,"PHASE3":8433,"PHASE4":8435,"NA":8437},{"trials":8418,"activeCount":100},[],{"trials":8420,"activeCount":100},[8421],{"nctId":8422,"briefTitle":8423,"status":126,"phases":8424,"primaryCompletion":8425,"completion":8425,"start":8426,"enrollment":2054,"conditions":8427,"interventions":8429},"NCT04155697","Thirdhand Smoke Contamination in a Neonatal Intensive Care Unit (NICU)",[88],"2018-09-11","2017-06-07",[8428],"Nicotine Exposure",[8415,8430],"62% ethyl alcohol-based hand sanitizer",{"trials":8432,"activeCount":100},[],{"trials":8434,"activeCount":100},[],{"trials":8436,"activeCount":100},[],{"trials":8438,"activeCount":100},[],{"intervention":8430,"totalTrials":120,"cells":8440},{"EARLY_PHASE1":8441,"PHASE1":8443,"PHASE2":8449,"PHASE3":8451,"PHASE4":8453,"NA":8455},{"trials":8442,"activeCount":100},[],{"trials":8444,"activeCount":100},[8445],{"nctId":8422,"briefTitle":8423,"status":126,"phases":8446,"primaryCompletion":8425,"completion":8425,"start":8426,"enrollment":2054,"conditions":8447,"interventions":8448},[88],[8428],[8415,8430],{"trials":8450,"activeCount":100},[],{"trials":8452,"activeCount":100},[],{"trials":8454,"activeCount":100},[],{"trials":8456,"activeCount":100},[],{"intervention":8458,"totalTrials":120,"cells":8459},"L. reuteri",{"EARLY_PHASE1":8460,"PHASE1":8462,"PHASE2":8473,"PHASE3":8475,"PHASE4":8477,"NA":8479},{"trials":8461,"activeCount":100},[],{"trials":8463,"activeCount":100},[8464],{"nctId":8465,"briefTitle":8466,"status":126,"phases":8467,"primaryCompletion":8468,"completion":8468,"start":8379,"enrollment":421,"conditions":8469,"interventions":8471},"NCT00922727","Safety of Lactobacillus Reuteri (L. Reuteri) in Healthy Adults",[88],"2011-07",[8244,8470],"Gastrointestinal Tract Infections",[8458,8472],"Sunflower Oil",{"trials":8474,"activeCount":100},[],{"trials":8476,"activeCount":100},[],{"trials":8478,"activeCount":100},[],{"trials":8480,"activeCount":100},[],{"intervention":8472,"totalTrials":120,"cells":8482},{"EARLY_PHASE1":8483,"PHASE1":8485,"PHASE2":8491,"PHASE3":8493,"PHASE4":8495,"NA":8497},{"trials":8484,"activeCount":100},[],{"trials":8486,"activeCount":100},[8487],{"nctId":8465,"briefTitle":8466,"status":126,"phases":8488,"primaryCompletion":8468,"completion":8468,"start":8379,"enrollment":421,"conditions":8489,"interventions":8490},[88],[8244,8470],[8458,8472],{"trials":8492,"activeCount":100},[],{"trials":8494,"activeCount":100},[],{"trials":8496,"activeCount":100},[],{"trials":8498,"activeCount":100},[],{"intervention":8500,"totalTrials":120,"cells":8501},"Oral fecal microbiota transplantation",{"EARLY_PHASE1":8502,"PHASE1":8504,"PHASE2":8515,"PHASE3":8517,"PHASE4":8519,"NA":8521},{"trials":8503,"activeCount":100},[],{"trials":8505,"activeCount":100},[8506],{"nctId":8507,"briefTitle":8508,"status":126,"phases":8509,"primaryCompletion":8510,"completion":8510,"start":8511,"enrollment":756,"conditions":8512,"interventions":8514},"NCT03329560","Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV",[88],"2019-10-08","2018-04-12",[8513],"HIV-1-infection",[8500],{"trials":8516,"activeCount":100},[],{"trials":8518,"activeCount":100},[],{"trials":8520,"activeCount":100},[],{"trials":8522,"activeCount":100},[],{"intervention":8524,"totalTrials":120,"cells":8525},"cyclosporine",{"EARLY_PHASE1":8526,"PHASE1":8528,"PHASE2":8539,"PHASE3":8541,"PHASE4":8543,"NA":8545},{"trials":8527,"activeCount":100},[],{"trials":8529,"activeCount":100},[8530],{"nctId":8531,"briefTitle":8532,"status":141,"phases":8533,"primaryCompletion":6322,"completion":6322,"start":3244,"enrollment":8534,"conditions":8535,"interventions":8537},"NCT00990795","Trial of Cyclosporine for Myocardial Protection During Open Heart Surgery",[88],72,[8536],"Cardiac Surgical Procedures",[8524,8538],"saline solution",{"trials":8540,"activeCount":100},[],{"trials":8542,"activeCount":100},[],{"trials":8544,"activeCount":100},[],{"trials":8546,"activeCount":100},[],{"intervention":8538,"totalTrials":120,"cells":8548},{"EARLY_PHASE1":8549,"PHASE1":8551,"PHASE2":8557,"PHASE3":8559,"PHASE4":8561,"NA":8563},{"trials":8550,"activeCount":100},[],{"trials":8552,"activeCount":100},[8553],{"nctId":8531,"briefTitle":8532,"status":141,"phases":8554,"primaryCompletion":6322,"completion":6322,"start":3244,"enrollment":8534,"conditions":8555,"interventions":8556},[88],[8536],[8524,8538],{"trials":8558,"activeCount":100},[],{"trials":8560,"activeCount":100},[],{"trials":8562,"activeCount":100},[],{"trials":8564,"activeCount":100},[],{"intervention":6166,"totalTrials":120,"cells":8566},{"EARLY_PHASE1":8567,"PHASE1":8569,"PHASE2":8575,"PHASE3":8577,"PHASE4":8579,"NA":8581},{"trials":8568,"activeCount":100},[],{"trials":8570,"activeCount":100},[8571],{"nctId":6157,"briefTitle":6158,"status":126,"phases":8572,"primaryCompletion":6160,"completion":6160,"start":6161,"enrollment":756,"conditions":8573,"interventions":8574},[88],[6163],[6165,6166],{"trials":8576,"activeCount":100},[],{"trials":8578,"activeCount":100},[],{"trials":8580,"activeCount":100},[],{"trials":8582,"activeCount":100},[],{"intervention":8584,"totalTrials":120,"cells":8585},"Indocyanine Green",{"EARLY_PHASE1":8586,"PHASE1":8588,"PHASE2":8598,"PHASE3":8600,"PHASE4":8602,"NA":8604},{"trials":8587,"activeCount":100},[],{"trials":8589,"activeCount":100},[8590],{"nctId":8591,"briefTitle":8592,"status":126,"phases":8593,"primaryCompletion":8594,"completion":8594,"start":8595,"enrollment":3080,"conditions":8596,"interventions":8597},"NCT02949726","Lymphatic and Systemic Immunity Changes in Post-radiation Lymphedema Development",[88],"2022-10-01","2017-04-24",[1682],[8584],{"trials":8599,"activeCount":100},[],{"trials":8601,"activeCount":100},[],{"trials":8603,"activeCount":100},[],{"trials":8605,"activeCount":100},[],{"intervention":8607,"totalTrials":120,"cells":8608},"Indocyanine green (ICG) dye",{"EARLY_PHASE1":8609,"PHASE1":8611,"PHASE2":8622,"PHASE3":8624,"PHASE4":8626,"NA":8628},{"trials":8610,"activeCount":100},[],{"trials":8612,"activeCount":100},[8613],{"nctId":8614,"briefTitle":8615,"status":126,"phases":8616,"primaryCompletion":3272,"completion":3272,"start":8617,"enrollment":96,"conditions":8618,"interventions":8621},"NCT05946837","Near-infrared Fluorescence Lymphatic Imaging Assessment of Lymphatic Response to Pneumatic Back\u002FNeck Lymphatic Drainage Delivered by a Pneumatic Manual Lymphatic Drainage Device",[88],"2023-08-29",[8619,8620],"Neck Pain","Back Pain",[8607],{"trials":8623,"activeCount":100},[],{"trials":8625,"activeCount":100},[],{"trials":8627,"activeCount":100},[],{"trials":8629,"activeCount":100},[],{"intervention":1575,"totalTrials":120,"cells":8631},{"EARLY_PHASE1":8632,"PHASE1":8634,"PHASE2":8640,"PHASE3":8642,"PHASE4":8644,"NA":8646},{"trials":8633,"activeCount":100},[],{"trials":8635,"activeCount":100},[8636],{"nctId":1568,"briefTitle":1569,"status":141,"phases":8637,"primaryCompletion":1571,"completion":1571,"start":1572,"enrollment":145,"conditions":8638,"interventions":8639},[88],[32],[1561,1575],{"trials":8641,"activeCount":100},[],{"trials":8643,"activeCount":100},[],{"trials":8645,"activeCount":100},[],{"trials":8647,"activeCount":100},[],{"intervention":8649,"totalTrials":120,"cells":8650},"Antibiotic treatment",{"EARLY_PHASE1":8651,"PHASE1":8653,"PHASE2":8665,"PHASE3":8667,"PHASE4":8669,"NA":8671},{"trials":8652,"activeCount":100},[],{"trials":8654,"activeCount":100},[8655],{"nctId":8656,"briefTitle":8657,"status":141,"phases":8658,"primaryCompletion":8659,"completion":8660,"start":3597,"enrollment":22,"conditions":8661,"interventions":8664},"NCT04198129","The Evaluation of Postoperative Antibiotics in Non-Infected Mandible Fractures",[88],"2022-01-20","2022-03-20",[8662,8663],"Jaw Fractures","Infection",[8649,8649],{"trials":8666,"activeCount":100},[],{"trials":8668,"activeCount":100},[],{"trials":8670,"activeCount":100},[],{"trials":8672,"activeCount":100},[],{"intervention":8674,"totalTrials":120,"cells":8675},"Arnica Montana",{"EARLY_PHASE1":8676,"PHASE1":8678,"PHASE2":8690,"PHASE3":8692,"PHASE4":8694,"NA":8696},{"trials":8677,"activeCount":100},[],{"trials":8679,"activeCount":100},[8680],{"nctId":8681,"briefTitle":8682,"status":126,"phases":8683,"primaryCompletion":7666,"completion":7666,"start":4291,"enrollment":8684,"conditions":8685,"interventions":8689},"NCT00504010","The Role of Arnica on Muscle Pain Following Eccentric Exercise",[88],55,[8686,8687,8688],"Muscles","Exercise","Arnica",[8674],{"trials":8691,"activeCount":100},[],{"trials":8693,"activeCount":100},[],{"trials":8695,"activeCount":100},[],{"trials":8697,"activeCount":100},[],{"intervention":8699,"totalTrials":120,"cells":8700},"Allo-MSCs",{"EARLY_PHASE1":8701,"PHASE1":8703,"PHASE2":8714,"PHASE3":8716,"PHASE4":8718,"NA":8720},{"trials":8702,"activeCount":100},[],{"trials":8704,"activeCount":100},[8705],{"nctId":8706,"briefTitle":8707,"status":126,"phases":8708,"primaryCompletion":8709,"completion":8710,"start":3194,"enrollment":2784,"conditions":8711,"interventions":8713},"NCT02509156","Stem Cell Injection in Cancer Survivors",[88],"2019-11","2020-04-20",[8712],"Cardiomyopathy Due to Anthracyclines",[8699],{"trials":8715,"activeCount":100},[],{"trials":8717,"activeCount":100},[],{"trials":8719,"activeCount":100},[],{"trials":8721,"activeCount":100},[],{"intervention":8723,"totalTrials":120,"cells":8724},"Skincerity",{"EARLY_PHASE1":8725,"PHASE1":8727,"PHASE2":8741,"PHASE3":8743,"PHASE4":8745,"NA":8747},{"trials":8726,"activeCount":100},[],{"trials":8728,"activeCount":100},[8729],{"nctId":8730,"briefTitle":8731,"status":126,"phases":8732,"primaryCompletion":8733,"completion":2675,"start":3403,"enrollment":2831,"conditions":8734,"interventions":8738},"NCT01031901","Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)",[88],"2011-02",[6838,8735,8736,8737],"Neurofibromatoses","Angiofibroma","Neurofibroma",[8723,8739,8740],"Skincerity plus sirolimus\u002Frapamycin","Skinercity plus sirolimus\u002Frapamycin",{"trials":8742,"activeCount":100},[],{"trials":8744,"activeCount":100},[],{"trials":8746,"activeCount":100},[],{"trials":8748,"activeCount":100},[],{"intervention":8739,"totalTrials":120,"cells":8750},{"EARLY_PHASE1":8751,"PHASE1":8753,"PHASE2":8759,"PHASE3":8761,"PHASE4":8763,"NA":8765},{"trials":8752,"activeCount":100},[],{"trials":8754,"activeCount":100},[8755],{"nctId":8730,"briefTitle":8731,"status":126,"phases":8756,"primaryCompletion":8733,"completion":2675,"start":3403,"enrollment":2831,"conditions":8757,"interventions":8758},[88],[6838,8735,8736,8737],[8723,8739,8740],{"trials":8760,"activeCount":100},[],{"trials":8762,"activeCount":100},[],{"trials":8764,"activeCount":100},[],{"trials":8766,"activeCount":100},[],{"intervention":8740,"totalTrials":120,"cells":8768},{"EARLY_PHASE1":8769,"PHASE1":8771,"PHASE2":8777,"PHASE3":8779,"PHASE4":8781,"NA":8783},{"trials":8770,"activeCount":100},[],{"trials":8772,"activeCount":100},[8773],{"nctId":8730,"briefTitle":8731,"status":126,"phases":8774,"primaryCompletion":8733,"completion":2675,"start":3403,"enrollment":2831,"conditions":8775,"interventions":8776},[88],[6838,8735,8736,8737],[8723,8739,8740],{"trials":8778,"activeCount":100},[],{"trials":8780,"activeCount":100},[],{"trials":8782,"activeCount":100},[],{"trials":8784,"activeCount":100},[],{"intervention":8786,"totalTrials":120,"cells":8787},"5-Azacytidine",{"EARLY_PHASE1":8788,"PHASE1":8797,"PHASE2":8799,"PHASE3":8801,"PHASE4":8803,"NA":8805},{"trials":8789,"activeCount":100},[8790],{"nctId":8791,"briefTitle":8792,"status":126,"phases":8793,"primaryCompletion":8794,"completion":8794,"start":7888,"enrollment":756,"conditions":8795,"interventions":8796},"NCT02940483","Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma",[87],"2018-11-28",[8063],[8786],{"trials":8798,"activeCount":100},[],{"trials":8800,"activeCount":100},[],{"trials":8802,"activeCount":100},[],{"trials":8804,"activeCount":100},[],{"trials":8806,"activeCount":100},[],{"intervention":8808,"totalTrials":120,"cells":8809},"Treatment with MTX110",{"EARLY_PHASE1":8810,"PHASE1":8821,"PHASE2":8823,"PHASE3":8825,"PHASE4":8827,"NA":8829},{"trials":8811,"activeCount":100},[8812],{"nctId":8813,"briefTitle":8814,"status":126,"phases":8815,"primaryCompletion":8816,"completion":8816,"start":8817,"enrollment":145,"conditions":8818,"interventions":8820},"NCT04315064","Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults with Recurrent Medulloblastoma",[87],"2023-05-02","2020-04-21",[8819],"Medulloblastoma",[8808],{"trials":8822,"activeCount":100},[],{"trials":8824,"activeCount":100},[],{"trials":8826,"activeCount":100},[],{"trials":8828,"activeCount":100},[],{"trials":8830,"activeCount":100},[],{"intervention":8065,"totalTrials":120,"cells":8832},{"EARLY_PHASE1":8833,"PHASE1":8839,"PHASE2":8841,"PHASE3":8843,"PHASE4":8845,"NA":8847},{"trials":8834,"activeCount":100},[8835],{"nctId":8057,"briefTitle":8058,"status":126,"phases":8836,"primaryCompletion":8060,"completion":8060,"start":8061,"enrollment":1620,"conditions":8837,"interventions":8838},[87],[8063],[8052,8065],{"trials":8840,"activeCount":100},[],{"trials":8842,"activeCount":100},[],{"trials":8844,"activeCount":100},[],{"trials":8846,"activeCount":100},[],{"trials":8848,"activeCount":100},[],{"intervention":8850,"totalTrials":120,"cells":8851},"SADBE 5%",{"EARLY_PHASE1":8852,"PHASE1":8864,"PHASE2":8866,"PHASE3":8868,"PHASE4":8870,"NA":8872},{"trials":8853,"activeCount":100},[8854],{"nctId":8855,"briefTitle":8856,"status":1858,"phases":8857,"primaryCompletion":8858,"completion":8859,"start":8860,"enrollment":4841,"conditions":8861,"interventions":8863},"NCT05414266","Study Evaluating Efficacy of Topical Squaric Acid Dibutyl Ester in Children and Adolescents With Alopecia Areata",[87],"2023-06-01","2024-05-22","2022-08-15",[8862],"Alopecia Areata",[8850],{"trials":8865,"activeCount":100},[],{"trials":8867,"activeCount":100},[],{"trials":8869,"activeCount":100},[],{"trials":8871,"activeCount":100},[],{"trials":8873,"activeCount":100},[],{"intervention":8875,"totalTrials":120,"cells":8876},"Candesartan",{"EARLY_PHASE1":8877,"PHASE1":8887,"PHASE2":8889,"PHASE3":8891,"PHASE4":8893,"NA":8895},{"trials":8878,"activeCount":100},[8879],{"nctId":8880,"briefTitle":8881,"status":789,"phases":8882,"primaryCompletion":8265,"completion":8883,"start":3597,"enrollment":100,"conditions":8884,"interventions":8886},"NCT04430959","Candesartan as an Adjunctive Treatment for Bipolar Depression",[87],"2022-09-01",[8885],"Bipolar Disorder Depression",[8875],{"trials":8888,"activeCount":100},[],{"trials":8890,"activeCount":100},[],{"trials":8892,"activeCount":100},[],{"trials":8894,"activeCount":100},[],{"trials":8896,"activeCount":100},[],{"intervention":8898,"totalTrials":120,"cells":8899},"5-Azacytidine and trastuzumab",{"EARLY_PHASE1":8900,"PHASE1":8911,"PHASE2":8913,"PHASE3":8915,"PHASE4":8917,"NA":8919},{"trials":8901,"activeCount":100},[8902],{"nctId":8903,"briefTitle":8904,"status":126,"phases":8905,"primaryCompletion":8906,"completion":8906,"start":8907,"enrollment":96,"conditions":8908,"interventions":8910},"NCT04958486","Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults with Recurrent or Residual Posterior Fossa Ependymoma",[87],"2023-09-29","2021-07-08",[8909],"Fossa Ependymoma",[8898],{"trials":8912,"activeCount":100},[],{"trials":8914,"activeCount":100},[],{"trials":8916,"activeCount":100},[],{"trials":8918,"activeCount":100},[],{"trials":8920,"activeCount":100},[],{"intervention":8922,"totalTrials":1620,"cells":8923},"Nicotine Patch",{"EARLY_PHASE1":8924,"PHASE1":8926,"PHASE2":8928,"PHASE3":8934,"PHASE4":8936,"NA":8938},{"trials":8925,"activeCount":100},[],{"trials":8927,"activeCount":100},[],{"trials":8929,"activeCount":100},[8930],{"nctId":7354,"briefTitle":7355,"status":126,"phases":8931,"primaryCompletion":7357,"completion":7358,"start":7359,"enrollment":7360,"conditions":8932,"interventions":8933},[89],[32,1090],[7345,7363],{"trials":8935,"activeCount":100},[],{"trials":8937,"activeCount":100},[],{"trials":8939,"activeCount":100},[8940,8948],{"nctId":8941,"briefTitle":8942,"status":126,"phases":8943,"primaryCompletion":8944,"completion":8944,"start":8945,"enrollment":856,"conditions":8946,"interventions":8947},"NCT04839198","Using Machine Learning to Develop Just-in-Time Adaptive Interventions for Smoking Cessation",[92],"2024-11-22","2024-02-06",[32],[8922],{"nctId":8949,"briefTitle":8950,"status":126,"phases":8951,"primaryCompletion":8952,"completion":8952,"start":2783,"enrollment":6101,"conditions":8953,"interventions":8955},"NCT02918630","E-cigarettes to Promote Smoking Reduction Among Individuals With Schizophrenia",[92],"2017-08",[8954],"Tobacco Smoking",[8922,8956],"E-cigarette",{"intervention":4144,"totalTrials":1620,"cells":8958},{"EARLY_PHASE1":8959,"PHASE1":8961,"PHASE2":8963,"PHASE3":8965,"PHASE4":8967,"NA":8982},{"trials":8960,"activeCount":100},[],{"trials":8962,"activeCount":100},[],{"trials":8964,"activeCount":100},[],{"trials":8966,"activeCount":100},[],{"trials":8968,"activeCount":100},[8969,8978],{"nctId":8970,"briefTitle":8971,"status":126,"phases":8972,"primaryCompletion":2167,"completion":1912,"start":8973,"enrollment":8974,"conditions":8975,"interventions":8977},"NCT01280409","Metformin Postpartum for GDM RCT for Reduced Weight Retention",[91],"2011-01",114,[8976],"Diabetes, Gestational",[4144],{"nctId":4135,"briefTitle":4136,"status":789,"phases":8979,"primaryCompletion":4138,"completion":4139,"start":4140,"enrollment":100,"conditions":8980,"interventions":8981},[91],[4142],[4122,4144],{"trials":8983,"activeCount":100},[8984],{"nctId":8985,"briefTitle":8986,"status":126,"phases":8987,"primaryCompletion":2676,"completion":2676,"start":7666,"enrollment":9,"conditions":8988,"interventions":8990},"NCT00678080","Metformin Versus Insulin in Pregnant Women With Type 2 Diabetes",[92],[8989],"Pregnancy Complications",[4144,8991],"Insulin",{"intervention":3901,"totalTrials":145,"cells":8993},{"EARLY_PHASE1":8994,"PHASE1":8996,"PHASE2":8998,"PHASE3":9000,"PHASE4":9002,"NA":9008},{"trials":8995,"activeCount":100},[],{"trials":8997,"activeCount":100},[],{"trials":8999,"activeCount":100},[],{"trials":9001,"activeCount":100},[],{"trials":9003,"activeCount":100},[9004],{"nctId":3891,"briefTitle":3892,"status":126,"phases":9005,"primaryCompletion":3894,"completion":3895,"start":215,"enrollment":3896,"conditions":9006,"interventions":9007},[91],[3898],[3900,3901,3902,3878],{"trials":9009,"activeCount":100},[9010],{"nctId":9011,"briefTitle":9012,"status":126,"phases":9013,"primaryCompletion":2114,"completion":2114,"start":6368,"enrollment":2210,"conditions":9014,"interventions":9016},"NCT02412761","Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension",[92],[9015],"Essential Hypertension",[3901,3900,3902],{"intervention":3900,"totalTrials":145,"cells":9018},{"EARLY_PHASE1":9019,"PHASE1":9021,"PHASE2":9023,"PHASE3":9025,"PHASE4":9027,"NA":9033},{"trials":9020,"activeCount":100},[],{"trials":9022,"activeCount":100},[],{"trials":9024,"activeCount":100},[],{"trials":9026,"activeCount":100},[],{"trials":9028,"activeCount":100},[9029],{"nctId":3891,"briefTitle":3892,"status":126,"phases":9030,"primaryCompletion":3894,"completion":3895,"start":215,"enrollment":3896,"conditions":9031,"interventions":9032},[91],[3898],[3900,3901,3902,3878],{"trials":9034,"activeCount":100},[9035],{"nctId":9011,"briefTitle":9012,"status":126,"phases":9036,"primaryCompletion":2114,"completion":2114,"start":6368,"enrollment":2210,"conditions":9037,"interventions":9038},[92],[9015],[3901,3900,3902],{"intervention":3902,"totalTrials":145,"cells":9040},{"EARLY_PHASE1":9041,"PHASE1":9043,"PHASE2":9045,"PHASE3":9047,"PHASE4":9049,"NA":9055},{"trials":9042,"activeCount":100},[],{"trials":9044,"activeCount":100},[],{"trials":9046,"activeCount":100},[],{"trials":9048,"activeCount":100},[],{"trials":9050,"activeCount":100},[9051],{"nctId":3891,"briefTitle":3892,"status":126,"phases":9052,"primaryCompletion":3894,"completion":3895,"start":215,"enrollment":3896,"conditions":9053,"interventions":9054},[91],[3898],[3900,3901,3902,3878],{"trials":9056,"activeCount":100},[9057],{"nctId":9011,"briefTitle":9012,"status":126,"phases":9058,"primaryCompletion":2114,"completion":2114,"start":6368,"enrollment":2210,"conditions":9059,"interventions":9060},[92],[9015],[3901,3900,3902],{"intervention":4296,"totalTrials":145,"cells":9062},{"EARLY_PHASE1":9063,"PHASE1":9065,"PHASE2":9067,"PHASE3":9069,"PHASE4":9071,"NA":9077},{"trials":9064,"activeCount":100},[],{"trials":9066,"activeCount":100},[],{"trials":9068,"activeCount":100},[],{"trials":9070,"activeCount":100},[],{"trials":9072,"activeCount":100},[9073],{"nctId":4288,"briefTitle":4289,"status":126,"phases":9074,"primaryCompletion":4291,"completion":4291,"start":4292,"enrollment":258,"conditions":9075,"interventions":9076},[91],[4294],[4275,4296],{"trials":9078,"activeCount":100},[9079],{"nctId":9080,"briefTitle":9081,"status":141,"phases":9082,"primaryCompletion":3597,"completion":3597,"start":9083,"enrollment":1809,"conditions":9084,"interventions":9086},"NCT02053766","Anesthesia in Patients With Mitochondrial Disease",[92],"2014-01-10",[9085],"Mitochondrial Diseases",[9087,4296,9088],"Sevoflurane","Propofol",{"intervention":9090,"totalTrials":145,"cells":9091},"raltegravir",{"EARLY_PHASE1":9092,"PHASE1":9094,"PHASE2":9096,"PHASE3":9098,"PHASE4":9100,"NA":9106},{"trials":9093,"activeCount":100},[],{"trials":9095,"activeCount":100},[],{"trials":9097,"activeCount":100},[],{"trials":9099,"activeCount":100},[],{"trials":9101,"activeCount":100},[9102],{"nctId":4313,"briefTitle":4314,"status":126,"phases":9103,"primaryCompletion":4316,"completion":4317,"start":1862,"enrollment":4318,"conditions":9104,"interventions":9105},[91],[4320],[4300,4322],{"trials":9107,"activeCount":100},[9108],{"nctId":9109,"briefTitle":9110,"status":1858,"phases":9111,"primaryCompletion":1821,"completion":1861,"start":9112,"enrollment":9113,"conditions":9114,"interventions":9116},"NCT02302950","A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas",[],"2014-09",254,[9115],"HIV Infection",[9090],{"intervention":9118,"totalTrials":145,"cells":9119},"IV Acetaminophen",{"EARLY_PHASE1":9120,"PHASE1":9122,"PHASE2":9124,"PHASE3":9126,"PHASE4":9128,"NA":9130},{"trials":9121,"activeCount":100},[],{"trials":9123,"activeCount":100},[],{"trials":9125,"activeCount":100},[],{"trials":9127,"activeCount":100},[],{"trials":9129,"activeCount":100},[],{"trials":9131,"activeCount":100},[9132,9140],{"nctId":9133,"briefTitle":9134,"status":126,"phases":9135,"primaryCompletion":9112,"completion":9112,"start":9136,"enrollment":506,"conditions":9137,"interventions":9139},"NCT01608308","Intraoperative and Post-operative Analgesic Effect of IV Acetaminophen for Sinus Surgery",[92],"2012-07",[9138],"Chronic Sinusitis",[9118],{"nctId":9141,"briefTitle":9142,"status":141,"phases":9143,"primaryCompletion":9144,"completion":9144,"start":7555,"enrollment":9145,"conditions":9146,"interventions":9148},"NCT02267772","IV Acetaminophen vs IV Morphine for Pain Control in Pregnant Women",[92],"2019-04-27",163,[9147],"Pain Management in Pregnant Women",[9118,9149],"IV Morphine",{"intervention":9151,"totalTrials":120,"cells":9152},"Propofol and Remifentanyl",{"EARLY_PHASE1":9153,"PHASE1":9155,"PHASE2":9157,"PHASE3":9159,"PHASE4":9161,"NA":9163},{"trials":9154,"activeCount":100},[],{"trials":9156,"activeCount":100},[],{"trials":9158,"activeCount":100},[],{"trials":9160,"activeCount":100},[],{"trials":9162,"activeCount":100},[],{"trials":9164,"activeCount":100},[9165],{"nctId":9166,"briefTitle":9167,"status":141,"phases":9168,"primaryCompletion":3078,"completion":3078,"start":9169,"enrollment":3105,"conditions":9170,"interventions":9171},"NCT01214057","Total Intravenous Anesthesia (TIVA) vs. Inhaled Anesthesia for Endoscopic Sinus Surgery.",[92],"2010-05",[5478],[9151,9172],"Sevoflurane and Remifentanyl",{"intervention":9172,"totalTrials":120,"cells":9174},{"EARLY_PHASE1":9175,"PHASE1":9177,"PHASE2":9179,"PHASE3":9181,"PHASE4":9183,"NA":9185},{"trials":9176,"activeCount":100},[],{"trials":9178,"activeCount":100},[],{"trials":9180,"activeCount":100},[],{"trials":9182,"activeCount":100},[],{"trials":9184,"activeCount":100},[],{"trials":9186,"activeCount":100},[9187],{"nctId":9166,"briefTitle":9167,"status":141,"phases":9188,"primaryCompletion":3078,"completion":3078,"start":9169,"enrollment":3105,"conditions":9189,"interventions":9190},[92],[5478],[9151,9172],{"intervention":9192,"totalTrials":120,"cells":9193},"Azithromycin",{"EARLY_PHASE1":9194,"PHASE1":9196,"PHASE2":9198,"PHASE3":9200,"PHASE4":9202,"NA":9204},{"trials":9195,"activeCount":100},[],{"trials":9197,"activeCount":100},[],{"trials":9199,"activeCount":100},[],{"trials":9201,"activeCount":100},[],{"trials":9203,"activeCount":100},[],{"trials":9205,"activeCount":100},[9206],{"nctId":9207,"briefTitle":9208,"status":126,"phases":9209,"primaryCompletion":9210,"completion":9210,"start":5719,"enrollment":856,"conditions":9211,"interventions":9213},"NCT02544984","The Anti-inflammatory Effect of Prophylactic Macrolides on Children With Chronic Lung Disease",[92],"2017-03-31",[9212],"Chronic Lung Disease",[9192],{"intervention":9215,"totalTrials":120,"cells":9216},"Sapropterin",{"EARLY_PHASE1":9217,"PHASE1":9219,"PHASE2":9221,"PHASE3":9223,"PHASE4":9225,"NA":9227},{"trials":9218,"activeCount":100},[],{"trials":9220,"activeCount":100},[],{"trials":9222,"activeCount":100},[],{"trials":9224,"activeCount":100},[],{"trials":9226,"activeCount":100},[],{"trials":9228,"activeCount":100},[9229],{"nctId":9230,"briefTitle":9231,"status":141,"phases":9232,"primaryCompletion":5136,"completion":5136,"start":2675,"enrollment":756,"conditions":9233,"interventions":9236},"NCT01541397","Bone Mineral Density in Adults With Hyperphenylalaninemia on Kuvan Therapy",[92],[9234,9235],"Hyperphenylalaninemia","Phenylketonuria",[9215],{"intervention":9238,"totalTrials":120,"cells":9239},"Strict Glycemic control",{"EARLY_PHASE1":9240,"PHASE1":9242,"PHASE2":9244,"PHASE3":9246,"PHASE4":9248,"NA":9250},{"trials":9241,"activeCount":100},[],{"trials":9243,"activeCount":100},[],{"trials":9245,"activeCount":100},[],{"trials":9247,"activeCount":100},[],{"trials":9249,"activeCount":100},[],{"trials":9251,"activeCount":100},[9252],{"nctId":9253,"briefTitle":9254,"status":141,"phases":9255,"primaryCompletion":8468,"completion":8468,"start":6812,"enrollment":1797,"conditions":9256,"interventions":9258},"NCT00353275","Hyperglycemia in Surgical Infections",[92],[9257],"Necrotizing Fasciitis",[9238,9259],"Conventional Glycemic Control",{"intervention":9259,"totalTrials":120,"cells":9261},{"EARLY_PHASE1":9262,"PHASE1":9264,"PHASE2":9266,"PHASE3":9268,"PHASE4":9270,"NA":9272},{"trials":9263,"activeCount":100},[],{"trials":9265,"activeCount":100},[],{"trials":9267,"activeCount":100},[],{"trials":9269,"activeCount":100},[],{"trials":9271,"activeCount":100},[],{"trials":9273,"activeCount":100},[9274],{"nctId":9253,"briefTitle":9254,"status":141,"phases":9275,"primaryCompletion":8468,"completion":8468,"start":6812,"enrollment":1797,"conditions":9276,"interventions":9277},[92],[9257],[9238,9259],{"intervention":9279,"totalTrials":120,"cells":9280},"FVIII concentrate",{"EARLY_PHASE1":9281,"PHASE1":9283,"PHASE2":9285,"PHASE3":9287,"PHASE4":9289,"NA":9291},{"trials":9282,"activeCount":100},[],{"trials":9284,"activeCount":100},[],{"trials":9286,"activeCount":100},[],{"trials":9288,"activeCount":100},[],{"trials":9290,"activeCount":100},[],{"trials":9292,"activeCount":100},[9293],{"nctId":9294,"briefTitle":9295,"status":126,"phases":9296,"primaryCompletion":9297,"completion":9297,"start":8468,"enrollment":9,"conditions":9298,"interventions":9300},"NCT01652027","Hemophilia Inhibitor Previously Untreated Patient Study",[],"2020-03",[9299],"Hemophilia A",[9279],{"intervention":8956,"totalTrials":120,"cells":9302},{"EARLY_PHASE1":9303,"PHASE1":9305,"PHASE2":9307,"PHASE3":9309,"PHASE4":9311,"NA":9313},{"trials":9304,"activeCount":100},[],{"trials":9306,"activeCount":100},[],{"trials":9308,"activeCount":100},[],{"trials":9310,"activeCount":100},[],{"trials":9312,"activeCount":100},[],{"trials":9314,"activeCount":100},[9315],{"nctId":8949,"briefTitle":8950,"status":126,"phases":9316,"primaryCompletion":8952,"completion":8952,"start":2783,"enrollment":6101,"conditions":9317,"interventions":9318},[92],[8954],[8922,8956],{"intervention":9320,"totalTrials":120,"cells":9321},"Liberal use of maternal oxygen",{"EARLY_PHASE1":9322,"PHASE1":9324,"PHASE2":9326,"PHASE3":9328,"PHASE4":9330,"NA":9332},{"trials":9323,"activeCount":100},[],{"trials":9325,"activeCount":100},[],{"trials":9327,"activeCount":100},[],{"trials":9329,"activeCount":100},[],{"trials":9331,"activeCount":100},[],{"trials":9333,"activeCount":100},[9334],{"nctId":9335,"briefTitle":9336,"status":126,"phases":9337,"primaryCompletion":9338,"completion":9338,"start":7036,"enrollment":9339,"conditions":9340,"interventions":9342},"NCT02752490","The Comparative Effectiveness of Liberal Versus Restricted Maternal Administration of Oxygen During Labor",[92],"2016-07-31",844,[9341],"Maternal Oxygen Use in Labor",[9320,9343],"Indicated use of maternal oxygen",{"intervention":9343,"totalTrials":120,"cells":9345},{"EARLY_PHASE1":9346,"PHASE1":9348,"PHASE2":9350,"PHASE3":9352,"PHASE4":9354,"NA":9356},{"trials":9347,"activeCount":100},[],{"trials":9349,"activeCount":100},[],{"trials":9351,"activeCount":100},[],{"trials":9353,"activeCount":100},[],{"trials":9355,"activeCount":100},[],{"trials":9357,"activeCount":100},[9358],{"nctId":9335,"briefTitle":9336,"status":126,"phases":9359,"primaryCompletion":9338,"completion":9338,"start":7036,"enrollment":9339,"conditions":9360,"interventions":9361},[92],[9341],[9320,9343],{"intervention":9363,"totalTrials":120,"cells":9364},"sapropterin dihydrochloride",{"EARLY_PHASE1":9365,"PHASE1":9367,"PHASE2":9369,"PHASE3":9371,"PHASE4":9373,"NA":9375},{"trials":9366,"activeCount":100},[],{"trials":9368,"activeCount":100},[],{"trials":9370,"activeCount":100},[],{"trials":9372,"activeCount":100},[],{"trials":9374,"activeCount":100},[],{"trials":9376,"activeCount":100},[9377],{"nctId":9378,"briefTitle":9379,"status":126,"phases":9380,"primaryCompletion":4420,"completion":4420,"start":5433,"enrollment":35,"conditions":9381,"interventions":9382},"NCT01141595","Tetrahydrobiopterin Treatment in Children With Idiopathic Cognitive Developmental Disorders",[92],[7167],[9363],{"intervention":9384,"totalTrials":120,"cells":9385},"Caffeine and sodium Benzoate 10 mg\u002Fkg IV",{"EARLY_PHASE1":9386,"PHASE1":9388,"PHASE2":9390,"PHASE3":9392,"PHASE4":9394,"NA":9396},{"trials":9387,"activeCount":100},[],{"trials":9389,"activeCount":100},[],{"trials":9391,"activeCount":100},[],{"trials":9393,"activeCount":100},[],{"trials":9395,"activeCount":100},[],{"trials":9397,"activeCount":100},[9398],{"nctId":9399,"briefTitle":9400,"status":141,"phases":9401,"primaryCompletion":6625,"completion":6625,"start":2187,"enrollment":2210,"conditions":9402,"interventions":9405},"NCT01349205","Caffeine in Children With Obstructive Sleep Apnea, Dose Response Study",[92],[9403,9404],"Obstructive Sleep Apnea","Enlargement of Tonsil or Adenoid",[9384,9406,9407],"Caffeine and Sodium Benzoate 20 mg\u002Fkg IV","0.9 NS Saline",{"intervention":9406,"totalTrials":120,"cells":9409},{"EARLY_PHASE1":9410,"PHASE1":9412,"PHASE2":9414,"PHASE3":9416,"PHASE4":9418,"NA":9420},{"trials":9411,"activeCount":100},[],{"trials":9413,"activeCount":100},[],{"trials":9415,"activeCount":100},[],{"trials":9417,"activeCount":100},[],{"trials":9419,"activeCount":100},[],{"trials":9421,"activeCount":100},[9422],{"nctId":9399,"briefTitle":9400,"status":141,"phases":9423,"primaryCompletion":6625,"completion":6625,"start":2187,"enrollment":2210,"conditions":9424,"interventions":9425},[92],[9403,9404],[9384,9406,9407],{"intervention":9407,"totalTrials":120,"cells":9427},{"EARLY_PHASE1":9428,"PHASE1":9430,"PHASE2":9432,"PHASE3":9434,"PHASE4":9436,"NA":9438},{"trials":9429,"activeCount":100},[],{"trials":9431,"activeCount":100},[],{"trials":9433,"activeCount":100},[],{"trials":9435,"activeCount":100},[],{"trials":9437,"activeCount":100},[],{"trials":9439,"activeCount":100},[9440],{"nctId":9399,"briefTitle":9400,"status":141,"phases":9441,"primaryCompletion":6625,"completion":6625,"start":2187,"enrollment":2210,"conditions":9442,"interventions":9443},[92],[9403,9404],[9384,9406,9407],{"intervention":9445,"totalTrials":120,"cells":9446},"Radium-223 dichloride",{"EARLY_PHASE1":9447,"PHASE1":9449,"PHASE2":9451,"PHASE3":9453,"PHASE4":9455,"NA":9457},{"trials":9448,"activeCount":100},[],{"trials":9450,"activeCount":100},[],{"trials":9452,"activeCount":100},[],{"trials":9454,"activeCount":100},[],{"trials":9456,"activeCount":100},[],{"trials":9458,"activeCount":100},[9459],{"nctId":9460,"briefTitle":9461,"status":126,"phases":9462,"primaryCompletion":9463,"completion":9463,"start":9464,"enrollment":16,"conditions":9465,"interventions":9467},"NCT03368989","The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.",[],"2017-02-07","2014-02-11",[9466],"Bony Metastases From Castrate Refractory Prostate Cancer",[9445],{"intervention":9087,"totalTrials":120,"cells":9469},{"EARLY_PHASE1":9470,"PHASE1":9472,"PHASE2":9474,"PHASE3":9476,"PHASE4":9478,"NA":9480},{"trials":9471,"activeCount":100},[],{"trials":9473,"activeCount":100},[],{"trials":9475,"activeCount":100},[],{"trials":9477,"activeCount":100},[],{"trials":9479,"activeCount":100},[],{"trials":9481,"activeCount":100},[9482],{"nctId":9080,"briefTitle":9081,"status":141,"phases":9483,"primaryCompletion":3597,"completion":3597,"start":9083,"enrollment":1809,"conditions":9484,"interventions":9485},[92],[9085],[9087,4296,9088],{"intervention":9088,"totalTrials":120,"cells":9487},{"EARLY_PHASE1":9488,"PHASE1":9490,"PHASE2":9492,"PHASE3":9494,"PHASE4":9496,"NA":9498},{"trials":9489,"activeCount":100},[],{"trials":9491,"activeCount":100},[],{"trials":9493,"activeCount":100},[],{"trials":9495,"activeCount":100},[],{"trials":9497,"activeCount":100},[],{"trials":9499,"activeCount":100},[9500],{"nctId":9080,"briefTitle":9081,"status":141,"phases":9501,"primaryCompletion":3597,"completion":3597,"start":9083,"enrollment":1809,"conditions":9502,"interventions":9503},[92],[9085],[9087,4296,9088],{"intervention":9505,"totalTrials":120,"cells":9506},"Minocycline",{"EARLY_PHASE1":9507,"PHASE1":9509,"PHASE2":9511,"PHASE3":9513,"PHASE4":9515,"NA":9517},{"trials":9508,"activeCount":100},[],{"trials":9510,"activeCount":100},[],{"trials":9512,"activeCount":100},[],{"trials":9514,"activeCount":100},[],{"trials":9516,"activeCount":100},[],{"trials":9518,"activeCount":100},[9519],{"nctId":9520,"briefTitle":9521,"status":1858,"phases":9522,"primaryCompletion":9523,"completion":9523,"start":5432,"enrollment":5913,"conditions":9524,"interventions":9525},"NCT01561742","Minocycline Augmentation in Schizophrenia",[92],"2015-01",[7237],[9505],{"intervention":9527,"totalTrials":120,"cells":9528},"Intravenous Methocarbamol",{"EARLY_PHASE1":9529,"PHASE1":9531,"PHASE2":9533,"PHASE3":9535,"PHASE4":9537,"NA":9539},{"trials":9530,"activeCount":100},[],{"trials":9532,"activeCount":100},[],{"trials":9534,"activeCount":100},[],{"trials":9536,"activeCount":100},[],{"trials":9538,"activeCount":100},[],{"trials":9540,"activeCount":100},[9541],{"nctId":9542,"briefTitle":9543,"status":126,"phases":9544,"primaryCompletion":9545,"completion":4443,"start":9546,"enrollment":9547,"conditions":9548,"interventions":9553},"NCT06659965","Intravenous Methocarbamol for Acute Pain After Spine Surgery",[],"2023-12-31","2020-01-01",1270,[9549,9550,5502,9551,9552],"Acute Post Operative Pain","Postsurgical Pain Management","Acute Pain, Postoperative","Multimodal Analgesia",[9527],{"intervention":8991,"totalTrials":120,"cells":9555},{"EARLY_PHASE1":9556,"PHASE1":9558,"PHASE2":9560,"PHASE3":9562,"PHASE4":9564,"NA":9566},{"trials":9557,"activeCount":100},[],{"trials":9559,"activeCount":100},[],{"trials":9561,"activeCount":100},[],{"trials":9563,"activeCount":100},[],{"trials":9565,"activeCount":100},[],{"trials":9567,"activeCount":100},[9568],{"nctId":8985,"briefTitle":8986,"status":126,"phases":9569,"primaryCompletion":2676,"completion":2676,"start":7666,"enrollment":9,"conditions":9570,"interventions":9571},[92],[8989],[4144,8991],{"intervention":9573,"totalTrials":120,"cells":9574},"Adenosine",{"EARLY_PHASE1":9575,"PHASE1":9577,"PHASE2":9579,"PHASE3":9581,"PHASE4":9583,"NA":9585},{"trials":9576,"activeCount":100},[],{"trials":9578,"activeCount":100},[],{"trials":9580,"activeCount":100},[],{"trials":9582,"activeCount":100},[],{"trials":9584,"activeCount":100},[],{"trials":9586,"activeCount":100},[9587],{"nctId":9588,"briefTitle":9589,"status":126,"phases":9590,"primaryCompletion":4527,"completion":4527,"start":9591,"enrollment":9592,"conditions":9593,"interventions":9595},"NCT02184117","CONTRAST (Can cONTrast Injection Better Approximate FFR compAred to Pure reSTing Physiology?)",[],"2014-07",763,[9594],"Coronary Artery Disease",[9573,9596,9597],"Contrast Media","Resting conditions",{"intervention":9596,"totalTrials":120,"cells":9599},{"EARLY_PHASE1":9600,"PHASE1":9602,"PHASE2":9604,"PHASE3":9606,"PHASE4":9608,"NA":9610},{"trials":9601,"activeCount":100},[],{"trials":9603,"activeCount":100},[],{"trials":9605,"activeCount":100},[],{"trials":9607,"activeCount":100},[],{"trials":9609,"activeCount":100},[],{"trials":9611,"activeCount":100},[9612],{"nctId":9588,"briefTitle":9589,"status":126,"phases":9613,"primaryCompletion":4527,"completion":4527,"start":9591,"enrollment":9592,"conditions":9614,"interventions":9615},[],[9594],[9573,9596,9597],{"intervention":9597,"totalTrials":120,"cells":9617},{"EARLY_PHASE1":9618,"PHASE1":9620,"PHASE2":9622,"PHASE3":9624,"PHASE4":9626,"NA":9628},{"trials":9619,"activeCount":100},[],{"trials":9621,"activeCount":100},[],{"trials":9623,"activeCount":100},[],{"trials":9625,"activeCount":100},[],{"trials":9627,"activeCount":100},[],{"trials":9629,"activeCount":100},[9630],{"nctId":9588,"briefTitle":9589,"status":126,"phases":9631,"primaryCompletion":4527,"completion":4527,"start":9591,"enrollment":9592,"conditions":9632,"interventions":9633},[],[9594],[9573,9596,9597],{"intervention":9635,"totalTrials":120,"cells":9636},"Insulin Glargine",{"EARLY_PHASE1":9637,"PHASE1":9639,"PHASE2":9641,"PHASE3":9643,"PHASE4":9645,"NA":9647},{"trials":9638,"activeCount":100},[],{"trials":9640,"activeCount":100},[],{"trials":9642,"activeCount":100},[],{"trials":9644,"activeCount":100},[],{"trials":9646,"activeCount":100},[],{"trials":9648,"activeCount":100},[9649],{"nctId":9650,"briefTitle":9651,"status":126,"phases":9652,"primaryCompletion":4792,"completion":4792,"start":3195,"enrollment":421,"conditions":9653,"interventions":9655},"NCT02006342","Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis",[92],[9654],"Diabetic Ketoacidosis",[9635,9656],"Regular Insulin",{"intervention":9656,"totalTrials":120,"cells":9658},{"EARLY_PHASE1":9659,"PHASE1":9661,"PHASE2":9663,"PHASE3":9665,"PHASE4":9667,"NA":9669},{"trials":9660,"activeCount":100},[],{"trials":9662,"activeCount":100},[],{"trials":9664,"activeCount":100},[],{"trials":9666,"activeCount":100},[],{"trials":9668,"activeCount":100},[],{"trials":9670,"activeCount":100},[9671],{"nctId":9650,"briefTitle":9651,"status":126,"phases":9672,"primaryCompletion":4792,"completion":4792,"start":3195,"enrollment":421,"conditions":9673,"interventions":9674},[92],[9654],[9635,9656],{"intervention":9676,"totalTrials":120,"cells":9677},"Polymorphisms measured",{"EARLY_PHASE1":9678,"PHASE1":9680,"PHASE2":9682,"PHASE3":9684,"PHASE4":9686,"NA":9688},{"trials":9679,"activeCount":100},[],{"trials":9681,"activeCount":100},[],{"trials":9683,"activeCount":100},[],{"trials":9685,"activeCount":100},[],{"trials":9687,"activeCount":100},[],{"trials":9689,"activeCount":100},[9690],{"nctId":9691,"briefTitle":9692,"status":126,"phases":9693,"primaryCompletion":2699,"completion":2699,"start":7667,"enrollment":9694,"conditions":9695,"interventions":9696},"NCT00037440","Genetic Epidemiology of Change in CVD Risk Factors",[],1735,[21,26],[9676],{"intervention":9149,"totalTrials":120,"cells":9698},{"EARLY_PHASE1":9699,"PHASE1":9701,"PHASE2":9703,"PHASE3":9705,"PHASE4":9707,"NA":9709},{"trials":9700,"activeCount":100},[],{"trials":9702,"activeCount":100},[],{"trials":9704,"activeCount":100},[],{"trials":9706,"activeCount":100},[],{"trials":9708,"activeCount":100},[],{"trials":9710,"activeCount":100},[9711],{"nctId":9141,"briefTitle":9142,"status":141,"phases":9712,"primaryCompletion":9144,"completion":9144,"start":7555,"enrollment":9145,"conditions":9713,"interventions":9714},[92],[9147],[9118,9149]]